References

  1. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep. 2015;64(RR3):1–137.
  2. Barrow RY, Ahmed F, Bolan GA, Workowski KA. Recommendations for providing quality sexually transmitted diseases clinical services, 2020. MMWR Morb Mortal Wkly Rep. 2020;68(RR-5):1–20.
  3. Centers for Disease Control and Prevention. A guide to taking a sexual history [Internet]. Atlanta, GA: US Department of Health and Human Services, CDC [cited 2020]. Available from: www.cdc.gov/std/treatment/SexualHistory.pdf
  4. Henderson JT, Senger CA, Henninger M, Bean SI, Redmond N, O’Connor EA. Behavioral counseling interventions to prevent sexually transmitted infections: updated evidence report and systematic review for the US Preventive Services Task Force. 2020;324(7):682–99.
  5. Kamb ML, Fishbein M, Douglas JM Jr, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA. 1998;280:1161–7.
  6. Metsch LR, Feaster DJ, Gooden L, et al. Effect of risk-reduction counseling with rapid HIV testing on risk of acquiring sexually transmitted infections: the AWARE randomized clinical trial. JAMA. 2013;310:1701–10.
  7. Brookmeyer KA, Hogben M, Kinsey J. The role of behavioral counseling in sexually transmitted disease prevention program settings. Sex Transm Dis. 2016;43(2 Suppl 1):S102–12.
  8. Patel P, Bush T, Mayer K, et al. Routine brief risk-reduction counseling with biannual STD testing reduces STD incidence among HIV-infected men who have sex with men in care. Sex Transm Dis. 2012;39:470–4.
  9. Warner L, Klausner JD, Rietmeijer CA, et al. Effect of a brief video intervention on incident infection among patients attending sexually transmitted disease clinics. PLoS Med. 2008;5:919–27.
  10. Mustanski B, Parsons JT, Sullivan PS, Madkins K, Rosenberg E, Swann G. Biomedical and behavioral outcomes of Keep It Up!: an ehealth HIV prevention program RCT. Am J Prev Med. 2018;55(2):151–58.
  11. Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68(32):698–702.
  12. Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67(1):1–31.
  13. Doshani M, Weng M, Moore KL, Romero JR, Nelson NP. Recommendations of the Advisory Committee on Immunization Practices for use of hepatitis A vaccine for persons experiencing homelessness. MMWR Morb Mortal Wkly Rep. 2019;68(6):153–6.
  14. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2002;(1):CD003255.
  15. Giannou FK, Tsiara CG, Nikolopoulos GK, et al. Condom effectiveness in reducing heterosexual HIV transmission: a systematic review and meta-analysis of studies on HIV serodiscordant couples. Expert Rev Pharmacoecon Outcomes Res. 2016;16(4):489–99.
  16. Smith DK, Herbst JH, Zhang X, Rose CE. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2015;68(3):337–44.
  17. Johnson WD, O’Leary A, Flores SA. Per-partner condom effectiveness against HIV for men who have sex with men. AIDS. 2018;32(11):1499–1505.
  18. Crosby RA, Charnigo RA, Weathers C, Caliendo AM, Shrier LA. Condom effectiveness against non-viral sexually transmitted infections: a prospective study using electronic daily diaries. Sex Transm Infect. 2012;88:484–9.
  19. Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ. 2004;82:454–61.
  20. Warner L, Stone KM, Macaluso M, Buehler JW, Austin HD. Condom use and risk of gonorrhea and Chlamydia: a systematic review of design and measurement factors assessed in epidemiologic studies. Sex Transm Dis. 2006;33:36–51.
  21. Bernabe-Ortiz A, Carcamo CP, Scott JD, Hughes JP, Garcia PJ, Holmes KK. HBV infection in relation to consistent condom use: a population-based study in Peru. PLoS One. 2011;6:e24721.
  22. Ness RB, Hillier SL, Kip KE, et al. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol. 2004;104:761–9.
  23. Martin IE, Gu W, Yang Y, Tsang RS. Macrolide resistance and molecular types of Treponema pallidum causing primary syphilis in Shanghai, China. Clin Infect Dis. 2009;49(4):515–21.
  24. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. New Engl J Med. 2006;354:2645–54.
  25. Bleeker MC, Hogewoning CJ, Voorhorst FJ, et al. Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. Int J Cancer. 2003;107:804–10.
  26. Hogewoning CJ, Bleeker MC, van den Brule AJ, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer. 2003;107(5):811–6.
  27. Koss CA, Dunne EF, Warner L. A systematic review of epidemiologic studies assessing condom use and risk of syphilis. Sex Transm Dis. 2009;36:401–5.
  28. Hernández-Romieu AC, Siegler AJ, Sullivan PS, Crosby R, Rosenberg ES. How often do condoms fail? A cross-sectional study exploring incomplete use of condoms, condom failures and other condom problems among black and white MSM in southern U.S.A. Sex Transm Infect. 2014;90(8):602–7.
  29. D’Anna LH, Margolis AD, Warner L, et al. Condom use problems during anal sex among men who have sex with men (MSM): findings from the Safe in the City study. AIDS Care. 2012;24:1028–38.
  30. Steiner MJ, Cates W Jr, Warner L. The real problem with male condoms is nonuse. Sex Transm Dis. 1999;26:459–62.
  31. Hatcher RA. Contraceptive Technology. 21st ed. Kowal D, Hatcher RA, Nelson AL, Trussell J, Cwiak C, Cason P, Policar MS, Edelman AB, Aiken ARA, Marrazzo JM, editors. Managing Contraception, LLC; 2017. 1048 p.
  32. Gallo MF, Kilbourne-Brook M, Coffey PS. A review of the effectiveness and acceptability of the female condom for dual protection. Sex Health. 2012;9:18–26.
  33. Mantell JE, Kelvin EA, Exner TM, Hoffman S, Needham S, Stein ZA. Anal use of the female condom: does uncertainty justify provider inaction? AIDS Care. 2009;21:1185–94.
  34. Rosenberg MJ, Davidson AJ, Chen JH, Judson FN, Douglas JM. Barrier contraceptives and sexually transmitted diseases in women: a comparison of female-dependent methods and condoms. Am J Public Health. 1992;82:669–74.
  35. de Bruyn G, Shiboski S, van der Straten A, et al. The effect of the vaginal diaphragm and lubricant gel on acquisition of HSV-2. Sex Transm Infect. 2011;87:301–5.
  36. Ramjee G, van der Straten A, Chipato T, et al. The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial. PLoS One. 2008;3:e3488.
  37. Lusti-Narasimhan M, Merialdi M, Holt B. Multipurpose prevention technologies: maximising positive synergies. BJOG. 2014;121(3):251.
  38. Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet. 2019;394(10195):303–13.
  39. Young Holt B, Dellplain L, Creinin MD, Peine KJ, Romano J, Hemmerling A. A strategic action framework for multipurpose prevention technologies combining contraceptive hormones and antiretroviral drugs to prevent pregnancy and HIV. Eur J Contracept Reprod Health Care. 2018;23(5):326–34.
  40. Wilkinson D, Tholandi M, Ramjee G, Rutherford GW. Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect Dis. 2002;2:613–7.
  41. McCormack S, Ramjee G, Kamali A, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010;376:1329–37.
  42. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1977–87.
  43. Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359:463–72.
  44. Feldblum PJ, Adeiga A, Bakare R, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One. 2008;3:e1474.
  45. Cottrell ML, Kashuba AD. Topical microbicides and HIV prevention in the female genital tract. J Clin Pharmacol. 2014;54(6):603–15.
  46. Abdool Karim SS, Abdool Karim Q, Kharsany ABM, et al. Tenofovir gel for the grevention of herpes simplex virus Type 2 infection. N Engl J Med. 2015;373(6):530–9.
  47. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.
  48. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.
  49. Delany-Moretlwe S, Lombard C, Baron D, et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2018;18(11):1241–50.
  50. Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121–32.
  51. Nel A, van Niekerk N, Kapiga S, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375(22):2133–43.
  52. Cranston RD, Lama JR, Richardson BA, et al. MTN-017: a rectal phase 2 extended safety and acceptability study of tenofovir reduced-glycerin 1% gel. Clin Infect Dis. 2017;64(5):614-20.
  53. Hooton TM, Roberts PL, Stamm WE. Effects of recent sexual activity and use of a diaphragm on the vaginal microflora. Clin Infect Dis. 1994;19:274–8.
  54. Fihn SD, Boyko EJ, Normand EH, et al. Association between use of spermicide-coated condoms and Escherichia coli urinary tract infection in young women. Am J Epidemiol. 1996;144:512–20.
  55. Polis CB, Curtis KM, Hannaford PC, et al. An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women. AIDS. 2016;30(17):2665–83.
  56. Kiweewa FM, Brown E, Mishra A, et al. Acquisition of sexually transmitted infections among women using a variety of contraceptive options: a prospective study among high-risk African women. J Int AIDS Soc. 2019;22(2):e25257.
  57. McCarthy KJ, Gollub EL, Ralph L, van de Wijgert J, Jones HE. Hormonal contraceptives and the acquisition of sexually transmitted infections: an updated systematic review. Sex Transm Dis. 2019;46(5):290–6.
  58. Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(3):1–103.
  59. Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(4):1–66.
  60. Cleland K, Zhu H, Goldstuck N, Cheng L, Trussell J. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience. Hum Rep. 2012;27:1994–2000.
  61. Shen J, Che Y, Showell E, Chen K, Cheng L. Interventions for emergency contraception. Cochrane Database Syst Rev. 2019;1(1):CD001324.
  62. Marcell AV, Waks AB, Rutkow L, McKenna R, Rompalo A, Hogan MT. What do we know about males and emergency contraception? a synthesis of the literature. Perspect Sex Reprod Health. 2012;44(3):184–93.
  63. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369:657–66.
  64. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369:643–56.
  65. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2:e298.
  66. Tobian AA, Serwadda D, Quinn TC, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med. 2009;360:1298–1309.
  67. Auvert B, Sobngwi-Tambekou J, Cutler E, et al. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis. 2009;199:14–9.
  68. Sobngwi-Tambekou J, Taljaard D, Lissouba P, et al. Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. J Infect Dis. 2009;199(7):958–64.
  69. Gray R, Kigozi G, Kong X, et al. The effectiveness of male circumcision for HIV prevention and effects on risk behaviors in a posttrial follow-up study. AIDS. 2012;26:609–15.
  70. Mehta SD, Moses S, Parker CB, Agot K, Maclean I, Bailey RC. Circumcision status and incident herpes simplex virus type 2 infection, genital ulcer disease, and HIV infection. AIDS. 2012;26:1141–9.
  71. World Health Organization/UNAIDS. New data on male circumcision and HIV prevention: policy and programme implications [Internet]. Geneva: WHO/UNAIDS Technical Consultation on Male Circumcision and HIV Prevention: Research Implications for Policy and Programming; 2007 [cited 2020]. Available from: https://www.who.int/hiv/pub/malecircumcision/research_implications/en/external icon
  72. American Urological Association Circumcision policy statement [Internet] 2017 [cited 2020] Available from: https://www.auanet.org/guidelines/circumcisionexternal icon
  73. Yuan T, Fitzpatrick T, Ko NY, et al. Circumcision to prevent HIV and other sexually transmitted infections in men who have sex with men: a systematic review and meta-analysis of global data. Lancet Glob Health. 2019;7(4):e436–47.
  74. Grohskopf LA, Chillag KL, Gvetadze R, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2013;64:79–86.
  75. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.
  76. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.
  77. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423–34.
  78. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083–90.
  79. Molina JM, Charreau I, Spire B, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4(9):e402–10.
  80. Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States–2017 Update: a clinical practice guideline [Internet]. US Department of Health and Human Services, CDC; Mar 2018 [cited 2019]; 77 p. Available from: https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf
  81. Jones J, Weiss K, Mermin J, et al. Proportion of incident human immunodeficiency virus cases among men who have sex with men attributable to gonorrhea and chlamydia: a modeling analysis. Sex Transm Dis. 2019;46(6):357–63.
  82. Pathela P, Braunstein SL, Blank S, Schillinger JA. HIV incidence among men with and those without sexually transmitted rectal infections: estimates from matching against an HIV case registry. Clin Infect Dis. 2013;57:1203–9.
  83. Pathela P, Braunstein SL, Blank S, Shepard C, Schillinger JA. The high risk of an HIV diagnosis following a diagnosis of syphilis: a population-level analysis of New York City men. Clin Infect Dis. 2015;61(2):281–7.
  84. Chou R, Evan C, Hoverman A, et al. Preexposure prophylaxis for the prevention of HIV infection: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2019;321(22):2214–30.
  85. Liu AY, Cohen SE, Vittinghoff E, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016;176(1):75–84.
  86. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. 2016;387(10013):53–60.
  87. Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;61(10):1601–3.
  88. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010;362:427–39.
  89. Celum C, Wal A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371(9630):2109–19.
  90. Bolan RK, Beymer MR, Weiss RE, Flynn RP, Leibowitz AA, Klausner JD. Doxycycline prophylaxis to reduce incident syphilis among HIV-infected men who have sex with men who continue to engage in high-risk sex: a randomized, controlled pilot study. Sex Transm Dis. 2015;42(2):98–103.
  91. Grant JS, Stafylis C, Celum C, et al. Doxycycline prophylaxis for bacterial sexually transmitted infections. Clin Infect Dis. 2020;70(6):1247–53.
  92. Myer L, Kuhn L, Stein ZA, Wright TC Jr, Denny L. Intravaginal practices, bacterial vaginosis, and women’s susceptibility to HIV infection: epidemiological evidence and biological mechanisms. Lancet Infect Dis. 2005;5:786–94.
  93. Molina JM, Charreau I, Chidiac C, et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2018;18(3):308–17.
  94. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.
  95. Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316(2):171–81.
  96. Bavinton BR, Pinto AN, Phanuphak N, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018;5(8):e438–47.
  97. Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019;393(10189):2428–38.
  98. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America [Internet]. US Department of Health and Human Services, AIDSinfo [cited 2019]. Available from: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf
  99. Golden MR, Kerani RP, Stenger M, et al. Effect of expedited partner therapy (EPT) on chlamydial prevalence: the Washington State Community-Level Trial. Presented at: 2012 STD Prevention Conference; 2012 Mar 12–15; Mineapolis, MN.
  100. Philip SS, Yu X, Donnell D, Vittinghoff E, Buchbinder S. Serosorting is associated with a decreased risk of HIV seroconversion in the EXPLORE Study Cohort. PLoS One. 2010;5(9):e12662.
  101. Vallabhaneni S, Li X, Vittinghoff E, Donnell D, Pilcher CD, Buchbinder SP. Seroadaptive practices: association with HIV acquisition among HIV-negative men who have sex with men. PLoS One. 2012;7:e45718.
  102. Jin F, Prestage GP, Templeton DJ, et al. The impact of HIV seroadaptive behaviors on sexually transmissible infections in HIV-negative homosexual men in Sydney, Australia. Sex Transm Dis. 2012;39:191–4.
  103. Hotton AL, Gratzer B, Mehta SD. Association between serosorting and bacterial sexually transmitted infection among HIV-negative men who have sex with men at an urban lesbian, gay, bisexual, and transgender health center. Sex Transm Dis. 2012;39:959–64.
  104. Anderson C, Gallo MF, Hylton-Kong T, et al. Randomized controlled trial on the effectiveness of counseling messages for avoiding unprotected sexual intercourse during sexually transmitted infection and reproductive tract infection treatment among female sexually transmitted infection clinic patients. Sex Transm Dis. 2013;40:105–10.
  105. Golden MR, Hogben M, Handsfield HH, St Lawrence JS, Potterat JJ, Holmes KK. Partner notification for HIV and STD in the United States: low coverage for gonorrhea, chlamydial infection, and HIV. Sex Transm Dis. 2003;30:490–6.
  106. Katz DA, Dombrowski JC, Kerani RP, et al. Integrating HIV testing as an outcome of STD partner services for men who have sex with men. AIDS Patient Care STDS. 2016;30(5):208–14.
  107. Katz DA, Dombrowski JC, Barry M, Spellman D, Bell TR, Golden MR. STD partner services to monitor and promote HIV pre-exposure prophylaxis use among men who have sex with men. J Acquir Immune Defic Syndr. 2019;80(5):533–41.
  108. Bocour A, Renaud TC, Udeagu CC, Shepard CW. HIV partner services are associated with timely linkage to HIV medical care. AIDS. 2013;27(18):2961–3.
  109. Tesoriero JM, Johnson BL, Hart-Malloy R, et al. Improving retention in HIV care through New York’s expanded partner services Data-to-Care pilot. J Public Health Manag Pract. 2017;23(3):255–63.
  110. Trelle S, Shang A, Nartey L, Cassell JA, Low N. Improved effectiveness of partner notification for patients with sexually transmitted infections: systematic review. BMJ. 2007;334:354.
  111. Centers for Disease Control and Prevention. Recommendations for partner services programs for HIV infection, syphilis, gonorrhea, and chlamydial infection. MMWR Recomm Rep. 2008;57(RR09):1–63.
  112. Thurman AR, Shain RN, Holden AE, Champion JD, Perdue ST, Piper JM. Partner notification of sexually transmitted infections: a large cohort of Mexican American and African American women. Sex Transm Dis. 2008;35(2):136–40.
  113. Kissinger PJ, Niccolai LM, Magnus M, et al. Partner notification for HIV and syphilis: effects on sexual behaviors and relationship stability. Sex Transm Dis. 2003;30(1):75–82.
  114. Smith SG, Zhang X, Basile,KC, et al. The National Intimate Partner and Sexual Violence Survey : 2015 data brief – updated release [Internet]. Atlanta (GA): CDC, National Center for Injury Prevention and Control; 2018 [cited 2020]. 32 p. Available from: https://www.cdc.gov/violenceprevention/pdf/2015data-brief508.pdfpdf icon
  115. Wilson TE, Hogben M, Malka ES, et al. A randomized controlled trial for reducing risks for sexually transmitted infections through enhanced patient-based partner notification. Am J Public Health. 2009;99(Suppl 1):S104–10.
  116. Yu YY, Frasure-Williams JA, Dunne EF, Bolan G, Markowitz L, Bauer HM. Chlamydia partner services for females in California family planning clinics. Sex Transm Dis. 2011;38:913–18.
  117. Mickiewicz T, Al-Tayyib A, Thrun M, Rietmeijer C. Implementation and effectiveness of an expedited partner therapy program in an urban clinic. Sex Transm Dis. 2012;39:923–9.
  118. Kachur R, Strona FV, Kinsey J, Collins D. Introducing technology into partner services: a toolkit for programs. Atlanta: Centers for Disease Control and Prevention; 2015. 84 p.
  119. Kachur R, Hall W, Coor A, Kinsey J, Collins D, Strona FV. The use of technology for sexually transmitted disease partner services in the United States: a structured review. Sex Transm Dis. 2018;45(11):707–12.
  120. Pellowski J, Mathews C, Kalichman MO, Dewing S, Lurie MN, Kalichman SC. Advancing partner notification through electronic communication technology: a review of acceptability and utilization research. J Health Commun. 2016;21(6):629–37.
  121. Borchardt LN, Pickett ML, Tan KT, Visotcky AM, Drendel AL. Expedited partner therapy: pharmacist refusal of legal prescriptions. Sex Transm Dis. 2018;45(5):350–3.
  122. Qin, JZ, Diniz CP, Coleman JS. Pharmacy-level barriers to implementing expedited partner therapy in Baltimore, Maryland. Am J Obstet Gynecol. 2018;218(5):504.e1–6.
  123. Schillinger J, Slutsker J, Tsang L, et al. P076 Do prescriptions for expedited partner therapy get filled? findings from a multi-jurisdictional evaluation, US, 2017–2018. Sex Transm Infect. 2019;95:A107.
  124. Slutsker JS, Tsang LB, Schillinger JA. Do prescriptions for expedited partner therapy for chlamydia get filled? findings from a multi-jurisdictional evaluation, United States, 2017-2019. Sex Transm Dis. 2020;47:376–82.
  125. Golden MR, Whittington WL, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med. 2005;352:676–85.
  126. Schillinger JA, Kissinger P, Calvet H, et al. Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women: a randomized, controlled trial. Sex Transm Dis. 2003;30(1):49–56.
  127. Kissinger P, Mohammed H, Richardson-Alston G, et al. Patient-delivered partner treatment for male urethritis: a randomized, controlled trial. Clin Infect Dis. 2005;41(5):623–9.
  128. Cameron ST, Glasier A, Scott G, et al. Novel interventions to reduce re-infection in women with chlamydia: a randomized controlled trial. Hum Reprod. 2009;24:888–95.
  129. Kissinger P, Schmidt N, Mohammed H, et al. Patient-delivered partner treatment for Trichomonas vaginalis infection: a randomized controlled trial. Sex Transm Dis. 2006;33:445–50.
  130. Schwebke JR, Desmond RA. A randomized controlled trial of partner notification methods for prevention of trichomoniasis in women. Sex Transm Dis. 2010;37:392–6.
  131. Stephens SC, Bernstein KT, Katz MH, Philip SS, Klausner JD. The effectiveness of patient-delivered partner therapy and chlamydial and gonococcal reinfection in San Francisco. Sex Transm Dis. 2010;37:525–9.
  132. Kerani RP, Fleming M, DeYoung B, Golden MR. A randomized, controlled trial of inSPOT and patient-delivered partner therapy for gonorrhea and chlamydial infection among men who have sex with men. Sex Transm Dis. 2011;38:941–6.
  133. Stekler J, Bachmann L, Brotman RM, et al. Concurrent sexually transmitted infections (STIs) in sex partners of patients with selected STIs: implications for patient-delivered partner therapy. Clin Infect Dis. 2005;40:787–93.
  134. McNulty A, the MF, Freedman E. Patient delivered partner therapy for chlamydial infection–what would be missed? Sex Transm Dis. 2008;35:834–6.
  135. Schillinger J, Jamison K, Slutsker J, et al. STI and HIV infections among MSM reporting exposure to gonorrhea or chlamydia: implications for expedited partner therapy. Sex Transm Infect. 2019;95:A107.
  136. Turner AN, Feldblum PJ, Hoke TH. Baseline infection with a sexually transmitted disease is highly predictive of reinfection during follow-up in Malagasy sex workers. Sex Transm Dis. 2010;37:559–62.
  137. Peterman TA, Tian LH, Metcalf CA, et al. High incidence of new sexually transmitted infections in the year following a sexually transmitted infection: a case for rescreening. Ann Intern Med. 2006;145:564–72.
  138. US Preventive Services Task Force; Owens DK, Davidson KW, et al. Screening for HIV infection: US Preventive Services Task Force recommendation statement. JAMA. 2019;321(23):2326–36.
  139. Health and Human Services Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States [Internet]. US Department of Health and Human Services, AIDSinfo [cited 2020]. 380 p. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdfpdf iconexternal icon
  140. Committee on Obstetric Practice HIV Expert Work Group. ACOG Committee opinion no. 752: prenatal and perinatal human immunodeficiency virus testing. Obstet Gynecol. 2018;132(3):e138–42.
  141. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2018 [Internet]. Atlanta (GA): U.S. Department of Health and Human Services, CDC; 2019. 176 p. Available from: https://www.cdc.gov/std/stats18/STDSurveillance2018-full-report.pdfpdf icon
  142. Warren HP, Cramer R, Kidd S, Leichliter JS. State requirements for prenatal syphilis screening in the United States, 2016. Matern Child Health J. 2018;22(9):1227–32.
  143. Lin JS, Eder M, Bean S. Screening for syphilis infection in pregnant women: a reaffirmation evidence update for the U.S. Preventive Services Task Force. Evidence Synthesis No. 167. AHRQ Publication No. 18-05238-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2018.
  144. Neblett Fanfair R, Tao G, Owusu-Edusei K, Gift TL, Bernstein KT. Suboptimal prenatal syphilis testing among commercially insured women in the United States, 2013. Sex Transm Dis. 2017;44(4):219–21.
  145. Patel CG, Huppert JS, Tao G. Provider adherence to syphilis testing recommendations for women delivering a stillbirth. Sex Transm Dis. 2017;44(11):685–90.
  146. Matthias JM, Rahman MM, Newman DR, Peterman TA. Effectiveness of prenatal screening and treatment to prevent congenital syphilis, Louisiana and Florida, 2013–2014. Sex Transm Dis. 2017;44(8):498–502.
  147. Albright CM, Emerson JB, Werner EF, Hughes BL. Third-trimester prenatal syphilis screening: a cost-effectiveness analysis. Obstet Gynecol. 2015;126(3):479–85.
  148. US Preventive Services Task Force; Owens DK, Davidson KW, et al. Screening for hepatitis B virus infection in pregnant women: US Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2019;322(4):349–54.
  149. LeFevre ML; U.S. Preventive Services Task Force. Screening for Chlamydia and gonorrhea: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161(12):902–10.
  150. Watts T, Stockman L, Martin J, Guilfoyle S, Vergeront JM. Increased risk for mother-to-infant transmission of hepatitis C virus among Medicaid recipients – Wisconsin, 2011–2015. MMWR Morb Mortal Wkly Rep. 2017;66(42):1136–9.
  151. Patrick SW, Bauer AM, Warren MD, Jones TF, Wester C. Hepatitis C virus infection among women giving birth – Tennessee and United States, 2009–2014. MMWR Morb Mortal Wkly Rep. 2017;66(18):470–3.
  152. Chappell CA, Hillier SL, Crowe D, Meyn LA, Bogen DL, Krans EE. Hepatitis C virus screening among children exposed during pregnancy. Pediatrics. 2018;141(6): e20173273.
  153. Gowda C, Kennedy S, Glover C, Prasad MR, Wang L, Honegger JR. Enhanced identification of maternal hepatitis C virus infection using existing public health surveillance systems. Paediatr Perinat Epidemiol. 2018;32(4):401–10.
  154. Waruingi W, Mhanna MJ, Kumar D, Abughali N. Hepatitis C virus universal screening versus risk based selective screening during pregnancy. J Neonatal Perinatal Med. 2015;8(4):371–8.
  155. Boudova S, Mark K, El-Kamary SS. Risk-based hepatitis C screening in pregnancy is less reliable than universal screening: a retrospective chart review. Open Forum Infect Dis. 2018;5(3):ofy043.
  156. Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC recommendations for hepatitis C screening among adults – United States, 2020. MMWR Recomm Rep. 2020;69(2):1–17.
  157. Moyer VA; U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(5):349–57.
  158. Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020;24(2):102–31.
  159. US Preventive Services Task Force, Owens DK, Davidson KW, et al. Screening for bacterial vaginosis in pregnant persons to prevent preterm delivery: US Preventive Services Task Force recommendation statement. JAMA. 2020;323(13):1286–92.
  160. American Academy of Pediatrics: Committee on Fetus and Newborn; American College of Obstetrics and Gynecology: Committee on Obstetric Practice. Guidelines for Perinatal Care. Kilpatrick SJ, Papile LA, editors; Macones GA, Watterberg KL, associate editors. 8th ed. [place unknown]: AAP, ACOG; 2017.
  161. US Preventive Services Task Force; Curry SJ, Krist AH, et al. Screening for syphilis infection in pregnant women: US Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2018;320(9):911–7.
  162. US Preventive Services Task Force; Bibbins-Domingo K, Grossman DC, et al. Serologic screening for genital herpes infection: US Preventive Services Task Force recommendation statement. JAMA. 2016;316(23):2525–30.
  163. Selph SS, Bougatsos C, Dana T, Grusing S, and Chou R. Screening for HIV infection in pregnant women: a systematic review for the U.S. Preventive Services Task Force. JAMA. 2019;321(23):2349–60.
  164. Henderson JT, Webber EM, Bean SI. Screening for hepatitis B virus infection in pregnant women: an updated systematic review for the U.S. Preventive Services Task Force. JAMA. 2019;322(4):360–2.
  165. Leichliter JS, Dittus PJ, Copen CE, Aral SO. Trends in factors indicating increased risk for STI among key subpopulations in the United States, 2002–2015. Sex Transm Infect, 2019.
  166. Blythe MJ, Del Beccaro MA. Standards for health information technology to ensure adolescent privacy. Pediatrics. 2012;130(5):987–90.
  167. American College of Obstetrics and Gynecologists. ACOG Committee opinion no. 599: Committee on Adolescent Health Care: adolescent confidentiality and electronic health records. Obstet Gynecol. 2014;123(5):1148–50.
  168. Thompson LA, Martinko T, Budd P, Mercado R, Schentrup AM. Meaningful use of a confidential adolescent patient portal. J Adolesc Health. 2016;58(2):134–40.
  169. Society for Adolescent Health and Medicine; American Academy of Pediatrics. Confidentiality protections for adolescents and young adults in the health care billing and insurance claims process. J Adolesc Health. 2016;58(3):374–7.
  170. Bamberger DM, Graham G, Dennis L, Gerkovich MM. Extragenital gonorrhea and chlamydia among men and women according to type of sexual exposure. Sex Transm Dis. 2019;46(5):329–34.
  171. Chan PA, Robinette A, Montgomery M, et al. Extragenital infections caused by chlamydia trachomatis and Neisseria gonorrhoeae: a review of the literature. Infect Dis Obstet Gynecol. 2016;2016:5758387.
  172. Owusu-Edusei K Jr, Hoover KW, Gift TL. Cost-effectiveness of opt-out chlamydia testing for high-risk young women in the U.S. Am J Prev Med. 2016;51(2):216–24.
  173. DiClemente RJ, Sales JM, Danner F, Crosby RA. Association between sexually transmitted diseases and young adults’ self-reported abstinence. Pediatrics. 2011;127(2):208–13.
  174. US Preventive Services Task Force; Curry SJ, Krist AH, et al. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;320(7):674–86.
  175. Committee on Practice Bulletins—Gynecology. Practice Bulletin No. 157: Cervical Cancer Screening and Prevention. Obstet Gynecol. 2016;127(1):e1–20.
  176. Benard VB, Watson M, Castle PE, Saraiya M. Cervical carcinoma rates among young females in the United States. Obstet Gynecol. 2012;120(5):1117–23.
  177. Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70(5):321–46.
  178. US Preventive Services Task Force; Owens DK, Davidson KW, et al. Preexposure prophylaxis for the prevention of HIV infection: US Preventive Services Task Force recommendation statement. JAMA. 2019;321(22):2203–13.
  179. Mayer KH, Bekker LG, Stall R, Grulich AE, Colfax G, Lama JR. Comprehensive clinical care for men who have sex with men: an integrated approach. Lancet. 2012;380:378–87.
  180. Buchbinder SP, Vittinghoff E, Heagerty PJ, et al. Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2005;39(1):82–9.
  181. Paz-Bailey G, Mendoza MC, Finlayson T, et al. Trends in condom use among MSM in the United States: the role of antiretroviral therapy and seroadaptive strategies. AIDS. 2016;30(12):1985–90.
  182. Spicknall IH, Gift TL, Bernstein KT, Aral SO. Sexual networks and infection transmission networks among men who have sex with men as causes of disparity and targets of prevention. Sex Transm Infect. 2017;93(5):307–8.
  183. Glick SN, Morris M, Foxman B, et al. A comparison of sexual behavior patterns among men who have sex with men and heterosexual men and women. J Acquir Immune Defic Syndr. 2012;60(1):83–90.
  184. Goodreau SM, Golden MR. Biological and demographic causes of high HIV and sexually transmitted disease prevalence in men who have sex with men. Sex Transm Infect. 2007;83(6):458–62.
  185. Chew Ng RA, Samuel MC, Lo T, et al. Sex, drugs (methamphetamines), and the Internet: increasing syphilis among men who have sex with men in California, 2004–2008. Am J Public Health. 2013;103:1450–6.
  186. Bernstein KT, Stephens SC, Strona FV, Kohn RP, Philip SS. Epidemiologic characteristics of an ongoing syphilis epidemic among men who have sex with men, San Francisco. Sex Transm Dis. 2013;40:11–17.
  187. Cohen SE, Chew Ng RA, Katz KA, et al. Repeat syphilis among men who have sex with men in California, 2002–2006: implications for syphilis elimination efforts. Am J Public Health. 2012;102:e1–8.
  188. Kirkcaldy RD, Harvey A, Papp JR, et al. Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance – The Gonococcal Isolate Surveillance Project, 27 sites, United States, 2014. MMWR Surveill Summ. 2016;65(7):1–19.
  189. Kirkcaldy RD, Zaidi A, Hook EW 3rd, et al. Neisseria gonorrhoeae antimicrobial resistance among men who have sex with men and men who have sex exclusively with women: the Gonococcal Isolate Surveillance Project, 2005–2010. Ann Intern Med. 2013;158(5 Pt 1):321–8.
  190. Newman LM, Dowell D, Bernstein K, et al. A tale of two gonorrhea epidemics: results from the STD Surveillance Network. Public Health Rep. 2012;127(3):282–92.
  191. Hess KL, Hu X, Lansky A, Mermin J, Hall HI. Lifetime risk of a diagnosis of HIV infection in the United States. Ann Epidemiol. 2017;27(4):238–43.
  192. Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J. Estimating per-act HIV transmission risk: a systematic review. AIDS. 2014;28(10):1509–19.
  193. Koblin BA, Husnik MJ, Colfax G, et al. Risk factors for HIV infection among men who have sex with men. AIDS. 2006;20(5):731–9.
  194. Ackers ML, Greenberg AE, Lin CY, et al. High and persistent HIV seroincidence in men who have sex with men across 47 U.S. cities. PLoS One. 2012;7(4):e34972.
  195. Zetola NM, Bernstein KT, Wong E, Louie B, Klausner JD. Exploring the relationship between sexually transmitted diseases and HIV acquisition by using different study designs. J Acquir Immune Defic Syndr. 2009;50:546–51.
  196. Solomon MM, Mayer KH, Glidden DV, et al. Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial. Clin Infect Dis. 2014;59:1020–6.
  197. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect. 1999;75:3–17.
  198. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006;20(1):73–83.
  199. Reynolds SJ, Risbud AR, Shepherd ME, et al. High rates of syphilis among STI patients are contributing to the spread of HIV-1 in India. Sex Transm Infect. 2006;82(2):121–6.
  200. Hoots BE, Wejnert C, Martin A, et al. Undisclosed HIV infection among MSM in a behavioral surveillance study. AIDS. 2019;33(5):913–8.
  201. Dolling DI, Desai M, McOwan A, et al. An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis. Trials. 2016;17:163.
  202. Oldenburg CE, Nunn AS, Montgomery M, et al. Behavioral changes following uptake of HIV pre-exposure prophylaxis among men who have sex with men in a clinical setting. AIDS Behav. 2018;22(4):1075–9.
  203. Montano MA, Dombrowski JC, Dasgupta S, et al. Changes in sexual behavior and STI diagnoses among MSM initiating PrEP in a clinic setting. AIDS Behav. 2019;23(2):548-55.
  204. Traeger MW, Schroeder SE, Wright EJ, et al. Effects of pre-exposure prophylaxis for the prevention of human immunodeficiency virus infection on sexual risk behavior in men who have sex with men: a systematic review and meta-analysis. Clin Infect Dis. 2018;67(5):676–86.
  205. Jenness SM, Weiss KM, Goodreau SM, et al. Incidence of gonorrhea and chlamydia following human immunodeficiency virus preexposure prophylaxis among men who have sex with men: a modeling study. Clin Infect Dis. 2017;65(5):712–8.
  206. Tang EC, Vittinghoff E, Philip SS, et al. Quarterly screening optimizes detection of sexually transmitted infections when prescribing HIV pre-exposure prophylaxis. AIDS, 2020. Epub ahead of print. PMID: 32205724.
  207. Barbee LA, Khosropour CM, Dombrowksi JC, Golden MR. New human immunodeficiency virus diagnosis independently associated with rectal gonorrhea and chlamydia in men who have sex with men. Sex Transm Dis. 2017;44(7):385–9.
  208. Bernstein KT, Marcus JL, Nieri G, Philip SS, Klausner JD. Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion. J Acquir Immune Defic Syndr. 2010;53:537–43.
  209. Barbee LA, Khosropour CM, Dombrowski JC, Manhart LE, Golden MR. An estimate of the proportion of symptomatic gonococcal, chlamydial and non-gonococcal non-chlamydial urethritis attributable to oral sex among men who have sex with men: a case-control study. Sex Transm Infect. 2016;92(2):155–60.
  210. Lafferty WE, Hughes JP, Handsfield HH. Sexually transmitted diseases in men who have sex with men. Acquisition of gonorrhea and nongonococcal urethritis by fellatio and implications for STD/HIV prevention. Sex Transm Dis. 1997;24:272–8.
  211. Bernstein KT, Stephens SC, Barry PM, et al. Chlamydia trachomatis and Neisseria gonorrhoeae transmission from the oropharynx to the urethra among men who have sex with men. Clin Infect Dis. 2009;49:1793–7.
  212. Patton ME, Kidd S, Llata E, et al. Extragenital gonorrhea and chlamydia testing and infection among men who have sex with men–STD Surveillance Network, United States, 2010-2012. Clin Infect Dis. 2014;58(11):1564–70.
  213. Kent CK, Chaw JK, Wong W, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis. 2005;41(1):67–74.
  214. Koedijk FD, van Bergen JE, Dukers-Muijrers NH, et al. The value of testing multiple anatomic sites for gonorrhoea and chlamydia in sexually transmitted infection centres in the Netherlands, 2006–2010. Int J STD AIDS. 2012;23(9):626–31.
  215. Barbee LA, Dombrowski JC, Kerani R, Golden MR. Effect of nucleic acid amplification testing on detection of extragenital gonorrhea and chlamydial infections in men who have sex with men sexually transmitted disease clinic patients. Sex Transm Dis. 2014;41(3):168–72.
  216. Danby CS, Cosentino LA, Rabe LK, et al. Patterns of extragenital chlamydia and gonorrhea in women and men who have sex with men reporting a history of receptive anal intercourse. Sex Transm Dis. 2016;43(2):105–9.
  217. van der Helm JJ, Hoebe CJ, van Rooijen MS, et al. High performance and acceptability of self-collected rectal swabs for diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in men who have sex with men and women. Sex Transm Dis. 2009;36:493–7.
  218. Alexander S, Ison C, Parry J, et al. Self-taken pharyngeal and rectal swabs are appropriate for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in asymptomatic men who have sex with men. Sex Transm Infect. 2008;84(6):488–92.
  219. Freeman AH, Bernstein KT, Kohn RP, Philip S, Rauch LM, Klausner JD. Evaluation of self-collected versus clinician-collected swabs for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae pharyngeal infection among men who have sex with men. Sex Transm Dis. 2011;38(11):1036–9.
  220. Chesson HW Bernstein KT, Gift TL, Marcus JL, Pipkin S, Kent CK. The cost-effectiveness of screening men who have sex with men for rectal chlamydial and gonococcal infection to prevent HIV infection. Sex Transm Dis. 2013;40:366–71.
  221. Jenness SM, Weiss KM, Prasad P, Zlotorzynska M, Sanchez T. Bacterial sexually transmitted infection screening rates by symptomatic status among men who have sex with men in the United States: a hierarchical Bayesian analysis. Sex Transm Dis. 2019;46(1):25–30.
  222. Hoover KW, Butler M, Workowski K, et al. STD screening of HIV-infected MSM in HIV clinics. Sex Transm Dis. 2010;37(12):771–6.
  223. de Voux A, Bernstein KT, Bradley H, et al. Syphilis testing among sexually active men who have sex with men and who are receiving medical care for human immunodeficiency virus in the United States: Medical Monitoring Project, 2013–2014. Clin Infect Dis. 2019;68(6):934–9.
  224. Gray RT, Hoare A, Prestage GP, Donovan B, Kaldor JM, Wilson DP. Frequent testing of highly sexually active gay men is required to control syphilis. Sex Transm Dis. 2010;37(5):298–305.
  225. Tuite AR, Fisman DN, Mishra S. Screen more or screen more often? Using mathematical models to inform syphilis control strategies. BMC Public Health. 2013;13:606.
  226. Tuite A, Fisman D. Go big or go home: impact of screening coverage on syphilis infection dynamics. Sex Transm Infect. 2016;92(1):49–54.
  227. Tuite AR, Shaw S, Reimer JN, Ross CP, Fisman DN, Mishra S. Can enhanced screening of men with a history of prior syphilis infection stem the epidemic in men who have sex with men? A mathematical modelling study. Sex Transm Infect. 2018;94(2):105–10.
  228. Raifman JR, Gebo KA, Mathews WC, et al. Gonorrhea and chlamydia case detection increased when testing increased in a multisite US HIV cohort, 2004-2014. J Acquir Immune Defic Syndr. 2017;76(4):409–16.
  229. Barbee LA, Dhanireddy S, Tat SA, Marrazzo JM. Barriers to bacterial sexually transmitted infection testing of HIV-infected men who have sex with men engaged in HIV primary care. Sex Transm Dis. 2015;42(10):590–4.
  230. McMillan A, Young H, Moyes A. Rectal gonorrhoea in homosexual men: source of infection. Int J STD AIDS. 2000;11(5):284–7.
  231. Chow EP, Cornelisse VJ, Read TR, Chen MY, Bradshaw CS, Fairley CK. Saliva use in sex: associations with use of smartphone dating applications in men who have sex with men. Int J STD AIDS. 2018;29(4):362–6.
  232. Cornelisse VJ, Priest D, Fairley CK, et al. The frequency of kissing as part of sexual activity differs depending on how men meet their male casual sexual partners. Int J STD AIDS. 2018;29(6):598–602.
  233. US Preventive Services Task Force; Krist AH, Davidson KW, Mangione CM, et al. Screening for hepatitis B virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. 2020;324(23):2415–22.
  234. Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology. 2010;52(4):1497–505.
  235. Wandeler G, Gsponer T, Bregenzer A, et al. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis. 2012;55:1408–16.
  236. Garg S, Taylor LE, Grasso C, Mayer KH. Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center. Clin Infect Dis. 2013;56:1480–7.
  237. Urbanus AT, van de Laar TJ, Stolte IG, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS. 2009;23(12):F1–7.
  238. Linas BP, Wong AY, Schackman BR, Kim AY, Freedberg KA. Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men. Clin Infect Dis. 2012;55:279–90.
  239. Taylor LE, DeLong AK, Maynard MA, et al. Acute hepatitis C virus in an HIV clinic: a screening strategy, risk factors, and perception of risk. AIDS Patient Care and STDS. 2011;25:571–7.
  240. Kaul R, Kimani J, Nagelkerke NJ, et al. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA. 2004;291(21):2555–62.
  241. Ong JJ, Baggaley RC, Wi TE, et al. Global epidemiologic characteristics of sexually transmitted infections among individuals using preexposure prophylaxis for the prevention of HIV infection: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(12):e1917134.
  242. Paz-Bailey G, Hoots BE, Xia M, et al. Trends in internet use among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2017;75 Suppl 3:S288–95.
  243. Badal HJ, Stryker JE, DeLuca N, Purcell DW. Swipe right: dating website and app use among men who have sex with men. AIDS Behav. 2018;22(4):1265–72.
  244. Chan PA, Crowley C, Rose JS, et al. A network analysis of sexually transmitted diseases and online hookup sites among men who have sex with men. Sex Transm Dis. 2018;45(7):462–8.
  245. Beymer MR, Weiss RE, Bolan RK, et al. Sex on demand: geosocial networking phone apps and risk of sexually transmitted infections among a cross-sectional sample of men who have sex with men in Los Angeles County. Sex Transm Infect. 2014;90(7):567–72.
  246. Medina MM, Crowley C, Montgomery MC, et al. Disclosure of HIV serostatus and pre-exposure prophylaxis use on internet hookup sites among men who have sex with men. AIDS Behav. 2019;23(7):1681–8.
  247. Chan PA, Towey C, Poceta J, et al. Online hookup sites for meeting sexual partners among men who have sex with men in Rhode Island, 2013: a call for public health action. Public Health Rep. 2016;131(2):264–71.
  248. Lampkin D, Crawley A, Lopez TP, Mejia CM, Yuen W, Levy V. Reaching suburban men who have sex with men for STD and HIV Services through online social networking outreach: a public health approach. J Acquir Immune Defic Syndr. 2016;72(1):73–8.
  249. Sun CJ, Stowers J, Miller C, Bachmann LH, Rhodes SD. Acceptability and feasibility of using established geosocial and sexual networking mobile applications to promote HIV and STD testing among men who have sex with men. AIDS Behav. 2015;19(3):543–52.
  250. Dritz SK, Back AF. Letter: Shigella enteritis venereally transmitted. N Engl J Med. 1974;291(22):1194.
  251. Aragon TJ, Vugia DJ, Shallow S, et al. Case-control study of shigellosis in San Francisco: the role of sexual transmission and HIV infection. Clin Infect Dis. 2007;44(3):327–34.
  252. Simms I, Field N, Jenkins C, et al. Intensified shigellosis epidemic associated with sexual transmission in men who have sex with men–Shigella flexneri and S. sonnei in England, 2004 to end of February 2015. Euro Surveill. 2015;20(15):pii=21097.
  253. Gilbart VL, Simms I, Jenkins C, et al. Sex, drugs and smart phone applications: findings from semistructured interviews with men who have sex with men diagnosed with Shigella flexneri 3a in England and Wales. Sex Transm Infect. 2015;91(8):598–602.
  254. Narayan S1, Galanis E2; BC STEI Group. Are enteric infections sexually transmitted in British Columbia? Can Commun Dis Rep. 2016;42(2):24–9.
  255. Mohan K, Hibbert M, Rooney G, et al. What is the overlap between HIV and shigellosis epidemics in England: further evidence of MSM transmission? Sex Transm Infect. 2018;94(1):67–71.
  256. Hughes G, Silalang P, Were J, et al. Prevalence and characteristics of gastrointestinal infections in men who have sex with men diagnosed with rectal chlamydia infection in the UK: an ‘unlinked anonymous’ cross-sectional study. Sex Transm Infect. 2018;94(7):518–21.
  257. O’Sullivan B, Delpech V, Pontivivo G, et al. Shigellosis linked to sex venues, Australia. Emerg Infect Dis. 2002;8(8):862–4.
  258. Marcus U, Zucs P, Bremer V, et al. Shigellosis – a re-emerging sexually transmitted infection: outbreak in men having sex with men in Berlin. Int J STD AIDS. 2004;15(8):533–7.
  259. Danila RN, Eikmeier DL, Robinson TJ, La Pointe A, DeVries AS. Two concurrent enteric disease outbreaks among men who have sex with men, Minneapolis-St. Paul area. Clin Infect Dis. 2014;59(7):987–9.
  260. Okame M, Adachi E, Sato H, et al. Shigella sonnei outbreak among men who have sex with men in Tokyo. Jpn J Infect Dis. 2012;65(3):277–8.
  261. Wilmer A, Romney MG, Gustafson R, et al. Shigella flexneri serotype 1 infections in men who have sex with men in Vancouver, Canada. HIV Med. 2015;16(3):168–75.
  262. Centers for Disease Control and Prevention. Shigella sonnei outbreak among men who have sex with men–San Francisco, California, 2000–2001. MMWR Morb Mortal Wkly Rep. 2001;50(42):922–6.
  263. Baer JT, Vugia DJ, Reingold AL, Aragon T, Angulo FJ, Bradford WZ. HIV infection as a risk factor for shigellosis. Emerg Infect Dis. 1999;5(6):820–3.
  264. Simms I, Gilbart VL, Byrne L, et al. Identification of verocytotoxin-producing Escherichia coli O117:H7 in men who have sex with men, England, November 2013 to August 2014. Euro Surveill. 2014;19(43):pii=20946.
  265. Quinn TC, Goodell SE, Fennell C, et al. Infections with Campylobacter jejuni and Campylobacter-like organisms in homosexual men. Ann Intern Med. 1984;101(2):187–192.
  266. Gaudreau C, Pilon PA, Sylvestre J-L, Boucher F, Bekal S. Multidrug-Resistant Campylobacter coli in men who have sex with men, Quebec, Canada, 2015. Emerg Infect Dis. 2016;22(9):1661–3.
  267. Chen GJ, Lin KY, Hung CC, Chang SC. Hepatitis A outbreak among men who have sex with men in a country of low endemicity of hepatitis A infection. J Infect Dis. 2017;215(8):1339–40.
  268. Lo YC, Ji DD, Hung CC. Prevalent and incident HIV diagnoses among Entamoeba histolytica-infected adult males: a changing epidemiology associated with sexual transmission–Taiwan, 2006–2013. PLoS Negl Trop Dis. 2014;8(10):e3222.
  269. Stark D, van Hal SJ, Matthews G, Harkness J, Marriott D. Invasive amebiasis in men who have sex with men, Australia. Emerg Infect Dis. 2008;14(7):1141–3.
  270. Mitchell H, Hughes G. Recent epidemiology of sexually transmissible enteric infections in men who have sex with men. Curr Opin Infect Dis. 2018;31(1):50–6.
  271. Weatherburn P, Hickson F, Reid D, Torres-Rueda S, Bourne A. Motivations and values associated with combining sex and illicit drugs (‘chemsex’) among gay men in South London: findings from a qualitative study. Sex Transm Infect. 2017;93(3):203–6.
  272. Baker KS, Dallman TJ, Ashton PM, et al. Intercontinental dissemination of azithromycin-resistant shigellosis through sexual transmission: a cross-sectional study. Lancet Infect Dis. 2015;15(8):913–21.
  273. Bowen A, Grass J, Bicknese A, Campbell D, Hurd J, Kirkcaldy RD. Elevated risk for antimicrobial drug-resistant Shigella infection among men who have sex with men, United States, 2011-2015. Emerg Infect Dis. 2016;22(9):1613–6.
  274. Gaudreau C, Rodrigues-Coutlée S, Pilon PA, Coutlée F, Bekal S. Long-lasting outbreak of erythromycin- and ciprofloxacin-resistant Campylobacter jejuni subspecies jejuni from 2003 to 2013 in men who have sex with men, Quebec, Canada. Clin Infect Dis. 2015;61(10):1549–52.
  275. Muzny CA, Sunesara IR, Martin DH, Mena LA. Sexually transmitted infections and risk behaviors among African American women who have sex with women: does sex with men make a difference? Sex Transm Dis. 2011;38:1118–25.
  276. Eisenberg M. Differences in sexual risk behaviors between college students with same-sex and opposite-sex experience: results from a national survey. Arch Sex Behav. 2001;30:575–89.
  277. Koh AS, Gómez CA, Shade S, Rowley E. Sexual risk factors among self-identified lesbians, bisexual women, and heterosexual women accessing primary care settings. Sex Transm Dis. 2005;32:563–9.
  278. Goodenow C, Szalacha LA, Robin LE, Westheimer K. Dimensions of sexual orientation and HIV-related risk among adolescent females: evidence from a statewide survey. Am J Public Health. 2008;98:1051–8.
  279. Muzny CA, Austin EL, Harbison HS, Hook EW 3rd. Sexual partnership characteristics of African American women who have sex with women; impact on sexually transmitted infection risk. Sex Transm Dis. 2014;41(10):611–7.
  280. Riskind RG, Tornello SL, Younger BC, Patterson CJ. Sexual identity, partner gender, and sexual health among adolescent girls in the United States. Am J Public Health. 2014;104(10):1957–63.
  281. Schick V, Rosenberger JG, Herbenick D, Reece M. Sexual behaviour and risk reduction strategies among a multinational sample of women who have sex with women. Sex Transm Infect. 2012;88:407–12.
  282. Richters J, Prestage G, Schneider K, Clayton S. Do women use dental dams? Safer sex practices of lesbians and other women who have sex with women. Sex Health. 2010;7:165–9.
  283. Rowen TS, Breyer BN, Lin TC, Li CS, Robertson PA, Shindel AW. Use of barrier protection for sexual activity among women who have sex with women. Int J Gynaecol Obstet. 2013;120:42–5.
  284. Lindley LL, Friedman DB, Struble C. Becoming visible: assessing the availability of online sexual health information for lesbians. Health Promot Pract. 2012;13:472–80.
  285. Chetcuti N, Beltzer N, Methy N, et al. Preventive care’s forgotten women: life course, sexuality, and sexual health among homosexually and bisexually active women in France. J Sex Res. 2013;50(6):587–97.
  286. Logie CH, Navia D, Loutfy MR. Correlates of a lifetime history of sexually transmitted infections among women who have sex with women in Toronto, Canada: results from a cross-sectional internet-based survey. Sex Transm Infect. 2015;91(4):278–83.
  287. Muzny CA, Harbison HS, Pembleton ES, Austin EL. Sexual behaviors, perception of sexually transmitted infection risk, and practice of safe sex among southern African American women who have sex with women. Sex Transm Dis. 2013;40(5):395–400.
  288. Przedworski JM, McAlpine DD, Karaca-Mandic P, VanKim NA. Health and health risks among sexual minority women: an examination of 3 subgroups. Am J Public Health. 2014;104(6):1045–7.
  289. Brenick A, Romano K, Kegler C, Eaton LA. Understanding the influence of stigma and medical mistrust on engagement in routine healthcare among Black women who have sex with women. LGBT Health. 2017;4(1):4–10.
  290. Fethers K, Marks C, Mindel A, Estcourt CS. Sexually transmitted infections and risk behaviours in women who have sex with women. Sex Transm Infect. 2000;76:345–9.
  291. Marrazzo JM, Koutsky LA, Eschenbach DA, Agnew K, Stine K, Hillier SL. Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. J Infect Dis. 2002;185:1307–13.
  292. Kellock D, O’Mahony CP. Sexually acquired metronidazole-resistant trichomoniasis in a lesbian couple. Genitourin Med. 1996;72:60–1.
  293. Muzny CA, Rivers CA, Mena LA, Schwebke JR. Genotypic characterization of Trichomonas vaginalis isolates among women who have sex with women in sexual partnerships. Sex Transm Dis. 2012;39:556–8.
  294. Chan SK, Thornton LR, Chronister KJ, et al. Likely female-to-female sexual transmission of HIV–Texas, 2012. MMWR Morb Mortal Wkly Rep. 2014;63(10):209–12.
  295. Kwakwa HA, Ghobrial MW. Female-to-female transmission of human immunodeficiency virus. Clin Infect Dis. 2003;36:e40–1.
  296. Marrazzo JM, Handsfield HH, Whittington WL. Predicting chlamydial and gonococcal cervical infection: implications for management of cervicitis. Obstet Gynecol. 2002;100:579–84.
  297. Diamant AL, Schuster MA, McGuigan K, Lever J. Lesbians’ sexual history with men: implications for taking a sexual history. Arch Intern Med. 1999;159:2730–6.
  298. Xu F, Sternberg MR, Markowitz LE. Women who have sex with women in the United States: prevalence, sexual behavior and prevalence of herpes simplex virus type 2 infection-results from national health and nutrition examination survey 2001-2006. Sex Transm Dis. 2010;37:407–13.
  299. Everett BG, Higgins JA, Haider S, Carpenter E. Do sexual minorities receive appropriate sexual and reproductive health care and counseling? J Womens Health (Larchmt). 2019;28(1):53–62.
  300. Marrazzo JM, Koutsky LA, Stine KL, et al. Genital human papillomavirus infection in women who have sex with women. J Infect Dis. 1998;178:1604–9.
  301. Marrazzo JM, Koutsky LA, Kiviat NB, Kuypers JM, Stine K. Papanicolaou test screening and prevalence of genital human papillomavirus among women who have sex with women. Am J Public Health. 2001;91:947–52.
  302. Bailey JV, Kavanagh J, Owen C, McLean KA, Skinner CJ. Lesbians and cervical screening. Br J Gen Pract. 2000;50:481–2.
  303. Anderson TA, Schick V, Herbenick D, Dodge B, Fortenberry JD. A study of human papillomavirus on vaginally inserted sex toys, before and after cleaning, among women who have sex with women and men. Sex Transm Infect. 2014;90(7):529–31.
  304. Marrazzo JM, Stine K, Wald A. Prevalence and risk factors for infection with herpes simplex virus type-1 and -2 among lesbians. Sex Transm Dis. 2003;30(12):890–5.
  305. Muzny CA, Kapil R, Austin EL, Hook EW, Geisler WM. Lower sexually transmissible infection prevalence among lifetime exclusive women who have sex with women compared with women who have sex with women and men. Sex Health. 2014;11(6):592–3.
  306. Muzny CA, Schwebke JR. The clinical spectrum of Trichomonas vaginalis infection and challenges to management. Sex Transm Infect. 2013;89(6):423–5.
  307. Muzny CA, Blackburn RJ, Sinsky RJ, Austin EL, Schwebke JR. Added benefit of nucleic acid amplification testing for the diagnosis of Trichomonas vaginalis among men and women attending a sexually transmitted diseases clinic. Clin Infect Dis. 2014;59(6):834–41.
  308. Singh D, Fine DN, Marrazzo JM. Chlamydia trachomatis infection among women reporting sexual activity with women screened in family planning clinics in the Pacific Northwest, 1997 to 2005. Am J Public Health. 2011;101:1284–90.
  309. Muzny CA, Kapil R, Austin EL, Brown L, Hook EW 3rd, Geisler WM. Chlamydia trachomatis infection in African American women who exclusively have sex with women. Int J STD AIDS. 2016;27(11):978–83.
  310. Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis. 2007;34(11):864–9.
  311. Evans AL, Scally AJ, Wellard SJ, Wilson JD. Prevalence of bacterial vaginosis in lesbians and heterosexual women in a community setting. Sex Transm Infect. 2007;83:470–5.
  312. Olson KM, Boohaker LJ, Schwebke JR, Aslibekyan S, Muzny CA. Comparisons of vaginal flora patterns among sexual behaviour groups of women: implications for the pathogenesis of bacterial vaginosis. Sex Health. 2018;15(1):61–7.
  313. Muzny CA, Lensing SY, Aaron KJ, Schwebke JR. Incubation period and risk factors support sexual transmission of bacterial vaginosis in women who have sex with women. Sex Transm Infect. 2019;95(7):511–5.
  314. Bradshaw CS, Walker SM, Vodstrcil LA, et al. The influence of behaviors and relationships on the vaginal microbiota of women and their female partners: the WOW Health Study. J Infect Dis. 2014;209(10):1562–72.
  315. Marrazzo JM, Antonio M, Agnew K, Hillier SL. Distribution of genital Lactobacillus strains shared by female sex partners. J Infect Dis. 2009;199:680–3.
  316. Marrazzo JM, Fiedler TL, Srinivasan S, et al. Extravaginal reservoirs of vaginal bacteria as risk factors for incident bacterial vaginosis. J Infect Dis. 2012;205:1580–8.
  317. Mitchell C, Manhart LE, Thomas K, Fiedler T, Fredricks DN, Marrazzo J. Behavioral predictors of colonization with Lactobacillus crispatus or Lactobacillus jensenii after treatment for bacterial vaginosis: a cohort study. Infect Dis Obstet Gynecol. 2012;2012:706540.
  318. Mitchell C, Manhart LE, Thomas KK, Agnew K, Marrazzo JM. Effect of sexual activity on vaginal colonization with hydrogen peroxide-producing Lactobacilli and Gardnerella vaginalis. Sex Transm Dis. 2011;38:1137–44.
  319. Fethers K, Twin J, Fairley CK, et al. Bacterial vaginosis (BV) candidate bacteria: associations with BV and behavioural practices in sexually-experienced and inexperienced women. PLoS One. 2012;7:e30633.
  320. Bradshaw CS, Vodstrcil LA, Hocking JS, et al. Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. Clin Infect Dis. 2013;56:777–86.
  321. Marrazzo JM, Thomas KK, Fiedler TL, Ringwood K, Fredricks DN. Risks for acquisition of bacterial vaginosis among women who report sex with women: a cohort study. PLoS One. 2010;5:e11139.
  322. Vodstrcil LA, Walker SM, Hocking JS, et al. Incident bacterial vaginosis (BV) in women who have sex with women is associated with behaviors that suggest sexual transmission of BV. Clin Infect Dis. 2015;60(7):1042–53.
  323. Muzny CA, Blanchard E, Taylor CM, et al. Identification of key bacteria involved in the induction of incident bacterial vaginosis: a prospective study. J Infect Dis. 2018;218(6):966–78.
  324. Marrazzo JM, Thomas KK, Ringwood K. A behavioural intervention to reduce persistence of bacterial vaginosis among women who report sex with women: results of a randomised trial. Sex Transm Infect. 2011;87(5):399–405.
  325. Bradshaw CS, Walker J, Fairley CK, et al. Prevalent and incident bacterial vaginosis are associated with sexual and contraceptive behaviours in young Australian women. PLoS One. 2013;8(3):e57688.
  326. Poteat T, Reisner SL, Radix A. HIV epidemics among transgender women. Curr Opin HIV AIDS. 2014;9(2):168–73.
  327. White Hughto JM, Reisner SL, Pachankis JE. Transgender stigma and health: a critical review of stigma determinants, mechanisms, and interventions. Soc Sci Med. 2015;147:222–31.
  328. Radix AE, Lelutiu-Weinberger C, Gamarel KE. Satisfaction and healthcare utilization of transgender and gender non-conforming individuals in NYC: a community-based participatory study. LGBT Health. 2014;1(4):302–8.
  329. Rapues J, Wilson EC, Packer T, Colfax GN, Raymond HF. Correlates of HIV infection among transfemales, San Francisco, 2010: results from a respondent-driven sampling study. Am J Public Health. 2013;103(8):1485–92.
  330. Sevelius JM, Patouhas E, Keatley JG, Johnson MO. Barriers and facilitators to engagement and retention in care among transgender women living with human immunodeficiency virus. Ann Behav Med. 2013;47(1):5–16.
  331. Sevelius JM. Gender affirmation: a framework for conceptualizing risk behavior among transgender women of color. Sex Roles. 2013;68(11-12):675–89.
  332. Reisner SL, White Hughto JM, Pardee D, Sevelius J. Syndemics and gender affirmation: HIV sexual risk in female-to-male trans masculine adults reporting sexual contact with cisgender males. Int J STD AIDS. 2016;27(11):955–66.
  333. Coleman E, Bockting W, Botzer M, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgend. 2012;13(4):165.
  334. Winter S, Diamond M, Green J, et al. Transgender people: health at the margins of society. Lancet. 2016;388(10042):390–400.
  335. Cahill S, Singal R, Grasso C, et al. Do ask, do tell: high levels of acceptability by patients of routine collection of sexual orientation and gender identity data in four diverse American community health centers. PLoS One. 2014;9(9):e107104.
  336. Cahill SR, Baker K, Deutsch MB, Keatley J, Makadon HJ. Inclusion of sexual orientation and gender identity in Stage 3 Meaningful Use Guidelines: a huge step forward for LGBT health. LGBT Health. 2016;3(2):100–2.
  337. Tordoff DM, Morgan J, Dombrowski JC, Golden MR, Barbee LA. increased ascertainment of transgender and non-binary patients using a 2-step versus 1-step gender identity intake question in an STD clinic setting. Sex Transm Dis. 2019;46(4):254–9.
  338. Grant JM, Mottet LA, Tanis J. National transgender discrimination survey report on health and health care. 2010: Washington, D.C.
  339. Jaffee KD, Shires DA, Stroumsa D. Discrimination and delayed health care among transgender women and men: implications for improving medical education and health care delivery. Med Care. 2016;54(11):1010–6.
  340. Glick JL, Theall KP, Andrinopoulos KM, Kendall C. The role of discrimination in care postponement among trans-feminine individuals in the U.S. National Transgender Discrimination Survey. LGBT Health. 2018;5(3):171–9.
  341. Callander D, Cook T, Cornelisse V, et al. Trans and gender diverse people’s experiences of sexual health care are associated with sexual health screening uptake. Sex Transm Infect. 2019;95(Suppl 1):A64.
  342. Casey LS, Reisner SL, Findling MG, et al., Discrimination in the United States: experiences of lesbian, gay, bisexual, transgender, and queer Americans. Health Serv Res. 2019;54 Suppl 2(Suppl 2):1454–66.
  343. Potter J, Peitzmeier SM, Bernstein I, et al. Cervical cancer screening for patients on the female-to-male spectrum: a narrative review and guide for clinicians. J Gen Intern Med. 2015;30(12):1857–64.
  344. Becasen JS, Denard CL, Mullins MM, Higa DH, Sipe TA. Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta-analysis, 2006-2017. Am J Public Health. 2019;109(1):e1–8.
  345. Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13:214–22.
  346. Allan-Blitz LT, Konda KA, Calvo GM, et al. High incidence of extra-genital gonorrheal and chlamydial infections among high-risk men who have sex with men and transgender women in Peru. Int J STD AIDS. 2018;29(6):568–76.
  347. Hiransuthikul A, Janamnuaysook R, Sungsing T, et al. High burden of chlamydia and gonorrhoea in pharyngeal, rectal and urethral sites among Thai transgender women: implications for anatomical site selection for the screening of STI. Sex Transm Infect. 2019;95(7):534–539.
  348. Kojima N, Park H, Konda KA, et al. The PICASSO Cohort: baseline characteristics of a cohort of men who have sex with men and male-to-female transgender women at high risk for syphilis infection in Lima, Peru. BMC Infect Dis. 2017;17(1):255.
  349. Pitasi MA, Kerani RP, Kohn R, et al. Chlamydia, gonorrhea, and human immunodeficiency virus infection among transgender women and transgender men attending clinics that provide sexually transmitted disease services in six US cities: results from the Sexually Transmitted Disease Surveillance Network. Sex Transm Dis. 2019;46(2):112–117.
  350. James S, Herman J L, Rankin S, Keisling M, Mottet L, Anafi M. The report of the 2015 US transgender survey. Washington, DC: National Center for Transgender Equality; 2016. 297 p.
  351. Hadj-Moussa M, Ohl DA, Kuzon WM Jr. Feminizing genital gender-confirmation surgery. Sex Med Rev. 2018;6(3):457–68.e2.
  352. Salgado CJ, Nugent A, Kuhn J, Janette M, Bahna H. Primary sigmoid vaginoplasty in transwomen: technique and outcomes. Biomed Res Int. 2018;2018:4907208.
  353. Radix AE, Harris AB, Belking U, Ting J, Goldsten ZG. Chlamydia trachomatis infection of the neovagina in transgender women. Open Forum Infect Dis. 2019;6(11):ofz470.
  354. Elfering L, van der Sluis WB, Mermans JF, Buncamper ME. Herpes neolabialis: herpes simplex virus type 1 infection of the neolabia in a transgender woman. Int J STD AIDS. 2017;28(8):841–3.
  355. van der Sluis WB, Buncamper ME, Bouman MB, et al. Prevalence of neovaginal high-risk human papillomavirus among transgender women in the Netherlands. Sex Transm Dis. 2016;43(8):503–5.
  356. Yang C, Liu S, Xu K, Xiang Q, Yang S, Zhang X. Condylomata gigantea in a male transsexual. Int J STD AIDS. 2009;20(3):211–2.
  357. Matsuki S, Kusatake K, Hein KZ, Anraku K, Morita E. Condylomata acuminata in the neovagina after male-to-female reassignment treated with CO2 laser and imiquimod. Int J STD AIDS. 2015;26(7):509–11.
  358. Bodsworth NJ, Price R, Davies SC. Gonococcal infection of the neovagina in a male-to-female transsexual. Sex Transm Dis. 1994;21(4):211–2.
  359. Haustein UF, Hautarzt JD, Zeitschrift V. [Pruritus of the artificial vagina of a transsexual patient caused by gonococcal infection]. Hautarzt. 1995;46(12):858–9. German.
  360. Yamada K, Shida D, Kato T, Yoshida H, Yoshinaga S, Kanemitsu Y. Adenocarcinoma arising in sigmoid colon neovagina 53 years after construction. World J Surg Oncol. 2018;16(1):88.
  361. Hiroi H, Yasugi T, Matsumoto K, et al. Mucinous adenocarcinoma arising in a neovagina using the sigmoid colon thirty years after operation: a case report. J Surg Oncol. 2001;77(1):61–4.
  362. Heller DS. Lesions of the neovagina–a review. J Low Genit Tract Dis. 2015;19(3):267–270.
  363. Scheim AI, Bauer GR, Travers R. HIV-related sexual risk among transgender men who are gay, bisexual, or have sex with men. J Acquir Immune Defic Syndr. 2017;74(4):e89–96.
  364. Sevelius J. “There’s no pamphlet for the kind of sex I have”: HIV-related risk factors and protective behaviors among transgender men who have sex with nontransgender men. J Assoc Nurses AIDS Care. 2009;20(5):398–410.
  365. Pitasi MA, Oraka E, Clark H, Town M, DiNenno EA. HIV testing among transgender women and men — 27 states and Guam, 2014–2015. MMWR Morb Mortal Wkly Rep. 2017;66(33):883–7.
  366. Reisner SL, Perkovich B, Mimiaga MJ. A mixed methods study of the sexual health needs of New England transmen who have sex with nontransgender men. AIDS Patient Care STDS. 2010;24:501–13.
  367. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(11):3869–903.
  368. Deutsch M, editor. Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People [Internet]. San Francisco (CA): UCSF Transgender Care, Department of Family and Community Medicine, University of California San Francisco. 2016 [cited 2020]. 199 p. Available from: https://transcare.ucsf.edu/sites/transcare.ucsf.edu/files/Transgender-PGACG-6-17-16.pdfpdf iconexternal icon; https://transcare.ucsf.edu/guidelinesexternal icon.
  369. Peitzmeier SM, Reisner SL, Harigopal P, Potter J. Female-to-male patients have high prevalence of unsatisfactory Paps compared to non-transgender females: implications for cervical cancer screening. J Gen Intern Med. 2014;29(5):778–84.
  370. Peitzmeier SM, Khullar K, Reisner SL, Potter J. Pap test use is lower among female-to-male patients than non-transgender women. Am J Prev Med. 2014;47(6):808–12.
  371. Reisner SL,Deutsch MB, Peitzmeier SM, et al. Test performance and acceptability of self- versus provider-collected swabs for high-risk HPV DNA testing in female-to-male trans masculine patients. PLoS One. 2018;13(3):e0190172.
  372. Centers for Disease Control and Prevention. Surveillance for Viral Hepatitis–United States, 2017 [Internet]. US Department of Health and Human Services, CDC; 2019 [cited 2020]; 66 p. Available from: https://www.cdc.gov/hepatitis/statistics/2017surveillance/pdfs/2017HepSurveillanceRpt.pdf
  373. Kouyoumdjian FG, Leto D, John S, Henein H, Bondy S. A systematic review and meta-analysis of the prevalence of chlamydia, gonorrhoea and syphilis in incarcerated persons. Int J STD AIDS. 2012;23(4):248–54.
  374. Centers for Disease Control and Prevention. Evaluation of large jail STD screening programs, 2008-2009 [Internet]. Atlanta, GA: US Department of Health and Human Services, CDC, NCHHSTP; 2011; 29 p. Available from: http://www.cdc.gov/std/publications/JailScreening2011.pdfpdf icon
  375. Pathela P, Hennessy RR, Blank S, Parvez F, Franklin W, Schillinger JA. The contribution of a urine-based jail screening program to citywide male Chlamydia and gonorrhea case rates in New York City. Sex Transm Dis. 2009;36(2 Suppl):S58–61.
  376. Joesoef MR, Weinstock HS, Kent CK, et al. Sex and age correlates of Chlamydia prevalence in adolescents and adults entering correctional facilities, 2005: implications for screening policy. Sex Transm Dis. 2009;36(2 Suppl):S67–71.
  377. Blank S, McDonnell DD, Rubin SR, et al. New approaches to syphilis control. Finding opportunities for syphilis treatment and congenital syphilis prevention in a women’s correctional setting. Sex Transm Dis. 1997;24(4):218–26.
  378. Owusu-Edusei K Jr, Gift TL, Chesson HW, Kent CK. Investigating the potential public health benefit of jail-based screening and treatment programs for chlamydia. Am J Epidemiol. 2013;177:463–73.
  379. Centers for Disease Control and Prevention. Male chlamydia consultation, Atlanta, GA, March 28-29, 2006; Meeting report, May 22, 2007 [Internet]. Atlanta, GA: US Department of Health and Human Services, CDC, NCHHSTP, DSTDP; 2007; 11 p. Available from: https://www.cdc.gov/std/chlamydia/chlamydiascreening-males.pdf
  380. Cole J, Hotton A, Zawitz C, Kessler H. Opt-out screening for Chlamydia trachomatis and Neisseria gonorrhoeae in female detainees at Cook County jail in Chicago, IL. Sex Transm Dis. 2014;41(3):161–5.
  381. Shaikh RA, Simonsen KA, O’Keefe A, et al. Comparison of opt-in versus opt-out testing for sexually transmitted infections among inmates in a county jail. J Correct Health Care. 2015;21(4):408–16.
  382. Spaulding AC, Kim MJ, Corpening KT, Carpenter T, Watlington P, Bowden CJ. Establishing an HIV screening program led by staff nurses in a county jail. J Public Health Manag Pract. 2015;21(6):538–45.
  383. Rosen DL, Wohl DA, Golin CE, et al. Comparing HIV case detection in prison during opt-in vs. opt-out testing policies. J Acquir Immune Defic Syndr. 2016;71(3):e85–8.
  384. Gratrix J, Smyczek P, Bertholet L, et al. A cross-sectional evaluation of opt-in testing for sexually transmitted and blood-borne infections in three Canadian provincial correctional facilities: a missed opportunity for public health? Int J Prison Health. 2019;15(3):273–81.
  385. Sutcliffe S, Newman SB, Hardick A, Gaydos CA. Prevalence and correlates of Trichomonas vaginalis infection among female US federal prison inmates. Sex Transm Dis. 2010;37:585–90.
  386. Freeman AH, Newman SB, Hardick A, Gaydos CA. Prevalence and correlates of Trichomonas vaginalis among incarcerated persons assessed using a highly sensitive molecular assay. Sex Transm Dis. 2010;37(3):165–8.
  387. Sosman J, Macgowan R, Margolis A, et al. Sexually transmitted infections and hepatitis in men with a history of incarceration. Sex Transm Dis. 2011;38(7):634–9.
  388. Javanbakht M, Stirland A, Stahlman S, et al. Prevalence and factors associated with Trichomonas vaginalis infection among high-risk women in Los Angeles. Sex Transm Dis. 2013;40(10):804–7.
  389. Nijhawan AE, Chapin KC, Salloway R, et al. Prevalence and predictors of trichomonas infection in newly incarcerated women. Sex Transm Dis. 2012;39(12):973–8.
  390. Nijhawan AE, DeLong AK, Celentano DD, et al. The association between Trichomonas infection and incarceration in HIV-seropositive and at-risk HIV-seronegative women. Sex Transm Dis. 2011;38:1094–100.
  391. Willers DM, Peipert JF, Allsworth JE, Stein MD, Rose JS, Clarke JG. Prevalence and predictors of sexually transmitted infection among newly incarcerated females. Sex Transm Dis. 2008;35:68–72.
  392. Nijhawan AE, Salloway R, Nunn AS, Poshkus M, Clarke JG. Preventive healthcare for underserved women: results of a prison survey. J Womens Health (Larchmt). 2010;19(1):17–22.
  393. Binswanger IA, White MC, Pérez-Stable EJ, Goldenson J, Tulsky JP. Cancer screening among jail inmates: frequency, knowledge, and willingness. Am J Public Health. 2005;95(10):1781–7.
  394. Brinkley-Rubinstein L, Peterson M, Arnold T, et al. Knowledge, interest, and anticipated barriers of pre-exposure prophylaxis uptake and adherence among gay, bisexual, and men who have sex with men who are incarcerated. PLoS One. 2018;13(12):e0205593.
  395. Brinkley-Rubinstein L, Dauria E, Tolou-Shams M, et al. The path to implementation of HIV pre-exposure prophylaxis for people involved in criminal justice systems. Curr HIV/AIDS Rep. 2018;15(2):93–5.
  396. Morrow KM; Project START Study Group. HIV, STD, and hepatitis risk behaviors of young men before and after incarceration. AIDS Care. 2009;21(2):235–43.
  397. Bryan AD, Magnan RE, Gillman AS, et al. Effect of including alcohol and cannabis content in a sexual risk-reduction intervention on the incidence of sexually transmitted infections in adolescents: a cluster randomized clinical trial. JAMA Pediatr. 2018;172(4):e175621.
  398. DiClemente RJ, Davis TL, Swartzendruber A, et al. Efficacy of an HIV/STI sexual risk-reduction intervention for African American adolescent girls in juvenile detention centers: a randomized controlled trial. Women Health. 2014;54(8):726–49.
  399. Fogel CI, Crandell JL, Neevel AM, et al. Efficacy of an adapted HIV and sexually transmitted infection prevention intervention for incarcerated women: a randomized controlled trial. Am J Public Health. 2015;105(4):802–9.
  400. Son J, Miller WM, Tossone K, Butcher F, Kuo K. The effect of interprofessional student-led reproductive health education on youths in juvenile detention. J Pediatr Adolesc Gynecol. 2017;30(3):370–5.
  401. Costumbrado J, Stirland A, Cox G, et al. Implementation of a hepatitis A/B vaccination program using an accelerated schedule among high-risk inmates, Los Angeles County Jail, 2007-2010. Vaccine. 2012;30(48):6878–82.
  402. Allison M, Musser B, Satterwhite C, Ault K, Kelly P, Ramaswamy M. Human papillomavirus vaccine knowledge and intention among adult inmates in Kansas, 2016-2017. Am J Public Health. 2018;108(8):1000–2.
  403. Lucas KD, Miller JL, Eckert V, Horne RL, Samuel MC, Mohle-Boetani JC. Risk, feasibility, and cost evaluation of a prisoner condom access pilot program in one California state prison. J Correct Health Care. 2014;20(3):184–94.
  404. Scott N, McBryde E, Kirwan A, Stoové M. Modelling the impact of condom distribution on the incidence and prevalence of sexually transmitted infections in an adult male prison system. PLoS One. 2015;10(12):e0144869.
  405. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996;125:257–64.
  406. Henn A, Flateau C, Gallien S. Primary HIV infection: clinical presentation, testing, and treatment. Curr Infect Dis Rep. 2017;19(10):37.
  407. Robb ML, Eller LA, Kibuuka H, et al. Prospective study of acute HIV-1 infection in adults in East Africa and Thailand. N Engl J Med. 2016;374(22):2120–30.
  408. Hoenigl M, Green N, Camacho M, et al. Signs or symptoms of acute HIV infection in a cohort undergoing community-based screening. Emerg Infect Dis. 2016;22(3):532–4.
  409. Legarth RA, Ahlström MG, Kronborg G, et al. Long-term mortality in HIV-infected individuals 50 years or older: a nationwide, population-based cohort study. J Acquir Immune Defic Syndr. 2016;71(2):213–8.
  410. Marcus JL, Chao CR, Leyden WA, et al. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. J Acquir Immune Defic Syndr. 2016;73(1):39–46.
  411. Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375(9):830–9.
  412. Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel. JAMA. 2018;320(4):379–96.
  413. Seth P, Wang G, Sizemore E, Hogben M. HIV testing and HIV service delivery to populations at high risk attending sexually transmitted disease clinics in the United States, 2011-2013. Am J Public Health. 2015;105(11):2374–81.
  414. Benton S, Smith J, Wang F, Heitgerd J, Belcher L, Patel H. HIV Testing, Diagnosis, and Linkage to Care among Persons Tested in Select CDC-funded Health Care and Non-health Care Settings, 2012-2017. Presented at: National HIV Prevention Conference; 2019 Mar 18–21; Atlanta, GA.
  415. Pathela P, Braunstein SL, Schillinger JA, Shepard C, Sweeney M, Blank S. Men who have sex with men have a 140-fold higher risk for newly diagnosed HIV and syphilis compared with heterosexual men in New York City. J Acquir Immune Defic Syndr. 2011;58(4):408–16.
  416. Chou R, Selph S, Dana T, et al. Screening for HIV: systematic review to update the 2005 U.S. Preventive Services Task Force recommendation. Ann Intern Med. 2012;157(10):706–
  417. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR14):1–17.
  418. DiNenno EA, Prejean J, Irwin K, et al. Recommendations for HIV screening of gay, bisexual, and other men who have sex with men — United States, 2017. MMWR Morb Mortal Wkly Rep. 2017;66(31):830–2.
  419. Centers for Disease Control and Prevention. HIV-2 infection surveillance–United States, 1987-2009. MMWR Morb Mortal Wkly Rep. 2011;60:985–8.
  420. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005;191:1403–9.
  421. Pilcher CD, Eron JJ Jr, Vemazza PL, et al. Sexual transmission during the incubation period of primary HIV infection. JAMA. 2001;286:1713–4.
  422. Calabrese SK, Mayer KH. Providers should discuss U=U with all patients living with HIV. Lancet HIV. 2019;6(4):e211–3.
  423. Gilbert P, Ciccarone D, Gansky SA, et al. Interactive “video doctor” counseling reduces drug and sexual risk behaviors among HIV-positive patients in diverse outpatient settings. PLoS One. 2008;3:e1988.
  424. Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58:e1–34.
  425. DiCarlo RP, Martin DH. The clinical diagnosis of genital ulcer disease in men. Clin Infect Dis. 1997;25:292–8.
  426. Lockett AE, Dance DA, Mabey DC, Drasar BS. Serum-free media for isolation of Haemophilus ducreyi. Lancet. 1991;338:326.
  427. Lewis DA, Mitjà O. Haemophilus ducreyi: from sexually transmitted infection to skin ulcer pathogen. Curr Opin Infect Dis. 2016;29(1):52–7.
  428. Romero L, Huerfano C, Grillo-Ardila CF. Macrolides for treatment of Haemophilus ducreyi infection in sexually active adults. Cochrane Database Syst Rev. 2017;12:CD012492.
  429. Jessamine PG, Plummer FA, Ndinya Achola JO, et al. Human immunodeficiency virus, genital ulcers and the male foreskin: synergism in HIV-1 transmission. Scand J Infect Dis Suppl. 1990;69:181–6.
  430. Briggs GC. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 11th Philadelphia (PA): Wolters Kluwer; 2017. 1646 p.
  431. Lewis DA. Epidemiology, clinical features, diagnosis and treatment of Haemophilus ducreyi – a disappearing pathogen? Expert Rev Anti Infect Ther. 2014;12(6):687–96.
  432. Mitjà O, Lukehart SA, Pokowas G, et al. Haemophilus ducreyi as a cause of skin ulcers in children from a yaws-endemic area of Papua New Guinea: a prospective cohort study. Lancet Glob Health. 2014;2(4):e235–41.
  433. Marks M, Chi KH, Vahi V, et al. Haemophilus ducreyi associated with skin ulcers among children, Solomon Islands. Emerg Infect Dis. 2014;20(10):1705–7.
  434. Ghinai R, El-Duah P, Chi KH, et al. A cross-sectional study of ‘yaws’ in districts of Ghana which have previously undertaken azithromycin mass drug administration for trachoma control. PLoS Negl Trop Dis. 2015;9(1):e0003496.
  435. McQuillan G, Kruszon-Moran D, Flagg EW, Paulose-Ram R. Prevalence of herpes simplex virus type 1 and type 2 in persons aged 14-49: United States, 2015-2016. National Center for Health Statistics Data Brief. 2018;(304):1–
  436. Ryder N, Jin F, McNulty AM, Grulich AE, Donovan B. Increasing role of herpes simplex virus type 1 in first-episode anogenital herpes in heterosexual women and younger men who have sex with men, 1992-2006. Sex Transm Infect. 2009;85:416–9.
  437. Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis. 2003;30:797–800.
  438. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med. 1994;121:847–54.
  439. Engelberg R, Carrell D, Krantz E, Corey L, Wald A. Natural history of genital herpes simplex virus type 1 infection. Sex Transm Dis. 2003;30:174–7.
  440. Masese L, Baeten JM, Richardson BA, et al. Changes in the contribution of genital tract infections to HIV acquisition among Kenyan high-risk women from 1993 to 2012. AIDS. 2015;29(9):1077–85.
  441. Sam SS, Caliendo AM, Ingersoll J, Abdul-Ali D, Kraft CS. Performance evaluation of the Aptima HSV-1 and 2 assay for the detection of HSV in cutaneous and mucocutaneous lesion specimens. J Clin Virol. 2018;99-100:1–4.
  442. Wald A, Huang ML, Carrell D, Selke S, Corey L. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis. 2003;188:1345–51.
  443. Van Der Pol B, Warren T, Taylor SN, et al. Type-specific identification of anogenital herpes simplex virus infections by use of a commercially available nucleic acid amplification test. J Clin Microbiol. 2012;50:3466–71.
  444. Binnicker MJ, Espy MJ, Duresko B, Irish C, Mandrekar J. Automated processing, extraction and detection of herpes simplex virus types 1 and 2: a comparative evaluation of three commercial platforms using clinical specimens. J Clin Virol. 2017;89:30–3.
  445. Teo JW, Chiang D, Jureen R, Lin RT. Clinical evaluation of a helicase-dependant amplification (HDA)-based commercial assay for the simultaneous detection of HSV-1 and HSV-2. Diagn Microbiol Infect Dis. 2015;83(3):261–2.
  446. Gitman MR, Ferguson D, Landry ML. Comparison of Simplexa HSV 1 & 2 PCR with culture, immunofluorescence, and laboratory-developed TaqMan PCR for detection of herpes simplex virus in swab specimens. J Clin Microbiol. 2013;51(11):3765–9.
  447. Corey L, Holmes KK. Genital herpes simplex virus infections: current concepts in diagnosis, therapy, and prevention. Ann Intern Med. 1983;98(6):973–83.
  448. Caviness AC, Oelze LL, Saz UE, Greer JM, Demmler-Harrison GJ. Direct immunofluorescence assay compared to cell culture for the diagnosis of mucocutaneous herpes simplex virus infections in children. J Clin Virol. 2010;49:58–60.
  449. Song B, Dwyer DE, Mindel A. HSV type specific serology in sexual health clinics: use, benefits, and who gets tested. Sex Transm Infect. 2004;80:113–7.
  450. Whittington WL, Celum CL, Cent A, Ashley RL. Use of a glycoprotein G-based type-specific assay to detect antibodies to herpes simplex virus type 2 among persons attending sexually transmitted disease clinics. Sex Transm Dis. 2001;28:99–104.
  451. Zimet GD, Rosenthal SL, Fortenberry JD, et al. Factors predicting the acceptance of herpes simplex virus type 2 antibody testing among adolescents and young adults. Sex Transm Dis. 2004;31:665–9.
  452. Turner KR, Wong EH, Kent CK, Klausner JD. Serologic herpes testing in the real world: validation of new type-specific serologic herpes simplex virus tests in a public health laboratory. Sex Transm Dis. 2002;29:422–5.
  453. Eing BR, Lippelt L, Lorentzen EU, et al. Evaluation of confirmatory strategies for detection of type-specific antibodies against herpes simplex virus type 2. J Clin Microbiol. 2002;40:407–13.
  454. Golden MR, Ashley-Morrow R, Swenson P, Hogrefe WR, Handsfield HH, Wald A. Herpes simplex virus type 2 (HSV-2) Western blot confirmatory testing among men testing positive for HSV-2 using the focus enzyme-linked immunosorbent assay in a sexually transmitted disease clinic. Sex Transm Dis. 2005;32:771–7.
  455. Morrow RA, Friedrich D, Meier A, Corey L. Use of “biokit HSV-2 Rapid Assay” to improve the positive predictive value of Focus HerpeSelect HSV-2 ELISA. BMC Infect Dis. 2005;5:84.
  456. Ngo TD, Laeyendecker O, La H, Hogrefe W, Morrow RA, Quinn TC. Use of commercial enzyme immunoassays to detect antibodies to the herpes simplex virus type 2 glycoprotein G in a low-risk population in Hanoi, Vietnam. Clin Vaccine Immunol. 2008;15:382–4.
  457. Agyemang E, Le QA, Warren T, et al. Performance of commercial enzyme-linked immunoassays for diagnosis of herpes simplex virus-1 and herpes simplex virus-2 infection in a clinical setting. Sex Transm Dis. 2017;44(12):763–7.
  458. Morrow R, Friedrich D. Performance of a novel test for IgM and IgG antibodies in subjects with culture-documented genital herpes simplex virus-1 or -2 infection. Clin Microbiol Infect. 2006;12:463–9.
  459. Ameli N, Bacchetti P, Morrow RA, et al. Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations. AIDS. 2006;20(7):1051–8.
  460. Bradley H, Markowitz LE, Gibson T, McQuillan GM. Seroprevalence of herpes simplex virus types 1 and 2–United States, 1999-2010. J Infect Dis. 2014;209:325–33.
  461. Bernstein DI, Bellamy AR, Hook EW 3rd, et al. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis. 2013;56:344–51.
  462. Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis. 2002;34:958–62.
  463. Wald A, Carrell D, Remington M, Kexel E, Zeh J, Corey L. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis. 2002;34:944–8.
  464. Aoki FY, Tyring S, Diaz-Mitoma F, Gross G, Gao J, Hamed K. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2006;42:8–13.
  465. Chosidow O, Drouault Y, Leconte-Veyriac F, et al. Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. Br J Dermatol. 2001;144:818–24.
  466. Bodsworth NJ, Crooks RJ, Borelli S, et al. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group. Genitourin Med. 1997;73:110–6.
  467. Fife KH, Barbarash RA, Rudolph T, Degregorio B, Roth R. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection: results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group. Sex Transm Dis. 1997;24:481–6.
  468. Diaz-Mitoma F, Sibbald RG, Shafran SD, Boon R, Saltzman RL. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. JAMA. 1998;280:887–92.
  469. Mertz GJ, Loveless MO, Levin MJ, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women: a multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. Arch Intern Med. 1997;157:343–9.
  470. Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group. J Infect Dis. 1998;178:603–10.
  471. Romanowski B, Marina RB, Roberts JN; Valtrex HS230017 Study Group. Patients’ preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study. Sex Transm Dis. 2003;30:226–31.
  472. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004;350:11–20.
  473. Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years’ experience with acyclovir. J Infect Dis. 2002;186 Suppl 1:S40–6.
  474. Bartlett BL, Tyring SK, Fife K, et al. Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: the RELIEF trial. J Clin Virol. 2008;43:190–5.
  475. Tronstein E, Johnston C, Huang ML, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA. 2011;305(14):1441–9.
  476. Bender Ignacio RA, Perti T, Magaret AS, et al. Oral and vaginal tenofovir for genital herpes simplex virus type 2 shedding in immunocompetent women: a double-blind, randomized, cross-over trial. J Infect Dis. 2015;212(12):1949–56.
  477. Wald A, Selke S, Warren T, et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis. 2006;33:529–33.
  478. Johnston C, Magaret A, Stern M, et al. Natural history of genital and oral herpes simplex virus-1 (HSV-1) shedding after first episode genital HSV-1 infection. Sex Transm Infect. 2019;95:A42.
  479. Tang YW, Cleavinger PJ, Li H, Mitchell PS, Smith TF, Persing DH. Analysis of candidate-host immunogenetic determinants in herpes simplex virus-associated Mollaret’s meningitis. Clin Infect Dis. 2000;30(1):176–8.
  480. Shalabi M, Whitley RJ. Recurrent benign lymphocytic meningitis. Clin Infect Dis. 2006;43(9):1194–7.
  481. Landry ML, Greenwold J, Vikram HR. Herpes simplex type-2 meningitis: presentation and lack of standardized therapy. Am J Med. 2009;122(7):688–91.
  482. Aurelius E, Franzen-Röhl E, Glimåker M, et al. Long-term valacyclovir suppressive treatment after herpes simplex virus type 2 meningitis: a double-blind, randomized controlled trial. Clin Infect Dis. 2012;54(9):1304–13.
  483. Magawa S, Tanaka H, Furuhashi F, et al. A literature review of herpes simplex virus hepatitis in pregnancy. J Matern Fetal Neonatal Med. 2020;33(10):1774–9.
  484. Masadeh M, Shen H, Lee Y, et al. A fatal case of herpes simplex virus hepatitis in a pregnant patient. Intractable Rare Dis Res. 2017;6(2):124–7.
  485. Martin ET, Krantz E, Gottlieb SL, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med. 2009;169:1233–40.
  486. Wald A, Langenberg AG, Krantz E, et al. The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med. 2005;143:707–13.
  487. Wald A, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA. 2001;285:3100–6.
  488. Magaret AS, Mujugira A, Hughes JP, et al. Effect of condom use on per-act HSV-2 transmission risk in HIV-1, HSV-2-discordant couples. Clin Infect Dis. 2016;62(4):456–61.
  489. Mehta SD, Moses S, Agot K, et al. Medical male circumcision and herpes simplex virus 2 acquisition: posttrial surveillance in Kisumu, Kenya. J Infect Dis. 2013;208(11):1869–76.
  490. Grund JM, Bryant TS, Jackson I, et al. Association between male circumcision and women’s biomedical health outcomes: a systematic review. Lancet Glob Health. 2017;5(11):e1113–22.
  491. Celum C, Morrow RA, Donnell D, et al. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Ann Intern Med. 2014;161(1):11–9.
  492. Abdool Karim SS, Abdool Karim Q, Gengiah TN. Tenofovir gel to prevent HSV-2 infection. N Engl J Med. 2015;373(20):1980–1.
  493. Marcus JL, Glidden DV, McMahan V, et al. Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men. PLoS One. 2014;9(3):e91513.
  494. Celum C, Hong T, Cent A, et al. Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS Study. J Infect Dis. 2017;215(6):907–10.
  495. Gilbert LK, Wyand F. Genital herpes education and counseling: testing a one-page ‘FAQ’ intervention. Herpes. 2009;15:51–6.
  496. Rosenthal SL, Zimet GD, Leichliter JS, et al. The psychosocial impact of serological diagnosis of asymptomatic herpes simplex virus type 2 infection. Sex Transm Infect. 2006;82:154–8.
  497. Miyai T, Turner KR, Kent CK, Klausner J. The psychosocial impact of testing individuals with no history of genital herpes for herpes simplex virus type 2. Sex Transm Dis. 2004;31:517–21.
  498. Ross K, Johnston C, Wald A. Herpes simplex virus type 2 serological testing and psychosocial harm: a systematic review. Sex Transm Infect. 2011;87:594–600.
  499. Henry RE, Wegmann JA, Hartle JE, Christopher GW. Successful oral acyclovir desensitization. Ann Allergy. 1993;70:386–8.
  500. Leeyaphan C, Surawan TM, Chirachanakul P, et al. Clinical characteristics of hypertrophic herpes simplex genitalis and treatment outcomes of imiquimod: a retrospective observational study. Int J Infect Dis. 2015;33:165–70.
  501. Keller MJ, Huber A, Espinoza L, et al. Impact of herpes simplex virus type 2 and human immunodeficiency virus dual infection on female genital tract mucosal immunity and the vaginal microbiome. J Infect Dis. 2019;220(5):852–61.
  502. Posavad CM, Wald A, Kuntz S, et al. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J Infect Dis. 2004;190:693–6.
  503. Tobian AA, Grabowski MK, Serwadda D, et al. Reactivation of herpes simplex virus type 2 after initiation of antiretroviral therapy. J Infect Dis. 2013;208:839–46.
  504. Mujugira A, Magaret AS, Celum C, et al. Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial. J Infect Dis. 2013;208:1366–74.
  505. Van Wagoner N, Geisler WM, Bachmann LH, Hook EW. The effect of valacyclovir on HIV and HSV-2 in HIV-infected persons on antiretroviral therapy with previously unrecognised HSV-2. Int J STD AIDS. 2015;26(8):574–81.
  506. Reyes M, Shaik NS, Graber JM, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med. 2003;163:76–80.
  507. Safrin S, Crumpacker C, Chatis P, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med. 1991;325:551–5.
  508. Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis. 2004;39 Suppl 5:S248–57.
  509. Tandon S, Singh J, Sinha S, Sharma DP. Recalcitrant hypertrophic herpes genitalis in HIV-infected patient successfully treated with topical imiquimod. Dermatol Ther. 2017;30(3).
  510. Perkins N, Nisbet M, Thomas M. Topical imiquimod treatment of aciclovir-resistant herpes simplex disease: case series and literature review. Sex Transm Infect. 2011;87:292–5.
  511. McElhiney LF. Topical cidofovir for treatment of resistant viral infections. Int J Pharm Compd. 2006;10(5):324–8.
  512. Erard V, Wald A, Corey L, Leisenring WM, Boeckh M. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis. 2007;196:266–70.
  513. Brown ZA, Selke S, Zeh J, Kopelman J, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med. 1997;337:509–15.
  514. Pinninti SG, Kimberlin DW. Maternal and neonatal herpes simplex virus infections. Am J Perinatol. 2013;30:113–9.
  515. Brown ZA, Benedetti J, Ashley R, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med. 1991;324:1247–52.
  516. Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA. 2003;289:203–9.
  517. Ahrens KA, Anderka MT, Feldkamp ML, et al. Antiherpetic medication use and the risk of gastroschisis: findings from the National Birth Defects Prevention Study, 1997-2007. Paediatr Perinat Epidemiol. 2013;27(4):340–5.
  518. Stone KM, Reiff-Eldridge R, White AD, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the international acyclovir pregnancy registry, 1984-1999. Birth Defects Res A Clin Mol Teratol. 2004;70:201–7.
  519. Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. 2010;304(8):859–66.
  520. Sheffield JS, Sánchez PJ, Wendel GD Jr, et al. Placental histopathology of congenital syphilis. Obstet Gynecol. 2002;100(1):126–33.
  521. Watts DH, Brown ZA, Money D, et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. Am J Obstet Gynecol. 2003;188:836–43.
  522. Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD Jr. Acyclovir suppression to prevent recurrent genital herpes at delivery. Infect Dis Obstet Gynecol. 2002;10:71–7.
  523. Pinninti SG, Angara R, Feja KN, et al. Neonatal herpes disease following maternal antenatal antiviral suppressive therapy: a multicenter case series. J Pediatr. 2012;161:134–8.
  524. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 82: Management of herpes in pregnancy. Obstet Gynecol. 2007;109:1489–98.
  525. Winer RL, Hughes JP, Feng Q, et al. Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev. 2011;20:699–707.
  526. Ahmed N, Pillay A, Lawler M, Bobat R, Archary M. Donovanosis causing lymphadenitis, mastoiditis, and meningitis in a child. Lancet. 2015;385(9987):2644.
  527. Arora AK, Kumaran MS, Narang T, Saikia UN, Handa S. Donovanosis and squamous cell carcinoma: the relationship conundrum! Int J STD AIDS. 2017;28(4):411–4.
  528. Liverani CA, Lattuada D, Mangano S, et al. Hypertrophic donavanosis in a young pregnant woman. J Pediatr Adolesc Gynecol. 2012;25(4):e81–3.
  529. Magalhães BM, Veasey JV, Mayor SAS, Lellis RF. Donovanosis in a child victim of sexual abuse: response to doxycycline treatment. An Bras Dermatol. 2018;93(4):592–4.
  530. Marfatia YS, Menon DS, Jose S, Patel BK. Nonhealing genital ulcer in AIDS: a diagnostic dilemma! Indian J Sex Transm Dis AIDS. 2016;37(2):197–200.
  531. Narang T, Kanwar AJ. Genital elephantiasis due to donovanosis: forgotten but not gone yet. Int J STD AIDS. 2012;23(11):835–6.
  532. Pilani A, Vora R, Anjaneyan G. Granuloma inguinale mimicking as squamous cell carcinoma of penis. Indian J Sex Transm Dis AIDS. 2014;35(1):56–8.
  533. Ramdial PK, Sing Y, Ramburan A, et al. Infantile donovanosis presenting as external auditory canal polyps: a diagnostic trap. Am J Dermatopathol. 2012;34(8):818–21.
  534. Wahal SP, Tuli D. Donovanosis: an incidental finding on Pap test. J Cytol. 2013;30(3):217–8.
  535. Bowden FJ; National Donovanosis Eradication Advisory Committee. Donovanosis in Australia: going, going… Sex Transm Infect. 2005;81:365–6.
  536. Bright A. National Notifiable Diseases Surveillance System surveillance report: sexually transmissible infections in Aboriginal and Torres Strait Islander people. Commun Dis Intell Q Rep. 2015;39:E584–9.
  537. O’Farrell N. Donovanosis. Sex Transm Infect. 2002;78:452–7.
  538. Mabey D, Peeling RW. Lymphogranuloma venereum. Sex Transm Infect. 2002;78:90–2.
  539. White JA. Manifestations and management of lymphogranuloma venereum. Curr Opin Infect Dis. 2009;22:57–66.
  540. de Vries HJ, Zingoni A, White JA, Ross JD, Kreuter A. 2013 European Guideline on the management of proctitis, proctocolitis and enteritis caused by sexually transmissible pathogens. Int J STD AIDS. 2014;25(7):465–74.
  541. Ward H, Martin I, Macdonald N, et al. Lymphogranuloma venereum in the United Kingdom. Clin Infect Dis. 2007;44:26–32.
  542. Martin-Iguacel R, Llibre JM, Nielsen H, et al. Lymphogranuloma venereum proctocolitis: a silent endemic disease in men who have sex with men in industrialised countries. Eur J Clin Microbiol Infect Dis. 2010;29:917–25.
  543. de Voux A, Kent JB, Macomber K, et al. Notes from the field: cluster of lymphogranuloma venereum cases among men who have sex with men – Michigan, August 2015-April 2016. MMWR Morb Mortal Wkly Rep. 2016;65(34):920–1.
  544. Pallawela SN, Sullivan AK, Macdonald N, et al. Clinical predictors of rectal lymphogranuloma venereum infection: results from a multicentre case-control study in the U.K. Sex Transm Infect. 2014;90:269–74.
  545. de Vrieze NH, de Vries HJ. Lymphogranuloma venereum among men who have sex with men. An epidemiological and clinical review. Expert Rev Anti Infect Ther. 2014;12:697–704.
  546. Koper NE, van der Sande MA, Gotz HM, Koedijk FD; Dutch STI Clinics. Lymphogranuloma venereum among men who have sex with men in the Netherlands: regional differences in testing rates lead to underestimation of the incidence, 2006-2012. Euro Surveill. 2013;18:20561.
  547. Haar K, Dudareva-Vizule S, Wisplinghoff H, et al. Lymphogranuloma venereum in men screened for pharyngeal and rectal infection, Germany. Emerg Infect Dis. 2013;19:488–92.
  548. Riera-Monroig J, Fuertes de Vega I. Lymphogranuloma venereum presenting as an ulcer on the tongue. Sex Transm Infect. 2019;95(3):169–70.
  549. Andrada MT, Dhar JK, Wilde H. Oral lymphogranuloma venereum and cervical lymphadenopathy. Case report. Mil Med. 1974;139(2):99–101.
  550. Ilyas S, Richmond D, Burns G, et al. Orolabial lymphogranuloma venereum, Michigan, USA. Emerg Infect Dis. 2019;25(11):2112–4.
  551. Kersh EN, Pillay A, de Voux A, Chen C. Laboratory processes for confirmation of lymphogranuloma venereum infection during a 2015 investigation of a cluster of cases in the United States. Sex Transm Dis. 2017;44(11):691–4.
  552. Papp JR, Schachter J, Gaydos CA, Van Der Pol B. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae–2014. MMWR Recomm Rep. 2014;63(RR-02):1–19.
  553. Pathela P, Jamison K, Kornblum J, Quinlan T, Halse TA, Schillinger JA. Lymphogranuloma venereum: an increasingly common anorectal infection among men who have sex with men attending New York City sexual health clinics. Sex Transm Dis. 2019;46(2):e14–7.
  554. Cohen S, Brosnan H, Kohn R, et al. P494 Diagnosis and management of lymphogranuloma venererum (LGV) in a municipal STD clinic, San Francisco, 2016–18. Sex Transm Infect. 2019;95:A229.
  555. Leeyaphan C, Ong JJ, Chow EP, et al. Systematic review and meta-analysis of doxycycline efficacy for rectal lymphogranuloma venereum in men who have sex with men. Emerg Infect Dis. 2016;22(10):1778–84.
  556. Cabello Úbeda A, Fernández Roblas R, García Delgado R, et al. Anorectal lymphogranuloma venereum in Madrid: a persistent emerging problem in men who have sex with men. Sex Transm Dis. 2016;43(7):414–9.
  557. Simons R, Candfield S, French P, White JA. Observed treatment responses to short-course doxycycline therapy for rectal lymphogranuloma venereum in men who have sex with men. Sex Transm Dis. 2018;45(6):406–8.
  558. Vall-Mayans M, Isaksson J, Caballero E, Sallés B, Herrmann B. Bubonic lymphogranuloma venereum with multidrug treatment failure. Int J STD AIDS. 2014;25(4):306–8.
  559. Blanco JL, Fuertes I, Bosch J, et al, Effective treatment of lymphogranuloma venereum (LGV) with 1g azithormycin administered weekly for 3 weeks in HIV-infected population in Conference on Retroviruses and Opportunist Infections. 2015: Seattle, WA.
  560. Kong FY, Rupasinghe TW, Simpson JA, et al. Pharmacokinetics of a single 1g dose of azithromycin in rectal tissue in men. PLoS One. 2017;12(3):e0174372.
  561. Elgalib A, Alexander S, Tong CY, White JA. Seven days of doxycycline is an effective treatment for asymptomatic rectal Chlamydia trachomatis infection. Int J STD AIDS. 2011;22(8):474–7.
  562. Wormser GP, Wormser RP, Strle F, Myers R, Cunha BA. How safe is doxycycline for young children or for pregnant or breastfeeding women? Diagn Microbiol Infect Dis. 2019;93(3):238–42.
  563. Towns JM, Leslie DE, Denham I, Azzato F, Fairley CK, Chen M. Painful and multiple anogenital lesions are common in men with Treponema pallidum PCR-positive primary syphilis without herpes simplex virus coinfection: a cross-sectional clinic-based study. Sex Transm Infect. 2016;92(2):110–5.
  564. Theel ES, Katz SS, Pillay A. Molecular and direct detection tests for Treponema pallidum subspecies pallidum: a review of the literature, 1964-2017. Clin Infect Dis. 2020; 71(Supplement_1):S4–12.
  565. Tuddenham S, Katz SS, Ghanem KG. Syphilis laboratory guidelines: performance characteristics of nontreponemal antibody tests. Clin Infect Dis. 2020;71(Supplement_1):S21–42.
  566. Park IU, Tran A, Pereira L, Fakile Y. Sensitivity and specificity of treponemal-specific tests for the diagnosis of syphilis. Clin Infect Dis. 2020;71(Supplement_1):S13–20.
  567. Bristow CC, Klausner JD, Tran A. Clinical test performance of a rapid point-of-care syphilis treponemal antibody test: a systematic review and meta-analysis. Clin Infect Dis. 2020;71(Supplement_1):S52–7.
  568. Nandwani R, Evans DT. Are you sure it’s syphilis? A review of false positive serology. Int J STD AIDS. 1995;6:241–8.
  569. Romanowski B, Sutherland R, Fick GH, Mooney D, Love EJ. Serologic response to treatment of infectious syphilis. Ann Intern Med. 1991;114:1005–9.
  570. Centers for Disease Control and Prevention. Syphilis testing algorithms using treponemal tests for initial screening–four laboratories, New York City, 2005-2006. MMWR Morb Mortal Wkly Rep. 2008;57:872–5.
  571. Centers for Disease Control and Prevention. Discordant results from reverse sequence syphilis screening–five laboratories, United States, 2006-2010. MMWR Morb Mortal Wkly Rep. 2011;60(5):133–7.
  572. Ortiz-Lopez N, Diez M, Diaz O, Simon F, Diaz A. Epidemiological surveillance of congenital syphilis in Spain, 2000-2010. Pediatr Infect Dis J. 2012;31:988–90.
  573. Berry GJ, Loeffelholz MJ. Use of treponemal screening assay strength of signal to avoid unnecessary confirmatory testing. Sex Transm Dis. 2016;43(12):737–40.
  574. Park IU, Chow JM, Bolan G, Stanley M, Shieh J, Schapiro JM. Screening for syphilis with the treponemal immunoassay: analysis of discordant serology results and implications for clinical management. J Infect Dis. 2011;204(9):1297–304.
  575. Loeffelholz MJ, Wen T, Patel JA. Analysis of bioplex syphilis IgG quantitative results in different patient populations. Clin Vaccine Immunol. 2011;18(11):2005–6.
  576. Fakile YF, Jost H, Hoover KW, et al. Correlation of treponemal immunoassay signal strength values with reactivity of confirmatory treponemal testing. J Clin Microbiol. 2017;56(1).
  577. Wong EH, Klausner JD, Caguin-Grygiel G, et al. Evaluation of an IgM/IgG sensitive enzyme immunoassay and the utility of index values for the screening of syphilis infection in a high-risk population. Sex Transm Dis. 2011;38:528–32.
  578. Dai S, Chi P, Lin Y, et al. Improved reverse screening algorithm for Treponema pallidum antibody using signal-to-cutoff ratios from chemiluminescence microparticle immunoassay. Sex Transm Dis. 2014;41(1):29–34.
  579. Li Z, Feng Z, Liu P, Yan C. Screening for antibodies against Treponema pallidum with chemiluminescent microparticle immunoassay: analysis of discordant serology results and clinical characterization. Ann Clin Biochem. 2016;53(Pt 5):588–92.
  580. Yen-Lieberman B, Daniel J, Means C, Waletzky J, Daly TM. Identification of false-positive syphilis antibody results using a semiquantitative algorithm. Clin Vaccine Immunol. 2011;18(6):1038–40.
  581. Yimtae K, Srirompotong S, Lertsukprasert K. Otosyphilis: a review of 85 cases. Otolaryngol Head Neck Surg. 2007;136(1):67–71.
  582. Gleich LL, Linstrom CJ, Kimmelman CP. Otosyphilis: a diagnostic and therapeutic dilemma. Laryngoscope. 1992;102(11):1255–9.
  583. Lukehart SA, Hook EW 3rd, Baker-Zander SA, Collier AC, Critchlow CW, Handsfield HH. Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment. Ann Intern Med. 1988;109:855–62.
  584. Harding AS, Ghanem KG. The performance of cerebrospinal fluid treponemal-specific antibody tests in neurosyphilis: a systematic review. Sex Transm Dis. 2012;39(4):291–7.
  585. Jaffe HW, Larsen SA, Peters M, Jove DF, Lopez B, Schroeter AL. Tests for treponemal antibody in CSF. Arch Intern Med. 1978;138:252–5.
  586. Marra CM, Maxwell CL, Smith SL, et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J Infect Dis. 2004;189:369–76.
  587. Centers for Disease Control and Prevention. Inadvertent use of Bicillin® C-R to treat syphilis infection-Los Angeles, California, 1999-2004. MMWR Morb Mortal Wkly Rep. 2005;54:217–9.
  588. Butler T. The Jarisch-Herxheimer reaction after antibiotic treatment of spirochetal infections: a review of recent cases and our understanding of pathogenesis. Am J Trop Med Hyg. 2017;96(1):46–52.
  589. Rolfs RT, Joesoef MR, Hendershot EF, et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. N Engl J Med. 1997;337(5):307–14.
  590. Yang CJ, Lee NY, Chen TC, et al. One dose versus three weekly doses of benzathine penicillin G for patients co-infected with HIV and early syphilis: a multicenter, prospective observational study. PLoS One. 2014;9(10):e109667.
  591. Ganesan A, Mesner O, Okulicz JF, et al. A single dose of benzathine penicillin G is as effective as multiple doses of benzathine penicillin G for the treatment of HIV-infected persons with early syphilis. Clin Infect Dis. 2015;60(4):653–60.
  592. Ghanem KG, Erbelding EJ, Wiener ZS, Rompalo AM. Serological response to syphilis treatment in HIV-positive and HIV-negative patients attending sexually transmitted diseases clinics. Sex Transm Infect. 2007;83:97–101.
  593. Seña AC, Wolff M, Martin DH, et al. Predictors of serological cure and Serofast State after treatment in HIV-negative persons with early syphilis. Clin Infect Dis. 2011;53:1092–9.
  594. Zhang RL, Wang QQ, Zhang JP, Yang LJ. Molecular subtyping of Treponema pallidum and associated factors of serofast status in early syphilis patients: identified novel genotype and cytokine marker. PLoS One. 2017;12(4):e0175477.
  595. Seña AC, Zhang XH, Li T, et al. A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy. BMC Infect Dis. 2015;15:479.
  596. Tong ML, Lin LR, Liu GL, et al. Factors associated with serological cure and the serofast state of HIV-negative patients with primary, secondary, latent, and tertiary syphilis. PLoS One. 2013;8(7):e70102.
  597. Seña AC, Wolff M, Behets F, et al. Response to therapy following retreatment of serofast early syphilis patients with benzathine penicillin. Clin Infect Dis. 2013;56:420–2.
  598. Ghanem KG, Erbelding EJ, Cheng WW, Rompalo AM. Doxycycline compared with benzathine penicillin for the treatment of early syphilis. Clin Infect Dis. 2006;42(6):e45–9.
  599. Wong T, Singh AE, De P. Primary syphilis: serological treatment response to doxycycline/tetracycline versus benzathine penicillin. Am J Med. 2008;121(10):903–8.
  600. Hook EW 3rd, Martin DH, Stephens J, Smith BS, Smith K. A randomized, comparative pilot study of azithromycin versus benzathine penicillin G for treatment of early syphilis. Sex Transm Dis. 2002;29:486–90.
  601. Cao Y, Su X, Wang Q, et al. A multicenter study evaluating ceftriaxone and benzathine penicillin G as treatment agents for early syphilis in Jiangsu, China. Clin Infect Dis. 2017;65(10):1683–8.
  602. Riedner G, Rusizoka M, Todd J, et al. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. N Engl J Med. 2005;353:1236–44.
  603. Hook EW 3rd, Behets F, Van Damme K, et al. A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis. J Infect Dis. 2010;201(11):1729–35.
  604. Lukehart SA, Godornes C, Molini BJ, et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med. 2004;351:154–8.
  605. Mitchell SJ, Engelman J, Kent CK, Lukehart SA, Godornes C, Klausner JD. Azithromycin-resistant syphilis infection: San Francisco, California, 2000-2004. Clin Infect Dis. 2006;42:337–45.
  606. A2058G Prevalence Workgroup. Prevalence of the 23S rRNA A2058G point mutation and molecular subtypes in Treponema pallidum in the United States, 2007 to 2009. Sex Transm Dis. 2012;39:794–8.
  607. Rolfs RT, Joesoef MR, Hendershot EF, et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. N Engl J Med. 1997;337(5):307–14
  608. Collart P, Poitevin M, Milovanovic A, Herlin A, Durel J. Kinetic study of serum penicillin concentrations after single doses of benzathine and benethamine penicillins in young and old people. Br J Vener Dis. 1980;56:355–62.
  609. Hagdrup HK, Lange Wantzin G, Secher L, Rosdahl VT. Penicillin concentrations in serum following weekly injections of benzathine penicillin G. Chemotherapy. 1986;32:99–101.
  610. Frentz G, Nielsen PB, Espersen F, Czartoryski A, Aastrup H. Penicillin concentrations in blood and spinal fluid after a single intramuscular injection of penicillin G benzathine. Eur J Clin Microbiol. 1984;3:147–9.
  611. Nathan L, Bawdon RE, Sidawi JE, Stettler RW, McIntire DM, Wendel GD Jr. Penicillin levels following the administration of benzathine penicillin G in pregnancy. Obstet Gynecol. 1993;82(3):338–42.
  612. Marra CM, Maxwell CL, Tantalo LC, Sahi SK, Lukehart SA. Normalization of serum rapid plasma reagin titer predicts normalization of cerebrospinal fluid and clinical abnormalities after treatment of neurosyphilis. Clin Infect Dis. 2008;47:893–9.
  613. Xiao Y, Tong ML, Lin LR, et al. Serological response predicts normalization of cerebrospinal fluid abnormalities at six months after treatment in HIV-negative neurosyphilis patients. Sci Rep. 2017;7(1):9911.
  614. Hook EW 3rd, Baker-Zander SA, Moskovitz BL, Lukehart SA, Handsfield HH. Ceftriaxone therapy for asymptomatic neurosyphilis: case report and Western blot analysis of serum and cerebrospinal fluid IgG response to therapy. Sex Transm Dis. 1986;13(3 Suppl):185–8.
  615. Shann S, Wilson J. Treatment of neurosyphilis with ceftriaxone. Sex Transm Infect. 2003;79:415–6.
  616. Ahmed KA, Fox SJ, Frigas E, Park MA. Clinical outcome in the use of cephalosporins in pediatric patients with a history of penicillin allergy. Int Arch Allergy Immunol. 2012;158:405–10.
  617. Park MA, Koch CA, Klemawesch P, Joshi A, Li JT. Increased adverse drug reactions to cephalosporins in penicillin allergy patients with positive penicillin skin test. Int Arch Allergy Immunol. 2010;153:268–73.
  618. Novalbos A, Sastre J, Cuesta J, et al. Lack of allergic cross-reactivity to cephalosporins among patients allergic to penicillins. Clin Exp Allergy. 2001;31:438–43.
  619. Pichichero ME, Casey JR. Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis. Otolaryngol Head Neck Surg. 2007;136(3):340–7.
  620. Kingston AA, Vujevich J, Shapiro M, et al. Seronegative secondary syphilis in 2 patients coinfected with human immunodeficiency virus. Arch Dermatol. 2005;141:431–3.
  621. Centers for Disease Control and Prevention. Symptomatic early neurosyphilis among HIV-positive men who have sex with men–four cities, United States, January 2002-June 2004. MMWR Morb Mortal Wkly Rep. 2007;56(25):625–8.
  622. Ghanem KG, Moore RD, Rompalo AM, Erbelding EJ, Zenilman JM, Gebo KA. Neurosyphilis in a clinical cohort of HIV-1-infected patients. AIDS. 2008;22:1145–51.
  623. Ghanem KG, Moore RD, Rompalo AM, Erbelding EJ, Zenilman JM, Gebo KA. Antiretroviral therapy is associated with reduced serologic failure rates for syphilis among HIV-infected patients. Clin Infect Dis. 2008;47:258–65.
  624. Tomkins A, Ahmad S, Cousins DE, Thng CM, Vilar FJ, Higgins SP. Screening for asymptomatic neurosyphilis in HIV patients after treatment of early syphilis: an observational study. Sex Transm Infect. 2018;94(5):337–9.
  625. Ghanem, K.G., Sensitivity and specificity of lumbar puncture in HIV-infected patients with syphilis and no neurologic symptoms reply. Clin Infect Dis, 2009. 49: p. 162–3.
  626. Marra CM, Boutin P, McArthur JC, et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2000;30(3):540–4.
  627. Dowell ME, Ross PG, Musher DM, Cate TR, Baughn RE. Response of latent syphilis or neurosyphilis to ceftriaxone therapy in persons infected with human immunodeficiency virus. Am J Med. 1992;93:481–8.
  628. Smith NH, Musher DM, Huang DB, et al. Response of HIV-infected patients with asymptomatic syphilis to intensive intramuscular therapy with ceftriaxone or procaine penicillin. Int J STD AIDS. 2004;15:328–32.
  629. Ahmed KA, Fox SJ, Frigas E, Park MA. Clinical outcome in the use of cephalosporins in pediatric patients with a history of penicillin allergy. Int Arch Allergy Immunol. 2012;158:405–10.
  630. Trivedi S, Williams C, Torrone E, Kidd S. National trends and reported risk factors among pregnant women with syphilis in the United States, 2012-2016. Obstet Gynecol. 2019;133(1):27–32.
  631. Park IU, Chow JM, Bolan G, Stanley M, Shieh J, Schapiro JM. Screening for syphilis with the treponemal immunoassay: analysis of discordant serology results and implications for clinical management. J Infect Dis. 2011;204(9):1297–304.
  632. Mmeje O, Chow JM, Davidson L, Shieh J, Schapiro JM, Park IU. Discordant syphilis immunoassays in pregnancy: perinatal outcomes and implications for clinical management. Clin Infect Dis. 2015;61(7):1049–53.
  633. Alexander JM, Sheffield JS, Sanchez PJ, Mayfield J, Wendel GD Jr. Efficacy of treatment for syphilis in pregnancy. Obstet Gynecol. 1999;93:5–8.
  634. Walker GJ. Antibiotics for syphilis diagnosed during pregnancy. Cochrane Database Syst Rev. 2001;(3):CD001143.
  635. Wendel GD Jr, Sheffield JS, Hollier LM, Hill JB, Ramsey PS, Sánchez PJ. Treatment of syphilis in pregnancy and prevention of congenital syphilis. Clin Infect Dis. 2002;35(Suppl 2):S200–9.
  636. Zhu L, Qin M, Du L, Xie RH, Wong T, Wen SW. Maternal and congenital syphilis in Shanghai, China, 2002 to 2006. Int J Infect Dis. 2010;14 Suppl 3:e45–8.
  637. Hawkes S, Matin N, Broutet N, Low N. Effectiveness of interventions to improve screening for syphilis in pregnancy: a systematic review and meta-analysis. Lancet Infect Dis. 2011;11:684–91.
  638. Hollier LM, Harstad TW, Sanchez PJ, Twickler DM, Wendel GD Jr. Fetal syphilis: clinical and laboratory characteristics. Obstet Gynecol. 2001;97:947–53.
  639. Rac MW, Bryant SN, McIntire DD, et al. Progression of ultrasound findings of fetal syphilis after maternal treatment. Am J Obstet Gynecol. 2014;211(4):426.e1–6.
  640. Zhou P, Gu Z, Xu J, Wang X, Liao K. A study evaluating ceftriaxone as a treatment agent for primary and secondary syphilis in pregnancy. Sex Transm Dis. 2005;32(8):495–8.
  641. Katanami Y, Hashimoto T, Takaya S, et al. Amoxicillin and ceftriaxone as treatment alternatives to penicillin for maternal syphilis. Emerg Infect Dis. 2017;23(5):827–9.
  642. Biswas HH, Chew Ng RA, Murray EL, et al. Characteristics associated with delivery of an infant with congenital syphilis and missed opportunities for prevention-California, 2012 to 2014. Sex Transm Dis. 2018;45(7):435–41.
  643. Slutsker JS, Hennessy RR, Schillinger JA. Factors contributing to congenital syphilis cases – New York City, 2010-2016. MMWR Morb Mortal Wkly Rep. 2018;67(39):1088–93.
  644. DiOrio D, Kroeger K, Ross A. Social vulnerability in congenital syphilis case mothers: qualitative assessment of cases in Indiana, 2014 to 2016. Sex Transm Dis. 2018;45(7):447–51.
  645. Kimball A, Torrone E, Miele K, et al. Missed opportunities for prevention of congenital syphilis – United States, 2018. MMWR Morb Mortal Wkly Rep. 2020;69(22):661–5.
  646. Kestenbaum LA, Ebberson J, Zorc JJ, Hodinka RL, Shah SS. Defining cerebrospinal fluid white blood cell count reference values in neonates and young infants. Pediatrics. 2010;125(2):257–64.
  647. Shah SS, Ebberson J, Kestenbaum LA, Hodinka RL, Zorc JJ. Age-specific reference values for cerebrospinal fluid protein concentration in neonates and young infants. J Hosp Med. 2011;6(1):22–7.
  648. Thomson J, Sucharew H, Cruz AT, et al. Cerebrospinal fluid reference values for young infants undergoing lumbar puncture. Pediatrics. 2018;141(3):e20173405.
  649. Kimberlin DW, Brady MT, Jackson MA, Long SS, editors. Red book: 2018 report of the Committee on Infectious Diseases. 31st Itasca (IL): American Academy of Pediatrics; 2018. 1213 p.
  650. Macy E, Contreras R. Adverse reactions associated with oral and parenteral use of cephalosporins: a retrospective population-based analysis. J Allergy Clin Immunol. 2015;135(3):745–52.e5.
  651. Macy E, Vyles D. Who needs penicillin allergy testing? Ann Allergy Asthma Immunol. 2018;121(5):523–9.
  652. Annè S, Reisman RE. Risk of administering cephalosporin antibiotics to patients with histories of penicillin allergy. Ann Allergy Asthma Immunol. 1995;74:167–70.
  653. Albin S, Agarwal S. Prevalence and characteristics of reported penicillin allergy in an urban outpatient adult population. Allergy Asthma Proc. 2014;35:489–94.
  654. Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Lancet. 2019;393(10167):183–98.
  655. Macy E, Poon K-Y T. Self-reported antibiotic allergy incidence and prevalence: age and sex effects. Am J Med. 2009;122(8):778(e1–7).
  656. Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and management of penicillin allergy: a review. JAMA. 2019;321(2):188–99.
  657. Gadde J, Spence M, Wheeler B, Adkinson NF Jr. Clinical experience with penicillin skin testing in a large inner-city STD clinic. JAMA. 1993;270:2456–63.
  658. Macy E, Ngor EW. Safely diagnosing clinically significant penicillin allergy using only penicilloyl-poly-lysine, penicillin, and oral amoxicillin. J Allergy Clin Immunol Pract. 2013;1:258–63.
  659. Jares EJ, Sánchez-Borges M, Cardona-Villa R, et al. Multinational experience with hypersensitivity drug reactions in Latin America. Ann Allergy Asthma Immunol. 2014;113(3):282–9.
  660. Macy E, Contreras R. Health care use and serious infection prevalence associated with penicillin “allergy” in hospitalized patients: a cohort study. J Allergy Clin Immunol. 2014;133(3):790–6.
  661. Blumenthal KG, Lu N, Zhang Y, Li Y, Walensky RP, Choi HK. Risk of meticillin resistant Staphylococcus aureus and Clostridium difficile in patients with a documented penicillin allergy: population based matched cohort study. BMJ. 2018;361:k2400.
  662. Blumenthal KG, Ryan EE, Li Y, Lee H, Kuhlen JL, Shenoy ES. The impact of a reported penicillin allergy on surgical site infection risk. Clin Infect Dis. 2018;66(3):329–36.
  663. Tucker MH, Lomas CM, Ramchandar N, Waldram JD. Amoxicillin challenge without penicillin skin testing in evaluation of penicillin allergy in a cohort of Marine recruits. J Allergy Clin Immunol Pract. 2017;5(3):813–5.
  664. Goldberg A, Confino-Cohen R. Skin testing and oral penicillin challenge in patients with a history of remote penicillin allergy. Ann Allergy Asthma Immunol. 2008;100(1):37–43.
  665. Iammatteo M, Alvarez Arango S, Ferastraoaru D, et al. Safety and outcomes of oral graded challenges to amoxicillin without prior skin testing. J Allergy Clin Immunol Pract. 2019;7(1):236–43.
  666. Cook DJ, Barbara DW, Singh KE, Dearani JA. Penicillin skin testing in cardiac surgery. J Thorac Cardiovasc Surg. 2014;147(6):1931–5.
  667. McDanel DL, Azar AE, Dowden AM, et al. Screening for beta-lactam allergy in joint arthroplasty patients to improve surgical prophylaxis practice. J Arthroplasty. 2017;32(9s):S101–8.
  668. Trubiano JA, Thursky KA, Stewardson AJ, et al. Impact of an integrated antibiotic allergy testing program on antimicrobial stewardship: a multicenter evaluation. Clin Infect Dis. 2017;65(1):166–74.
  669. Siew LQC, Li PH, Watts TJ, et al. Identifying low-risk beta-lactam allergy patients in a UK tertiary centre. J Allergy Clin Immunol Pract. 2019;7(7):2173–81.e1.
  670. Chen JR, Tarver SA, Alvarez KS, Tran T, Khan DA. A proactive approach to penicillin allergy testing in hospitalized patients. J Allergy Clin Immunol Pract. 2017;5(3):686–93.
  671. Leis JA, Palmay L, Ho G, et al. Point-of-care β-lactam allergy skin testing by antimicrobial stewardship programs: a pragmatic multicenter prospective evaluation. Clin Infect Dis. 2017;65(7):1059–65.
  672. Banks TA, Tucker M, Macy E. Evaluating penicillin allergies without skin testing. Curr Allergy Asthma Rep. 2019;19(5):27.
  673. Pham MN, Ho HE, Desai M. Penicillin desensitization: treatment of syphilis in pregnancy in penicillin-allergic patients. Ann Allergy Asthma Immunol. 2017;118(5):537–41.
  674. Sogn DD, Evans R 3rd, Shepherd GM, et al. Results of the National Institute of Allergy and Infectious Diseases Collaborative Clinical Trial to test the predictive value of skin testing with major and minor penicillin derivatives in hospitalized adults. Arch Intern Med. 1992;152:1025–32.
  675. Solensky R, Jacobs J, Lester M, et al. Penicillin allergy evaluation: a prospective, multicenter, open-label evaluation of a comprehensive penicillin skin test kit. J Allergy Clin Immunol Pract. 2019;7(6):1876–85.e3.
  676. Heil EL, Bork JT, Schmalzle SA, et al. Implementation of an infectious disease fellow-managed penicillin allergy skin testing service. Open Forum Infect Dis. 2016;3(3):ofw155.
  677. du Plessis T, Walls G, Jordan A, Holland DJ. Implementation of a pharmacist-led penicillin allergy de-labelling service in a public hospital. J Antimicrob Chemother. 2019;74(5):1438–46.
  678. Macy E, Blumenthal KG. Are cephalosporins safe for use in penicillin allergy without prior allergy evaluation? J Allergy Clin Immunol Pract. 2018;6(1):82–9.
  679. Zagursky RJ, Pichichero ME. Cross-reactivity in β-lactam allergy. J Allergy Clin Immunol Pract. 2018;6(1):72–81.e1.
  680. Blumenthal KG, Shenoy ES, Varughese CA, Hurwitz S, Hooper DC, Banerji A. Impact of a clinical guideline for prescribing antibiotics to inpatients reporting penicillin or cephalosporin allergy. Ann Allergy Asthma Immunol. 2015;115(4):294–300.e2.
  681. Kuruvilla M, Wolf F, Sexton M, Wiley Z, Thomas J. Perioperative use of cefazolin without preliminary skin testing in patients with reported penicillin allergy. Surgery. 2019;165(2):486–96.
  682. Lee P, Shanson D. Results of a UK survey of fatal anaphylaxis after oral amoxicillin. J Antimicrob Chemother. 2007;60(5):1172–3.
  683. Blumenthal KG, Shenoy ES, Wolfson AR, et al. Addressing inpatient beta-lactam allergies: a multihospital implementation. J Allergy Clin Immunol Pract. 2017;5(3):616–25.e7.
  684. Mustafa SS, Conn K, Ramsey A. Comparing direct challenge to penicillin skin testing for the outpatient evaluation of penicillin allergy: a randomized controlled trial. J Allergy Clin Immunol Pract. 2019;7(7):2163–70.
  685. Chastain DB, Hutzley VJ, Parekh J, Alegro JVG. Antimicrobial desensitization: a review of published protocols. Pharmacy (Basel). 2019;7(3):112.
  686. Wendel GD Jr, Stark BJ, Jamison RB, Molina RD, Sullivan TJ. Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med. 1985;312:1229–32.
  687. Borish L, Tamir R, Rosenwasser LJ. Intravenous desensitization to beta-lactam antibiotics. J Allergy Clin Immunol. 1987;80(3 Pt 1):314–9.
  688. Legere HJ 3rd, Palis RI, Rodriguez Bouza T, Uluer AZ, Castells MC. A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity. J Cyst Fibros. 2009;8:418–24.
  689. Manhart LE, Holmes KK, Hughes JP, Houston LS, Totten PA. Mycoplasma genitalium among young adults in the United States: an emerging sexually transmitted infection. Am J Public Health. 2007;97(6):1118–25.
  690. Ross JDC, Jensen JS. Mycoplasma genitalium as a sexually transmitted infection: implications for screening, testing, and treatment. Sex Transm Infect. 2006;82:269–71.
  691. Taylor-Robinson D, Gilroy CB, Thomas BJ, Hay PE. Mycoplasma genitalium in chronic non-gonococcal urethritis. Int J STD AIDS. 2004;15:21–5.
  692. Dupin N, Bijaoui G, Schwarzinger M, et al. Detection and quantification of Mycoplasma genitalium in male patients with urethritis. Clin Infect Dis. 2003;37:602–5.
  693. Krieger JN, Riley DE, Roberts MC, Berger RE. Prokaryotic DNA sequences in patients with chronic idiopathic prostatitis. J Clin Microbiol. 1996;34:3120–8.
  694. le Roux MC, Hoosen AA. Quantitative real-time polymerase chain reaction for the diagnosis of Mycoplasma genitalium infection in South African men with and without symptoms of urethritis. 2017;44(1):17–20.
  695. Bachmann LH, Kirkcaldy RD, Geisler WM, et al. Prevalence of Mycoplasma genitalium infection, antimicrobial resistance mutations and symptom resolution following treatment of urethritis. Clin Infect Dis. 2020;71(10):e624–32.
  696. Nye MB, Schwebke JR, Body BA. Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women. Am J Obstet Gynecol. 2009;200:188.e1–7.
  697. Bradshaw CS, Tabrizi SN, Read TR, et al. Etiologies of nongonococcal urethritis: bacteria, viruses, and the association with orogenital exposure. J Infect Dis. 2006;193:336–45.
  698. Dombrowski JC, Harrington RD, Golden MR. Evidence for the long-term stability of HIV transmission-associated sexual behavior after HIV diagnosis. Sex Transm Dis. 2013;40(1):41–5.
  699. Rane VS, Fairley CK, Weerakoon A, et al. Characteristics of acute nongonococcal urethritis in men differ by sexual preference. J Clin Microbiol. 2014;52(8):2971–6.
  700. Pond MJ, Nori AV, Witney AA, Lopeman RC, Butcher PD, Sadiq ST. High prevalence of antibiotic-resistant Mycoplasma genitalium in nongonococcal urethritis: the need for routine testing and the inadequacy of current treatment options. Clin Infect Dis. 2014;58(5):631–7.
  701. Khatib N, Bradbury C, Chalker V, et al. Prevalence of Trichomonas vaginalis, Mycoplasma genitalium and Ureaplasma urealyticum in men with urethritis attending an urban sexual health clinic. Int J STD AIDS. 2015;26(6):388–92.
  702. Cox C, McKenna JP, Watt AP, Coyle PV. Ureaplasma parvum and Mycoplasma genitalium are found to be significantly associated with microscopy-confirmed urethritis in a routine genitourinary medicine setting. Int J STD AIDS. 2016;27(10):861–7.
  703. Li Y, Su X, Le W, et al. Mycoplasma genitalium in symptomatic male urethritis: macrolide use is associated with increased resistance. Clin Infect Dis. 2020;70(5):805–10.
  704. Ito S, Hanaoka N, Shimuta K, et al. Male non-gonococcal urethritis: from microbiological etiologies to demographic and clinical features. Int J Urol. 2016;23(4):325–31.
  705. Horner P, Donders G, Cusini M, Gomberg M, Jensen JS, Unemo M. Should we be testing for urogenital Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum in men and women? – a position statement from the European STI Guidelines Editorial Board. J Eur Acad Dermatol Venereol. 2018;32(11):1845–51.
  706. van der Veer C, van Rooijen MS, Himschoot M, de Vries HJ, Bruisten SM. Trichomonas vaginalis and Mycoplasma genitalium: age-specific prevalence and disease burden in men attending a sexually transmitted infections clinic in Amsterdam, the Netherlands. Sex Transm Infect. 2016;92(1):83–5.
  707. Seike K, Maeda S, Kubota Y, Tamaki M, Yasuda M, Deguchi T. Prevalence and morbidity of urethral Trichomonas vaginalis in Japanese men with or without urethritis. Sex Transm Infect. 2013;89(6):528–30.
  708. Napierala M, Munson E, Wenten D, et al. Detection of Mycoplasma genitalium from male primary urine specimens: an epidemiologic dichotomy with Trichomonas vaginalis. Diagn Microbiol Infect Dis. 2015;82(3):194–8.
  709. Sviben M, Missoni EM, Meštrović T, Vojnović G, Galinović GM. Epidemiology and laboratory characteristics of Trichomonas vaginalis infection in Croatian men with and without urethritis syndrome: a case-control study. Sex Transm Infect. 2015;91(5):360–4.
  710. Rietmeijer CA, Mungati M, Machiha A, et al., The etiology of male urethral discharge in Zimbabwe: results from the Zimbabwe STI Etiology Study. Sex Transm Dis. 2018;45(1):56–60.
  711. Bazan JA, Peterson AS, Kirkcaldy RD, et al. Notes from the field: increase in Neisseria meningitidis-associated urethritis among men at two sentinel clinics – Columbus, Ohio, and Oakland County, Michigan, 2015. MMWR Morb Mortal Wkly Rep. 2016;65(21):550–2.
  712. Jannic A, Mammeri H, Larcher L, et al. Orogenital transmission of Neisseria meningitidis causing acute urethritis in men who have sex with men. Emerg Infect Dis. 2019;25(1):175–6.
  713. Hayakawa K, Itoda I, Shimuta K, Takahashi H, Ohnishi M. Urethritis caused by novel Neisseria meningitidis serogroup W in man who has sex with men, Japan. Emerg Infect Dis. 2014;20(9):1585–7.
  714. Bazan JA, Tzeng YL, Stephens DS, et al. Repeat episodes of symptomatic urethritis due to a uropathogenic meningococcal clade. Sex Transm Dis. 2020;47(1):e1–4.
  715. Ong JJ, Morton AN, Henzell HR, et al. Clinical characteristics of herpes simplex virus urethritis compared with chlamydial urethritis among men. Sex Transm Dis. 2017;44(2):121–5.
  716. Avolio M, De Rosa R, Modolo ML, Stano P, Camporese A. When should adenoviral non-gonococcal urethritis be suspected? Two case reports. New Microbiol. 2014;37(1):109–12.
  717. You C, Hamasuna R, Ogawa M, et al. The first report: an analysis of bacterial flora of the first voided urine specimens of patients with male urethritis using the 16S ribosomal RNA gene-based clone library method. Microb Pathog. 2016;95:95–100.
  718. Deguchi T, Ito S, Hatazaki K, et al. Antimicrobial susceptibility of Haemophilus influenzae strains isolated from the urethra of men with acute urethritis and/or epididymitis. J Infect Chemother. 2017;23(11):804–7.
  719. Ito S, Hatazaki K, Shimuta K, et al. Haemophilus influenzae isolated from men with acute urethritis: its pathogenic roles, responses to antimicrobial chemotherapies, and antimicrobial susceptibilities. Sex Transm Dis. 2017;44(4):205–10.
  720. Horie K, Ito S, Hatazaki K, et al. ‘Haemophilus quentini’ in the urethra of men complaining of urethritis symptoms. J Infect Chemother. 2018;24(1):71–4.
  721. Frølund M, Falk L, Ahrens P, Jensen JS. Detection of ureaplasmas and bacterial vaginosis associated bacteria and their association with non-gonococcal urethritis in men. PLoS One. 2019;14(4):e0214425.
  722. Deza G, Martin-Ezquerra G, Gómez J, Villar-García J, Supervia A, Pujol RM. Isolation of Haemophilus influenzae and Haemophilus parainfluenzae in urethral exudates from men with acute urethritis: a descriptive study of 52 cases. Sex Transm Infect. 2016;92(1):29–31.
  723. Magdaleno-Tapial J, Valenzuela-Oñate C, Giacaman-von der Weth MM, et al. Haemophilus species isolated in urethral exudates as a possible causative agent in acute urethritis: a study of 38 cases. Actas Dermosifiliogr. 2019;110(1):38–42. English, Spanish.
  724. Abdolrasouli A, Roushan A. Corynebacterium propinquum associated with acute, nongonococcal urethritis. Sex Transm Dis. 2013;40(10):829–31.
  725. Ongrádi J, Stercz B, Kövesdi V, Nagy K, Chatlynne L. Isolation of Kurthia gibsonii from non-gonorrheal urethritis: implications for the pathomechanism upon surveying the literature. Acta Microbiol Immunol Hung. 2014;61(1):79–87.
  726. Gherardi G, Di Bonaventura G, Pompilio A, Savini V. Corynebacterium glucuronolyticum causing genitourinary tract infection: case report and review of the literature. IDCases. 2015;2(2):56–8.
  727. Meštrović T. A microbial game of whack-a-mole: clinical case series of the urethral uncloaking phenomenon caused by Corynebacterium glucuronolyticum in men treated for Chlamydia trachomatis urethritis. Infection. 2019;47(1):121–4.
  728. Frikh M, El Yaagoubi I, Lemnouer A, Elouennass M. Urethritis due to corynebacterium striatum: an emerging germ. Tunis Med. 2015;93(1):43–4.
  729. Babaeer AA, Nader C, Iacoviello V, Tomera K. Necrotizing urethritis due to Aerococcus urinae. Case Rep Urol. 2015;2015:136147.
  730. Grandolfo M, Vestita M, Bonamonte D, Filoni A. Acute urethritis and Balonoposthitis associated to Neisseria elongata. Sex Transm Dis. 2016;43(12):778–9.
  731. Frølund M, Lidbrink P, Wikström A, Cowan S, Ahrens P, Jensen JS. Urethritis-associated pathogens in urine from men with non-gonococcal urethritis: a case-control study. Acta Derm Venereol. 2016;96(5):689–94.
  732. Chambers LC, Morgan JL, Lowens MS, et al. Cross-sectional study of urethral exposures at last sexual episode associated with non-gonococcal urethritis among STD clinic patients. Sex Transm Infect. 2019;95(3):212–8.
  733. Manhart LE, Khosropour CM, Liu C, et al. Bacterial vaginosis-associated bacteria in men: association of Leptotrichia/Sneathia spp. with nongonococcal urethritis. Sex Transm Dis. 2013;40(12):944–9.
  734. Ashraf J, Radford AR, Turner A, Subramaniam R. Preliminary experience with instillation of triamcinolone acetonide into the urethra for idiopathic urethritis: a prospective pilot study. J Laparoendosc Adv Surg Tech A. 2017;27(11):1217–21.
  735. Taylor SN, DiCarlo RP, Martin DH. Comparison of methylene blue/gentian violet stain to Gram’s stain for the rapid diagnosis of gonococcal urethritis in men. Sex Transm Dis. 2011;38(11):995–6.
  736. Reitmeijer CA, Mettenbrink CJ. Recalibrating the Gram stain diagnosis of male urethritis in the era of nucleic acid amplification testing. Sex Transm Dis. 2012;39:18–20.
  737. Geisler WM, Yu S, Hook EW 3rd. Chlamydial and gonococcal infection in men without polymorphonuclear leukocytes on Gram stain: implications for diagnostic approach and management. Sex Transm Dis. 2005;32:630–4.
  738. Gottesman T, Yossepowitch O, Samra Z, Rosenberg S, Dan M. Prevalence of Mycoplasma genitalium in men with urethritis and in high risk asymptomatic males in Tel Aviv: a prospective study. Int J STD AIDS. 2017;28(2):127–32.
  739. Kim HJ, Park JK, Park SC, et al. The prevalence of causative organisms of community-acquired urethritis in an age group at high risk for sexually transmitted infections in Korean Soldiers. J R Army Med Corps. 2017;163(1):20–2.
  740. Libois A, Hallin M, Crucitti T, Delforge M, De Wit S. Prevalence of Mycoplasma genitalium in men with urethritis in a large public hospital in Brussels, Belgium: an observational, cross-sectional study. PLoS One. 2018;13(4):e0196217.
  741. Bachmann LH, Manhart LE, Martin DH, et al. Advances in the understanding and treatment of male urethritis. Clin Infect Dis. 2015;61 Suppl 8:S763–9.
  742. Samaraweera GR, Garcia K, Druce J, et al. Characteristics of adenovirus urethritis among heterosexual men and men who have sex with men: a review of clinical cases. Sex Transm Infect. 2016;92(3):172–4.
  743. Horner P, Blee K, O’Mahony C, et al. 2015 UK National Guideline on the management of non-gonococcal urethritis. Int J STD AIDS. 2016;27(2):85–96.
  744. Sarier M, Sepin N, Duman I, et al. Microscopy of Gram-stained urethral smear in the diagnosis of urethritis: which threshold value should be selected? Andrologia. 2018;50(10):e13143.
  745. Sarier, M. and E. Kukul, Classification of non-gonococcal urethritis: a review. Int Urol Nephrol, 2019. 51(6): p. 901–7.
  746. Kong FY, Tabrizi SN, Law M, et al. Azithromycin versus doxycycline for the treatment of genital chlamydia infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;59(2):193–205.
  747. Páez-Canro C, Alzate JP, González LM, Rubio-Romero JA, Lethaby A, Gaitán HG. Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non-pregnant women. Cochrane Database Syst Rev. 2019;1(1):CD010871.
  748. McIver R, Jalocon D, McNulty A, et al. Men who have sex with men with Mycoplasma genitalium-positive nongonococcal urethritis are more likely to have macrolide resistant strains than men with only female partners: a prospective study. Sex Transm Dis. 2019 Apr 17. doi: 10.1097/OLQ.0000000000001009. Epub ahead of print. PMID: 31008841.
  749. Lau A, Bradshaw CS, Lewis D, et al. The efficacy of azithromycin for the treatment of genital Mycoplasma genitalium: a systematic review and meta-analysis. Clin Infect Dis. 2015;61(9):1389–99.
  750. Horner P. Mycoplasma genitalium nongonococcal urethritis is likely to increase in men who have sex with men who practice unsafe sex: what should we do? Sex Transm Dis. 2019;46(8):518–20.
  751. Hosenfeld CB, Workowski KA, Berman S, et al. Repeat infection with Chlamydia and gonorrhea among females: a systematic review of the literature. Sex Transm Dis. 2009;36:478–89.
  752. Fung M, Scott KC, Kent CK, Klausner JD. Chlamydial and gonococcal reinfection among men: a systematic review of data to evaluate the need for retesting. Sex Transm Infect. 2007;83:304–9.
  753. Kissinger PJ, White S, Manhart LE, et al. Azithromycin treatment failure for Chlamydia trachomatis among heterosexual men with nongonococcal urethritis. Sex Transm Dis. 2016;43(10):599–602.
  754. Schwebke JR, Rompalo A, Taylor S, et al. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens–a randomized clinical trial. Clin Infect Dis. 2011;52(2):163–70.
  755. Manhart LE, Khosropour CM, Gillespie CW, Lowens MS, Golden MR, Totten PA. Treatment outcomes for persistent Mycoplasma genitalium-associated NGU: evidence of moxifloxacin treatment failures. Sex Transm Infect. 2013;89(Suppl 1):A29.
  756. Romano SS, Jensen JS, Lowens MS, et al. Long duration of asymptomatic Mycoplasma genitalium infection after syndromic treatment for nongonococcal urethritis. Clin Infect Dis. 2019;69(1):113–20.
  757. Read TRH, Fairley CK, Murray GL, et al. Outcomes of resistance-guided sequential treatment of Mycoplasma genitalium infections: a prospective evaluation. Clin Infect Dis. 2019;68(4):554–60.
  758. Dowe G, Smikle M, King SD, Baum M, Chout R, Williams Y. Symptomatic and asymptomatic chlamydial non-gonococcal urethritis in Jamaica: the potential for HIV transmission. Int J STD AIDS. 2000;11(3):187–90.
  759. Lusk MJ, Garden FL, Rawlinson WD, Naing ZW, Cumming RG, Konecny P. Cervicitis aetiology and case definition: a study in Australian women attending sexually transmitted infection clinics. Sex Transm Infect. 2016;92(3):175–81.
  760. Lusk MJ, Konecny P. Cervicitis: a review. Curr Opin Infect Dis. 2008;21:49–55.
  761. Marrazzo JM, Martin DH. Management of women with cervicitis. Clin Infect Dis. 2007;44(Suppl 3):S102–10.
  762. Manavi K, Young H, Clutterbuck D. Sensitivity of microscopy for the rapid diagnosis of gonorrhoea in men and women and the role of gonorrhoea serovars. Int J STD AIDS. 2003;14(6):390–4.
  763. Lillis RA, Martin DH, Nsuami MJ. Mycoplasma genitalium infections in women attending a sexually transmitted disease clinic in New Orleans. Clin Infect Dis. 2018;69(3):459–65.
  764. Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. Clin Infect Dis. 2015;61(3):418–26.
  765. Oliphant J, Azariah S. Cervicitis: limited clinical utility for the detection of Mycoplasma genitalium in a cross-sectional study of women attending a New Zealand sexual health clinic. Sex Health. 2013;10(3):263–7.
  766. Sethi S, Rajkumari N, Dhaliwal L, Roy A. P3.294 Association of Mycoplasma genitalium with cervicitis in North Indian women attending gynecologic clinics. Sex Transm Infect. 2013;89(Suppl 1):A240–1.
  767. Taylor SN, Lensing S, Schwebke J, et al. Prevalence and treatment outcome of cervicitis of unknown etiology. Sex Transm Dis. 2013;40:379–85.
  768. Mobley VL, Hobbs MM, Lau K, Weinbaum BS, Getman DK, Seña AC. Mycoplasma genitalium infection in women attending a sexually transmitted infection clinic: diagnostic specimen type, coinfections, and predictors. Sex Transm Dis. 2012;39(9):706–9.
  769. Marrazzo JM, Wiesenfeld HC, Murray PJ, et al. Risk factors for cervicitis among women with bacterial vaginosis. J Infect Dis. 2006;193:617–24.
  770. Gaydos C, Maldeis NE, Hardick A, Hardick J, Quinn TC. Mycoplasma genitalium as a contributor to the multiple etiologies of cervicitis in women attending sexually transmitted disease clinics. Sex Transm Dis. 2009;36:598–606.
  771. Clark LR, Atendido M. Group B streptococcal vaginitis in postpubertal adolescent girls. J Adolesc Health. 2005;36(5):437–40.
  772. Hester EE, Middleman AB. A clinical conundrum: chronic cervicitis. J Pediatr Adolesc Gynecol. 2019;32(3):342–4.
  773. Liu L, Cao G, Zhao Z, Zhao F, Huang Y. High bacterial loads of Ureaplasma may be associated with non-specific cervicitis. Scand J Infect Dis. 2014;46(9):637–41.
  774. Leli C, Mencacci A, Latino MA, et al. Prevalence of cervical colonization by Ureaplasma parvum, Ureaplasma urealyticum, Mycoplasma hominis and Mycoplasma genitalium in childbearing age women by a commercially available multiplex real-time PCR: an Italian observational multicentre study. J Microbiol Immunol Infect. 2018;51(2):220–5.
  775. Manhart LE. Has the time come to systematically test for Mycoplasma genitalium? Sex Transm Dis. 2009;36:607–8.
  776. Liu HL, Chen CM, Pai LW, Hwu YJ, Lee HM, Chung YC. Comorbidity profiles among women with postcoital bleeding: a nationwide health insurance database. Arch Gynecol Obstet. 2017;295(4):935–41.
  777. Coleman JS, Hitti J, Bukusi EA, et al. Infectious correlates of HIV-1 shedding in the female upper and lower genital tracts. AIDS. 2007;21:755–9.
  778. Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. Sex Transm Dis. 2008;35(11):946–59.
  779. McClelland RS, Wang CC, Mandaliya K, et al. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS. 2001;15:105–10.
  780. Gatski M, Martin DH, Theall K, et al. Mycoplasma genitalium infection among HIV-positive women: prevalence, risk factors and association with vaginal shedding. Int J STD AIDS. 2011;22:155–9.
  781. Gitau RW, Graham SM, Masese LN, et al. Effect of acquisition and treatment of cervical infections on HIV-1 shedding in women on antiretroviral therapy. AIDS. 2010;24:2733–77.
  782. Aghaizu A, Reid F, Kerry S, et al. Frequency and risk factors for incident and redetected Chlamydia trachomatis infection in sexually active, young, multi-ethnic women: a community based cohort study. Sex Transm Infect. 2014;90(7):524–8.
  783. Scholes D, Satterwhite CL, Yu O, Fine D, Weinstock H, Berman S. Long-term trends in Chlamydia trachomatis infections and related outcomes in a U.S. managed care population. Sex Transm Dis. 2012;39:81–8.
  784. Kamwendo F, Forslin L, Bodin L, Danielsson D. Decreasing incidences of gonorrhea- and chlamydia-associated acute pelvic inflammatory disease: a 25-year study from an urban area of central Sweden. Sex Transm Dis. 1996;23:384–91.
  785. Rietmeijer CA, Hopkins E, Geisler WM, Orr DP, Kent CK. Chlamydia trachomatis positivity rates among men tested in selected venues in the United States: a review of the recent literature. Sex Transm Dis. 2008;35:S8–18.
  786. Gift TL, Blake DR, Gaydos CA, Marrazzo JM. The cost-effectiveness of screening men for Chlamydia trachomatis: a review of the literature. Sex Transm Dis. 2008;35(Supp1):S51–60.
  787. Gift TL, Gaydos CA, Kent CK, et al. The program cost and cost-effectiveness of screening men for Chlamydia to prevent pelvic inflammatory disease in women. Sex Transm Dis. 2008;35(Supp1):S66–75.
  788. Gopalappa C, Huang YL, Gift TL, Owusu-Edusei K, Taylor M, Gales V. Cost-effectiveness of screening men in Maricopa County jails for chlamydia and gonorrhea to avert infections in women. Sex Transm Dis. 2013;40(10):776–83.
  789. Masek BJ, Arora N, Quinn N, et al. Performance of three nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae by use of self-collected vaginal swabs obtained via an internet-based screening program. J Clin Microbiol. 2009;47:1663–7.
  790. Knox J, Tabrizi SN, Miller P, et al. Evaluation of self-collected samples in contrast to practitioner-collected samples for detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis by polymerase chain reaction among women living in remote areas. Sex Transm Dis. 2002;29:647–54.
  791. Schachter J, Chernesky MA, Willis DE, et al. Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for both infections. Sex Transm Dis. 2005;32:725–8.
  792. Doshi JS, Power J, Allen E. Acceptability of chlamydia screening using self-taken vaginal swabs. Int J STD AIDS. 2008;19:507–9.
  793. Chernesky MA, Jang D, Portillo E, et al. Self-collected swabs of the urinary meatus diagnose more Chlamydia trachomatis and Neisseria gonorrhoeae infections than first catch urine from men. Sex Transm Infect. 2013;89(2):102–4.
  794. Dize L, Barnes P Jr, Barnes M, et al. Performance of self-collected penile-meatal swabs compared to clinician-collected urethral swabs for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium by nucleic acid amplification assays. Diagn Microbiol Infect Dis. 2016;86(2):131–5.
  795. Berry L, Stanley B. Comparison of self-collected meatal swabs with urine specimens for the diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in men. J Med Microbiol. 2017;66(2):134–6.
  796. Chernesky M, Freund GG, Hook E 3rd, Leone P, D’Ascoli P, Martens M. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae infections in North American women by testing SurePath liquid-based Pap specimens in APTIMA assays. J Clin Microbiol. 2007;45:2434–8.
  797. Schachter J, Moncada J, Liska S, Shayevich C, Klausner JD. Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections of the oropharynx and rectum in men who have sex with men. Sex Transm Dis. 2008;35:637–42.
  798. Mimiaga MJ, Mayer KH, Reisner SL, et al. Asymptomatic gonorrhea and chlamydial infections detected by nucleic acid amplification tests among Boston area men who have sex with men. Sex Transm Dis. 2008;35:495–8.
  799. Bachmann LH, Johnson RE, Cheng H, Markowitz LE, Papp JR, Hook EW 3rd. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae oropharyngeal infections. J Clin Microbiol. 2009;47:902–7.
  800. Bachmann LH, Johnson RE, Cheng H, et al. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis rectal infections. J Clin Microbiol. 2010;48:1827–32.
  801. Cosentino LA, Danby CS, Rabe LK, et al. Use of nucleic acid amplification testing for diagnosis of extragenital sexually transmitted infections. J Clin Microbiol. 2017;55(9):2801–7.
  802. Food and Drug Administration. Microbiology Devices Panel of the Medical Devices Advisory Committee Meeting Announcement [Internet]. FDA; Mar 2019 [cited 2019]. Available from: https://www.fda.gov/advisory-committees/advisory-committee-calendar/march-8-2019-microbiology-devices-panel-medical-devices-advisory-committee-meeting-announcement#event-materialsexternal icon.
  803. Sexton ME, Baker JJ, Nakagawa K, et al. How reliable is self-testing for gonorrhea and chlamydia among men who have sex with men? J Fam Pract. 2013;62:70–8.
  804. Herbst de Cortina S, Bristow CC, Joseph Davey D, Klausner JD. A systematic review of point of care testing for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. Infect Dis Obstet Gynecol. 2016;2016:4386127.
  805. Rivard KR, Dumkow LE, Draper HM, Brandt KL, Whalen DW, Egwuatu NE. Impact of rapid diagnostic testing for chlamydia and gonorrhea on appropriate antimicrobial utilization in the emergency department. Diagn Microbiol Infect Dis. 2017;87(2):175–9.
  806. Wingrove I, McOwan A, Nwokolo N, Whitlock G. Diagnostics within the clinic to test for gonorrhoea and chlamydia reduces the time to treatment: a service evaluation. Sex Transm Infect. 2014;90(6):474.
  807. Geisler WM, Wang C, Morrison SG, Black CM, Bandea CI, Hook EW 3rd. The natural history of untreated Chlamydia trachomatis infection in the interval between screening and returning for treatment. Sex Transm Dis. 2008;35:119–23.
  808. Dukers-Muijrers NHTM, Wolffs PFG, De Vries H, et al. Treatment effectiveness of azithromycin and doxycycline in uncomplicated rectal and vaginal Chlamydia trachomatis infections in women: a multicentre observational study (FemCure). Clin Infect Dis. 2019;69(11):1946‐54.
  809. Dombrowski JC, Wierzbicki MR, Newman L, et al. A randomized trial of azithromycin vs. doxycycline for the treatment of rectal chlamydia in men who have sex with men. Presented at: National STD Prevention Conference; 2020 Sep 14–24; Atlanta, GA.
  810. Dukers-Muijrers NH, Schachter J, van Liere GA, Wolffs PF, Hoebe CJ. What is needed to guide testing for anorectal and pharyngeal Chlamydia trachomatis and Neisseria gonorrhoeae in women and men? evidence and opinion. BMC Infect Dis. 2015;15:533.
  811. Marcus JL, Kohn RP, Barry PM, Philip SS, Bernstein KT. Chlamydia trachomatis and Neisseria gonorrhoeae transmission from the female oropharynx to the male urethra. Sex Transm Dis. 2011;38:372–3.
  812. Manavi K, Hettiarachchi N, Hodson J. Comparison of doxycycline with azithromycin in treatment of pharyngeal chlamydia infection. Int J STD AIDS. 2016;27(14):1303–8.
  813. Rank RG, Yeruva L. An alternative scenario to explain rectal positivity in Chlamydia-infected individuals. Clin Infect Dis. 2015;60(10):1585–6.
  814. Geisler WM, Koltun WD, Abdelsayed N, et al. Safety and efficacy of WC2031 versus vibramycin for the treatment of uncomplicated urogenital Chlamydia trachomatis infection: a randomized, double-blind, double-dummy, active-controlled, multicenter trial. Clin Infect Dis. 2012;55:82–8.
  815. Renault CA, Israelski DM, Levy V, Fujikawa BK, Kellogg TA, Klausner JD. Time to clearance of Chlamydia trachomatis ribosomal RNA in women treated for chlamydial infection. Sex Health. 2011;8:69–73.
  816. Lazenby GB, Korte JE, Tillman S, Brown FK, Soper DE. A recommendation for timing of repeat Chlamydia trachomatis test following infection and treatment in pregnant and nonpregnant women. Int J STD AIDS. 2017;28(9):902–9.
  817. Dunne EF, Chapin JB, Rietmeijer CA, et al. Rate and predictors of repeat Chlamydia trachomatis infection among men. Sex Transm Dis. 2008;35(Supp1):S40–4.
  818. Kjaer HO, Dimcevski G, Hoff G, Olesen F, Ostergaard L. Recurrence of urogenital Chlamydia trachomatis infection evaluated by mailed samples obtained at home: 24 weeks’ prospective follow up study. Sex Transm Infect. 2000;76:169–72.
  819. Whittington WL, Kent C, Kissinger P, et al. Determinants of persistent and recurrent Chlamydia trachomatis infection in young women: results of a multicenter cohort study. Sex Transm Dis. 2001;28:117–23.
  820. Kapil R, Press CG, Hwang ML, Brown L, Geisler WM. Investigating the epidemiology of repeat Chlamydia trachomatis detection after treatment by using C. trachomatis OmpA genotyping. J Clin Microbiol. 2015;53(2):546–9.
  821. Jacobson GF, Autry AM, Kirby RS, Liverman EM, Motley RU. A randomized controlled trial comparing amoxicillin and azithromycin for the treatment of Chlamydia trachomatis in pregnancy. Am J Obstet Gynecol. 2001;184:1352–4.
  822. Kacmar J, Cheh E, Montagno A, Peipert JF. A randomized trial of azithromycin versus amoxicillin for the treatment of Chlamydia trachomatis in pregnancy. Infect Dis Obstet Gynecol. 2001;9:197–202.
  823. Rahangdale L, Guerry S, Bauer HM, et al. An observational cohort study of Chlamydia trachomatis treatment in pregnancy. Sex Transm Dis. 2006;33:106–10.
  824. Aggarwal A, Spitzer RF, Caccia N, Stephens D, Johnstone J, Allen L. Repeat screening for sexually transmitted infection in adolescent obstetric patients. J Obstet Gynaecol Can. 2010;32:956–61.
  825. Phillips Campbell R, Kintner J, Whittimore J, Schoborg RV. Chlamydia muridarum enters a viable but non-infectious state in amoxicillin-treated BALB/c mice. Microbes Infect. 2012;14:1177–85.
  826. Wyrick PB. Chlamydia trachomatis persistence in vitro: an overview. J Infect Dis. 2010;201(Suppl 2):S88–95.
  827. Fan H, Li L, Wijlaars L, Gilbert RE. Associations between use of macrolide antibiotics during pregnancy and adverse child outcomes: a systematic review and meta-analysis. PLoS One. 2019;14(2):e0212212.
  828. Fan H, Gilbert R, O’Callaghan F, Li L. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. BMJ. 2020;368:m331.
  829. Mallah N, Tohidinik HR, Etminan M, Figueiras A, Takkouche B. Prenatal exposure to macrolides and risk of congenital malformations: a meta-analysis. Drug Saf. 2020;43(3):211–21.
  830. Hammerschlag MR, Cummings C, Roblin PM, Williams TH, Delke I. Efficacy of neonatal ocular prophylaxis for the prevention of chlamydial and gonococcal conjunctivitis. N Engl J Med. 1989;320(12):769–72.
  831. Zikic A, Schünemann H, Wi T, Lincetto O, Broutet N, Santesso N. Treatment of neonatal chlamydial conjunctivitis: a systematic review and meta-analysis. J Pediatric Infect Dis Soc. 2018;7(3):e107–15.
  832. Hammerschlag MR, Chandler JW, Alexander ER, English M, Koutsky L. Longitudinal studies on chlamydial infections in the first year of life. Ped Infect Dis. 1982;1:395–401.
  833. Beem MO, Saxon E, Tipple MA. Treatment of chlamydial pneumonia of infancy. Pediatrics. 1979;63:198–203.
  834. Brownell AD, Shapiro RA, Hammerschlag MR. Caution is required when using non-Food and Drug Administration-cleared assays to diagnose sexually transmitted infections in children. J Pediatr. 2019;206:280–2.
  835. Lunny C, Taylor D, Hoang L, et al. Self-collected versus clinician-collected sampling for chlamydia and gonorrhea screening: a systemic review and meta-analysis. PLoS One. 2015;10(7):e0132776.
  836. Schick V, Van Der Pol B, Dodge B, Baldwin A, Fortenberry JD. A mixed methods approach to assess the likelihood of testing for STI using self-collected samples among behaviourally bisexual women. Sex Transm Infect. 2015;91(5):329–33.
  837. Mustanski B, Feinstein BA, Madkins K, Sullivan P, Swann G. Prevalence and risk factors for rectal and urethral sexually transmitted infections from self-collected samples among young men who have sex with men participating in the Keep It Up! 2.0 randomized controlled trial. Sex Transm Dis. 2017;44(8):483–8.
  838. Salow KR, Cohen AC, Bristow CC, McGrath MR, Klausner JD. Comparing mail-in self-collected specimens sent via United States Postal Service versus clinic-collected specimens for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in extra-genital sites. PLoS One. 2017;12(12):e0189515.
  839. Drake C, Barenfanger J, Lawhorn J, Verhulst S. Comparison of Easy-Flow Copan Liquid Stuart’s and Starplex swab transport systems for recovery of fastidious aerobic bacteria. J Clin Microbiol. 2005;43:1301–3.
  840. Wade JJ, Graver MA. Survival of six auxotypes of Neisseria gonorrhoeae in transport media. J Clin Microbiol. 2003;41:1720–1.
  841. Arbique JC, Forward KR, LeBlanc J. Evaluation of four commercial transport media for the survival of Neisseria gonorrhoeae. Diagn Microbiol Infect Dis. 2000;36:163–8.
  842. Hook EW 3rd, Kirkcaldy RD. A brief history of evolving diagnostics and therapy for gonorrhea: lessons learned. Clin Infect Dis. 2018;67(8):1294–9.
  843. Unemo M, Shafer WM. Future treatment of gonorrhea–novel emerging drugs are essential and in progress? Expert Opin Emerg Drugs. 2015;20(3):357–60.
  844. Sánchez-Busó L, Golparian D, Corander J, et al. The impact of antimicrobials on gonococcal evolution. Nat Microbiol. 2019;4(11):1941–50.
  845. Schwarcz SK, Zenilman JM, Schnell D, et al. National surveillance of antimicrobial resistance in Neisseria gonorrhoeae. JAMA. 1990;264:1413–7.
  846. Centers for Disease Control and Prevention. Update to CDC’s sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep. 2007;56(14):332–6.
  847. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2013. Atlanta: U.S. Department of Health and Human Services, CDC; 2014. 176 p.
  848. Muratani T, Akasaka S, Kobayashi T, et al. Outbreak of cefozopran (penicillin, oral cephems, and aztreonam)-resistant Neisseria gonorrhoeae in Japan. Antimicrob Agents Chemother. 2001;45:3603–6.
  849. Yokoi S, Deguchi T, Ozawa T, et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis. 2007;13:1275–7.
  850. Lo JY, Ho KM, Leung AO, et al. Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection. Antimicrob Agents Chemother. 2008;52:3564–7.
  851. Deguchi T, Yasuda M, Yokoi S, et al. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother. 2003;9:35–9.
  852. Unemo M, Golparian D, Hestner A. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill. 2011;16(6):19792.
  853. Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill. 2010;15:19721.
  854. Unemo M, Golparian D, Potočnik M, Jeverica S. Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011. Euro Surveill. 2012;17:20200.
  855. Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill. 2011;16:19833.
  856. Forsyth S, Penney P, Rooney G. Cefixime-resistant Neisseria gonorrhoeae in the UK: a time to reflect on practice and recommendations. Int J STD AIDS. 2011;22:296–7.
  857. Lewis DA, Sriruttan C, Müller EE, et al. Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrob Chemother. 2013;68:1267–70.
  858. Ota KV, Fisman DN, Tamari IE, et al. Incidence and treatment outcomes of pharyngeal Neisseria gonorrhoeae and Chlamydia trachomatis infections in men who have sex with men: a 13-year retrospective cohort study. Clin Infect Dis. 2009;48:1237–43.
  859. Allen VG, Mitterni L, Seah C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA. 2013;309:163–70.
  860. Chen MY, Stevens K, Tideman R, et al. Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia. J Antimicrob Chemother. 2013;68:1445–7.
  861. Tapsall J, Read P, Carmody C, et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol. 2009;58(Pt 5):683–7.
  862. Ohnishi M, Saika T, Hoshina S, et al. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis. 2011;17:148–9.
  863. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012;56:1273–80.
  864. Centers for Disease Control and Prevention. Update to CDC’s sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep. 2012;61(31):590–4.
  865. Wind CM, de Vries E, Schim van der Loeff MF, et al. Decreased azithromycin susceptibility of Neisseria gonorrhoeae isolates in patients recently treated with azithromycin. Clin Infect Dis. 2017;65(1):37–45.
  866. Kong FYS, Horner P, Unemo M, Hocking JS. Pharmacokinetic considerations regarding the treatment of bacterial sexually transmitted infections with azithromycin: a review. J Antimicrob Chemother. 2019;74(5):1157–66.
  867. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019 [Internet]. Atlanta (GA): U.S. Department of Health and Human Services, CDC; 2019 [cited 2020]. 150 p. Available from: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdfpdf icon
  868. St Cyr S, Barbee L, Workowski KA, et al. Update to CDC’s Treatment Guidelines for Gonococcal Infection, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(50):1911–6.
  869. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twentieth informational supplement. Clinical and Laboratory Standards Institute document M100-S20. Wayne (PA): Clinical and Laboratory Standards Institute;2010.
  870. Centers for Disease Control and Prevention. Cephalosporin-resistant Neisseria gonorrhoeae public health response plan [Internet]. US Department of Health and Human Services, CDC, NCHHSTP, DSTDP; Aug 2012 [cited 2020]; 43 p. Available from: http://www.cdc.gov/std/treatment/Ceph-R-ResponsePlanJuly30-2012.pdfpdf icon
  871. Poncin T, Merimeche M, Braille A, et al., Two cases of multidrug-resistant Neisseria gonorrhoeae related to travel in south-eastern Asia, France, June 2019. Euro Surveill. 2019;24(36):1900528.
  872. Carnicer-Pont D, Smithson A, Fina-Homar E, Bastida MT; Gonococcus Antimicrobial Resistance Surveillance Working Group. First cases of Neisseria gonorrhoeae resistant to ceftriaxone in Catalonia, Spain, May 2011. Enferm Infecc y Microbiol Clin. 2012;30:218–9. English, Spanish.
  873. Cámara J, Serra J, Ayats J, et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother. 2012;67:1858–60.
  874. Eyre DW, Sanderson ND, Lord E, et al. Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Euro Surveill. 2018;23(27):1800323.
  875. Fifer, H., et al., Lessons learnt from ceftriaxone-resistant gonorrhoea in the UK and Australia. Lancet Infect Dis, 2020. 20(3): p. 276–8.
  876. Chisholm SA, Hughes G, Whiley D, Lahra MM. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother. 2010;65(10):2141–8.
  877. Connolly KL, Eakin AE, Gomez C, Osborn BL, Unemo M, Jerse AE. Pharmacokinetic data are predictive of in vivo efficacy for cefixime and ceftriaxone against susceptible and resistant Neisseria gonorrhoeae strains in the gonorrhea mouse model. Antimicrob Agents Chemother. 2019;63(3):e01644–18.
  878. Blondeau JM, Hansen G, Metzler K, Hedlin P. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J Chemother. 2004;16 Suppl 3:1–19.
  879. Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis. 1995;20 Suppl 1:S47–65.
  880. Unemo M, Golparian D, Eyre DW. Antimicrobial resistance in Neisseria gonorrhoeae and treatment of gonorrhea. Methods Mol Biol. 2019;1997:37–58.
  881. Kirkcaldy RD, Weinstock HS, Moore PC, et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis. 2014;59:1083–91.
  882. Ross JDC, Brittain C, Cole M, et al. Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial. Lancet. 2019;393(10190):2511–20.
  883. Singh V, Bala M, Bhargava A, Kakran M, Bhatnagar R. In vitro efficacy of 21 dual antimicrobial combinations comprising novel and currently recommended combinations for treatment of drug resistant gonorrhoea in future era. PLoS One. 2018;13(3):e0193678.
  884. Mayer KH, Klausner JD, Handsfield HH. Intersecting epidemics and educable moments – sexually transmitted disease risk assessment and screening in men who have sex with men. Sex Transm Dis. 2001;28:464–7.
  885. Linhart Y, Shohat T, Amitai Z, et al. Sexually transmitted infections among brothel-based sex workers in Tel-Aviv area, Israel: high prevalence of pharyngeal gonorrhoea. Int J of STD AIDS. 2008;19:656–9.
  886. Johnson Jones ML, Chapin-Bardales J, Bizune D, et al. Extragenital chlamydia and gonorrhea among community venue-attending men who have sex with men – five cities, United States, 2017. MMWR Morb Mortal Wkly Rep. 2019;68(14):321–5.
  887. Chow EP, Williamson DA, Fortune R, et al. Prevalence of genital and oropharyngeal chlamydia and gonorrhoea among female sex workers in Melbourne, Australia, 2015-2017: need for oropharyngeal testing. Sex Transm Infect. 2019;95(6):398–401.
  888. Cornelisse VJ, Williamson D, Zhang L, et al. Evidence for a new paradigm of gonorrhoea transmission: cross-sectional analysis of Neisseria gonorrhoeae infections by anatomical site in both partners in 60 male couples. Sex Transm Infect. 2019;95(6):437–42.
  889. Kissinger PJ, Reilly K, Taylor SN, Leichliter JS, Rosenthal S, Martin DH. Early repeat Chlamydia trachomatis and Neisseria gonorrhoeae infections among heterosexual men. Sex Transm Dis. 2009;36:498–500.
  890. Berenger BM, Demczuk W, Gratrix J, Pabbaraju K, Smyczek P, Martin I. Genetic characterization and enhanced surveillance of ceftriaxone-resistant Neisseria gonorrhoeae strain, Alberta, Canada, 2018. Emerg Infect Dis. 2019;25(9):1660–7.
  891. Rob F, Klubalová B, Nyčová E, Hercogová J, Unemo M. Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial. Clin Microbiol Infect. 2020;26(2):207–12.
  892. Romano A, Gaeta F, Valluzzi RL, Caruso C, Rumi G, Bousquet PJ. IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of penicillins, monobactams, and carbapenems. J Allergy Clin Immunol. 2010;126:994–9.
  893. American College of Obstetricians and Gynecologists’ Committee on Obstetric Practice. Committee opinion No. 717: Sulfonamides, nitrofurantoin, and risk of birth defects. Obstet Gynecol. 2017;130(3):e150–2.
  894. Haimovici R, Roussel TJ. Treatment of gonococcal conjunctivitis with single-dose intramuscular ceftriaxone. Am J Ophthalmol. 1989;107:511–4.
  895. Bleich AT, Sheffield JS, Wendel GD Jr, Sigman A, Cunningham FG. Disseminated gonococcal infection in women. Obstet Gynecol. 2012;119(3):597–602.
  896. Belkacem A, Caumes E, Ouanich J, et al. Changing patterns of disseminated gonococcal infection in France: cross-sectional data 2009-2011. Sex Transm Infect. 2013;89:613–5.
  897. Birrell JM, Gunathilake M, Singleton S, Williams S, Krause V. Characteristics and impact of disseminated gonococcal infection in the “Top End” of Australia. Am J Trop Med Hyg. 2019;101(4):753–60.
  898. Crew PE, Abara WE, McCulley L, et al. Disseminated gonococcal infections in patients receiving eculizumab: a case series. Clin Infect Dis. 2019;69(4):596–600.
  899. S. Preventive Services Task Force, Curry SJ, Krist AH, et al. Ocular prophylaxis for gonococcal ophthalmia neonatorum: US Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2019;321(4):394–8.
  900. Kreisel K, Weston E, Braxton J, Llata E, Torrone E. Keeping an eye on chlamydia and gonorrhea conjunctivitis in infants in the United States, 2010-2015. Sex Transm Dis. 2017;44(6):356–8.
  901. Scott WJ, Eck CD. Povidone-iodine and ophthalmia neonatorum. Ophthalmology. 2012;119:653–4.
  902. David M, Rumelt S, Weintraub Z. Efficacy comparison between povidone iodine 2.5% and tetracycline 1% in prevention of ophthalmia neonatorum. Ophthalmology. 2011;118:1454–8.
  903. Binenbaum G, Bruno CJ, Forbes BJ, et al. Periocular ulcerative dermatitis associated with gentamicin ointment prophylaxis in newborns. J Pediatr. 2010;156:320–1.
  904. Nathawad R, Mendez H, Ahmad A, et al. Severe ocular reactions after neonatal ocular prophylaxis with gentamicin ophthalmic ointment. Pediatr Infect Dis J. 2011;30:175–6.
  905. Taylor-Robinson D, Jensen JS. Mycoplasma genitalium: from Chrysalis to multicolored butterfly. Clin Microbiol Rev. 2011;24(3):498–514.
  906. Seña AC, Lensing S, Rompalo A, et al. Chlamydia trachomatis, Mycoplasma genitalium, and Trichomonas vaginalis infections in men with nongonococcal urethritis: predictors and persistence after therapy. J Infect Dis. 2012;206(3):357–65.
  907. Huppert JS, Mortensen JE, Reed JL, Kahn JA, Rich KD, Hobbs MM. Mycoplasma genitalium detected by transcription-mediated amplification is associated with Chlamydia trachomatis in adolescent women. Sex Transm Dis. 2008;35:250–4.
  908. Mena L, Wang X, Mroczkowski TF, Martin DH. Mycoplasma genitalium infections in asymptomatic men and men with urethritis attending a sexually transmitted diseases clinic in New Orleans. Clin Infect Dis. 2002;35:1167–73.
  909. Falk L. The overall agreement of proposed definitions of mucopurulent cervicitis in women at high risk of chlamydia infection. Acta Derm Venereol. 2010;90:506–11.
  910. Anagrius C, B Loré, Jensen JS. Mycoplasma genitalium: prevalence, clinical significance, and transmission. Sex Transm Infect. 2005;81:458–62.
  911. Manhart LE, Critchlow CW, Holmes KK, et al. Mucopurulent cervicitis and Mycoplasma genitalium. J Infect Dis. 2003;187:650–7.
  912. Lusk MJ, Konecny P, Naing ZW, Garden FL, Cumming RG, Rawlinson WD. Mycoplasma genitalium is associated with cervicitis and HIV infection in an urban Australian STI clinic population. Sex Transm Infect. 2011;87:107–9.
  913. Dehon PM, McGowin CL. The immunopathogenesis of Mycoplasma genitalium infections in women: a narrative review. Sex Transm Dis. 2017;44(7):428–32.
  914. Bjartling C, Osser S, Persson K. The association between Mycoplasma genitalium and pelvic inflammatory disease after termination of pregnancy. Brit J Obstet Gynecol. 2010;117:361–4.
  915. Bjartling C, Osser S, Persson K. Mycoplasma genitalium in cervicitis and pelvic inflammatory disease among women at a gynecologic outpatient service. Am J Obstet Gynecol. 2012;206(6):476.e1–8.
  916. Taylor BD, Zheng X, O’Connell CM, Wiesenfeld HC, Hillier SL, Darville T. Risk factors for Mycoplasma genitalium endometritis and incident infection: a secondary data analysis of the T cell Response Against Chlamydia (TRAC) Study. Sex Transm Infect. 2018;94(6):414–20.
  917. Cohen CR, Mugo NR, Astete SG, et al. Detection of Mycoplasma genitalium in women with laparoscopically diagnosed acute salpingitis. Sex Transm Infect. 2005;81:463–6.
  918. Haggerty CL, Totten PA, Astete SG, Ness RB. Mycoplasma genitalium among women with nongonococcal, nonchlamydial pelvic inflammatory disease. Infect Dis Obstet Gynecol. 2006;2006:30184.
  919. Short VL, Totten PA, Ness RB, Astete SG, Kelsey SF, Haggerty CL. Clinical presentation of Mycoplasma genitalium Infection versus Neisseria gonorrhoeae infection among women with pelvic inflammatory disease. Clin Infect Dis. 2009;48(1):41–7.
  920. Simms I, Eastick K, Mallinson H, et al. Associations between Mycoplasma genitalium, Chlamydia trachomatis, and pelvic inflammatory disease. Sex Transm Infect. 2003;79:154–6.
  921. Oakeshott P, Aghaizu A, Hay P, et al. Is Mycoplasma genitalium in women the “New Chlamydia?” A community-based prospective cohort study. Clin Infect Dis. 2010;51(10):1160–6.
  922. Wiesenfeld HC, Hillier SL, Meyn L, et al. Mycoplasma genitalium – is it a pathogen in acute pelvic inflammatory disease (PID)? Sex Transm Infect. 2013;89(Suppl 1):A34.
  923. Møller BR, Taylor-Robinson D, Furr PM, Freundt EA. Acute upper genital-tract disease in female monkeys provoked experimentally by Mycoplasma genitalium. Br J Exp Pathol. 1985;66(4):417–26.
  924. Wiesenfeld HC, Manhart LE. Mycoplasma genitalium in women: current knowledge and research priorities for this recently emerged pathogen. J Infect Dis. 2017;216(suppl_2):S389–95.
  925. Clausen HF, Fedder J, Drasbek M, et al. Serological investigation of Mycoplasma genitalium in infertile women. Hum Reprod. 2001;16(9):1866–74.
  926. Svenstrup HF, Fedder J, Kristoffersen SE, Trolle B, Birkelund S, Christiansen G. Mycoplasma genitalium, Chlamydia trachomatis, and tubal factor infertility–a prospective study. Fertil Steril. 2008;90(3):513–20.
  927. Idahl A, Jurstrand M, Olofsson JI, Fredlund H. Mycoplasma genitalium serum antibodies in infertile couples and fertile women. Sex Transm Infect. 2015;91(8):589–91.
  928. Edwards RK, Ferguson RJ, Reyes L, Brown M, Theriaque DW, Duff P. Assessing the relationship between preterm delivery and various microorganisms recovered from the lower genital tract. J Matern Fetal Neonatal Med. 2006;19:357–63.
  929. Vandepitte J, Bukenya J, Hughes P, et al. Clinical characteristics associated with Mycoplasma genitalium infection among women at high risk of HIV and other STI in Uganda. Sex Transm Dis. 2012;39:487–91.
  930. Rowlands S, Danielewski JA, Tabrizi SN, Walker SP, Garland SM. Microbial invasion of the amniotic cavity in midtrimester pregnancies using molecular microbiology. Am J Obstet Gynecol. 2017;217(1):71.e1–5.
  931. Jurstrand M, Jensen JS, Magnuson A, Kamwendo F, Fredlund H. A serological study of the role of Mycoplasma genitalium in pelvic inflammatory disease and ectopic pregnancy. Sex Transm Infect. 2007;83:319–23.
  932. Ashshi AM, Batwa SA, Kutbi SY, Malibary FA, Batwa M, Refaat B. Prevalence of 7 sexually transmitted organisms by multiplex real-time PCR in Fallopian tube specimens collected from Saudi women with and without ectopic pregnancy. BMC Infect Dis. 2015;15:569.
  933. Bissessor M, Tabrizi SN, Bradshaw CS, et al. The contribution of Mycoplasma genitalium to the aetiology of sexually acquired infectious proctitis in men who have sex with men. Clin Microbiol Infect. 2016;22(3):260–5.
  934. Ong JJ, Aung E, Read TRH, et al. Clinical characteristics of anorectal Mycoplasma genitalium infection and microbial cure in men who have sex with men. Sex Transm Dis. 2018;45(8):522–6.
  935. Read TRH, Murray GL, Danielewski JA, et al. symptoms, sites, and significance of Mycoplasma genitalium in men who have sex with men. Emerg Infect Dis. 2019;25(4):719–27.
  936. Cina M, Baumann L, Egli-Gany D, et al. Mycoplasma genitalium incidence, persistence, concordance between partners and progression: systematic review and meta-analysis. Sex Transm Infect. 2019;95(5):328–35.
  937. Baumann L, Cina M, Egli-Gany D, et al. Prevalence of Mycoplasma genitalium in different population groups: systematic review andmeta-analysis. Sex Transm Infect. 2018;94(4):255–62.
  938. Vandepitte J, Weiss HA, Bukenya J, et al. Association between Mycoplasma genitalium infection and HIV acquisition among female sex workers in Uganda: evidence from a nested case-control study. Sex Transm Infect. 2014;90(7):545–9.
  939. Ferré VM, Ekouevi DK, Gbeasor-Komlanvi FA, et al. Prevalence of human papillomavirus, human immunodeficiency virus and other sexually transmitted infections among female sex workers in Togo: a national cross-sectional survey. Clin Microbiol Infect. 2019;25(12):1560.e1–7.
  940. Mavedzenge SN, Van Der Pol B, Weiss HA, et al. The association between Mycoplasma genitalium and HIV-1 acquisition in African women. AIDS. 2012;26(5):617–24.
  941. Salado-Rasmussen K, Jensen JS. Mycoplasma genitalium testing pattern and macrolide resistance: a Danish nationwide retrospective survey. Clin Infect Dis. 2014;59(1):24–30.
  942. Wold C, Sorthe J, Hartgill U, Olsen AO, Moghaddam A, Reinton N. Identification of macrolide-resistant Mycoplasma genitalium using real-time PCR. J Eur Acad Dermatol Venereol. 2015;29(8):1616–20.
  943. Gesink D, Racey CS, Seah C, et al. Mycoplasma genitalium in Toronto, Ont: estimates of prevalence and macrolide resistance. Can Fam Physician. 2016;62(2):e96–101.
  944. Kristiansen GQ, Lisby JG, Schønning K. A 5′ nuclease genotyping assay for identification of macrolide-resistant Mycoplasma genitalium in clinical specimens. J Clin Microbiol. 2016;54(6):1593–7.
  945. Braam JF, Slotboom B, Van Marm S, et al. High prevalence of the A2058T macrolide resistance-associated mutation in Mycoplasma genitalium strains from the Netherlands. J Antimicrob Chemother. 2017;72(5):1529–30.
  946. Murray GL, Bradshaw CS, Bissessor M, et al. Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium. Emerg Infect Dis. 2017;23(5):809–12.
  947. Chernesky MA, Jang D, Martin I, et al. Mycoplasma genitalium antibiotic resistance-mediating mutations in Canadian women with or without Chlamydia trachomatis infection. Sex Transm Dis. 2017;44(7):433–5.
  948. Barberá MJ, Fernández-Huerta M, Jensen JS, Caballero E, Andreu A. Mycoplasma genitalium macrolide and fluoroquinolone resistance: prevalence and risk factors among a 2013-2014 cohort of patients in Barcelona, Spain. Sex Transm Dis. 2017;44(8):457–62.
  949. Sweeney EL, Trembizki E, Bletchly C, et al. Levels of Mycoplasma genitalium antimicrobial resistance differ by both region and gender in the state of Queensland, Australia: implications for treatment guidelines. J Clin Microbiol. 2019;57(3):e01555-18.
  950. Bissessor M, Tabrizi SN, Twin J, et al. Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens. Clin Infect Dis. 2015;60(8):1228–36.
  951. Piñeiro L, Idigoras P, de la Caba I, López-Olaizola M, Cilla G. Guided antibiotic therapy for Mycoplasma genitalium infections: analysis of mutations associated with resistance to macrolides and fluoroquinolones. Enferm Infecc Microbiol Clin. 2019;37(6):394–7. English, Spanish.
  952. Dionne-Odom J, Geisler WM, Aaron KJ, et al. High prevalence of multidrug-resistant Mycoplasma genitalium in human immunodeficiency virus-infected men who have sex with men in Alabama. Clin Infect Dis. 2018;66(5):796–8.
  953. Pitt R, Fifer H, Woodford N, Alexander S. Detection of markers predictive of macrolide and fluoroquinolone resistance in Mycoplasma genitalium from patients attending sexual health services in England. Sex Transm Infect. 2018;94(1):9–13.
  954. Unemo M, Salado-Rasmussen K, Hansen M, et al. Clinical and analytical evaluation of the new Aptima Mycoplasma genitalium assay, with data on M. genitalium prevalence and antimicrobial resistance in M. genitalium in Denmark, Norway and Sweden in 2016. Clin Microbiol Infect. 2018;24(5):533–9.
  955. Anderson T, Coughlan E, Werno A. Mycoplasma genitalium macrolide and fluoroquinolone resistance detection and clinical implications in a selected cohort in New Zealand. J Clin Microbiol. 2017;55(11):3242–8.
  956. Shimada Y, Deguchi T, Nakane K, et al. Emergence of clinical strains of Mycoplasma genitalium harbouring alterations in ParC associated with fluoroquinolone resistance. Int J Antimicrob Agents. 2010;36(3):255–8.
  957. Muller EE, Mahlangu MP, Lewis DA, Kularatne RS. Macrolide and fluoroquinolone resistance-associated mutations in Mycoplasma genitalium in Johannesburg, South Africa, 2007-2014. BMC Infect Dis. 2019;19(1):148.
  958. Chambers LC, Jensen JS, Morgan JL, et al. Lack of association between the S83I ParC mutation in Mycoplasma genitalium and treatment outcomes among men who have sex with men with nongonococcal urethritis. Sex Transm Dis. 2019;46(12):805–9.
  959. Durukan D, Read TRH, Murray G, et al. Resistance-guided antimicrobial therapy using doxycycline-moxifloxacin and doxycycline-2.5g azithromycin for the treatment of Mycoplasma genitalium infection: efficacy and tolerability. Clin Infect Dis. 2020;71(6):1461–8.
  960. Li Y, Le WJ, Li S, Cao YP, Su XH. Meta-analysis of the efficacy of moxifloxacin in treating Mycoplasma genitalium infection. Int J STD AIDS. 2017;28(11):1106–14.
  961. Mondeja BA, Couri J, Rodríguez NM, Blanco O, Fernández C, Jensen JS. Macrolide-resistant Mycoplasma genitalium infections in Cuban patients: an underestimated health problem. BMC Infect Dis. 2018;18(1):601.
  962. Glaser AM, Geisler WM, Ratliff AE, Xiao L, Waites KB, Gaisa M. Two cases of multidrug-resistant genitourinary Mycoplasma genitalium infection successfully eradicated with minocycline. Int J STD AIDS. 2019;30(5):512–4.
  963. Xiao L, Waites KB, Van Der Pol B, Aaron KJ, Hook EW 3rd, Geisler WM. Mycoplasma genitalium infections with macrolide and fluoroquinolone resistance-associated mutations in heterosexual African American couples in Alabama. Sex Transm Dis. 2019;46(1):18–24.
  964. Slifirski JB, Vodstrcil LA, Fairley CK, et al. Mycoplasma genitalium infection in adults reporting sexual contact with infected partners, Australia, 2008-2016. Emerg Infect Dis. 2017;23(11):1826–33.
  965. Anderson MR, Klink K, Cohrssen A. Evaluation of vaginal complaints. 2004;291(11):1368–79.
  966. Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol. 2005;106(5 Pt 1):1013–23.
  967. Brotman RM, Klebanoff MA, Nansel TR, et al. Bacterial vaginosis assessed by Gram stain and diminished colonization resistance to incident gonococcal, chlamydial, and trichomonal genital infection. J Infect Dis. 2010;202:1907–15.
  968. Peebles K, Velloza J, Balkus JE, McClelland RS, Barnabas RV. High global burden and costs of bacterial vaginosis: a systematic review and meta-analysis. Sex Transm Dis. 2019;46(5):304–11.
  969. Kenyon CR, Buyze J, Klebanoff M, Brotman RM. Association between bacterial vaginosis and partner concurrency: a longitudinal study. Sex Transm Infect. 2018;94(1):75–7.
  970. Sanchez S, Garcia PJ, Thomas KK, Catlin M, Holmes KK. Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial. Am J Obstet Gynecol. 2004;191(6):1898–906.
  971. Ness RB, Soper DE, Holley RL, et al. Douching and endometritis: results from the PID evaluation and clinical health (PEACH) study. Sex Transm Dis. 2001;28(4):240–5.
  972. Gondwe T, Ness R, Totten PA, et al. Novel bacterial vaginosis-associated organisms mediate the relationship between vaginal douching and pelvic inflammatory disease. Sex Transm Infect. 2020;96(6):439–44.
  973. Abbai NS, Reddy T, Ramjee G. Prevalent bacterial vaginosis infection – a risk factor for incident sexually transmitted infections in women in Durban, South Africa. Int J STD AIDS. 2016;27(14):1283–8.
  974. Morris BJ, Hankins CA, Banerjee J, et al. Does male circumcision reduce women’s risk of sexually transmitted infections, cervical cancer, and associated conditions? Front Public Health. 2019;7:4.
  975. Srinivasan S, Liu C, Mitchell CM, et al. Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis. PLoS One. 2010;5(4):e10197.
  976. Gajer P, Brotman RM, Bai G, et al. Temporal dynamics of the human vaginal microbiota. Sci Transl Med. 2012;4(132):132ra52.
  977. Fethers KA, Fairley CK, Morton A, et al. Early sexual experiences and risk factors for bacterial vaginosis. J Infect Dis. 2009;200:1662–70.
  978. Achilles SL, Austin MN, Meyn LA, Mhlanga F, Chirenje ZM, Hillier SL. Impact of contraceptive initiation on vaginal microbiota. Am J Obstet Gynecol. 2018;218(6):622.e1–10.
  979. Vodstrcil LA, Plummer ME, Fairley CK, et al. Combined oral contraceptive pill-exposure alone does not reduce the risk of bacterial vaginosis recurrence in a pilot randomised controlled trial. Sci Rep. 2019;9(1):3555.
  980. Brooks JP, Edwards DJ, Blithe DL, et al. Effects of combined oral contraceptives, depot medroxyprogesterone acetate and the levonorgestrel-releasing intrauterine system on the vaginal microbiome. Contraception. 2017;95(4):405–13.
  981. Moore KR, Harmon QE, Baird DD. Serum 25-hydroxyvitamin D and risk of self-reported bacterial vaginosis in a prospective cohort study of Young African American women. J Womens Health (Larchmt). 2018;27(10):1278–84.
  982. Lokken EM, Balkus JE, Kiarie J, et al. Association of recent bacterial vaginosis with acquisition of Mycoplasma genitalium. Am J Epidemiol. 2017;186(2):194–201.
  983. Brusselaers N, Shrestha S, van de Wijgert J, Verstraelen H. Vaginal dysbiosis and the risk of human papillomavirus and cervical cancer: systematic review and meta-analysis. Am J Obstet Gynecol. 2019;221(1):9–18.e8.
  984. Abbai NS, Nyirenda M, Naidoo S, Ramjee G. Prevalent herpes simplex virus-2 increases the risk of incident bacterial vaginosis in women from South Africa. AIDS Behav. 2018;22(7):2172–80.
  985. Laxmi U, Agrawal S, Raghunandan C, Randhawa VS, Saili A. Association of bacterial vaginosis with adverse fetomaternal outcome in women with spontaneous preterm labor: a prospective cohort study. J Matern Fetal Neonatal Med. 2012;25:64–7.
  986. Cherpes TL, Wiesenfeld HC, Melan MA, et al. The associations between pelvic inflammatory disease, Trichomonas vaginalis infection, and positive herpes simplex virus type 2 serology. Sex Transm Dis. 2006;33:747–52.
  987. Nelson DB, Hanlon A, Hassan S, et al. Preterm labor and bacterial vaginosis-associated bacteria among urban women. J Perinat Med. 2009;37:130–4.
  988. Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS. 2008;22(12):1493–501.
  989. Gosmann C, Anahtar MN, Handley SA, et al. Lactobacillus-deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young South African women. Immunity. 2017;46(1):29–37.
  990. McClelland RS, Lingappa JR, Srinivasan S, et al. Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case-control study. Lancet Infect Dis. 2018;18(5):554–64.
  991. Johnston C, Magaret A, Srinivasan S, et al. P239 Genital HSV-2 suppression is not associated with alterations in the vaginal microbiome: a one-way, cross-over study. Sex Transm Infect. 2019;95(Suppl 1):A148.
  992. Zozaya M, Ferris MJ, Siren JD, et al. Bacterial communities in penile skin, male urethra, and vaginas of heterosexual couples with and without bacterial vaginosis. Microbiome. 2016;4:16.
  993. Liu CM, Hungate BA, Tobian AA, et al. Penile microbiota and female partner bacterial vaginosis in Rakai, Uganda. mBio. 2015;6(3):e00589.
  994. Mehta SD. Systematic review of randomized trials of treatment of male sexual partners for improved bacteria vaginosis outcomes in women. Sex Transm Dis. 2012;39:822–30.
  995. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74(1):14–22.
  996. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol. 1991;29(2):297–301.
  997. Schwebke JR, Hillier SL, Sobel JD, McGregor JA, Sweet RL. Validity of the vaginal Gram stain for the diagnosis of bacterial vaginosis. Obstet Gynecol. 1996;88:573–6.
  998. Coleman JS, Gaydos CA. Molecular diagnosis of bacterial vaginosis: an update. J Clin Microbiol. 2018;56(9):e00342-18.
  999. Myziuk L, Romanowski B, Johnson SC. BVBlue test for diagnosis of bacterial vaginosis. J Clin Microbiol. 2003;41(5):1925–8.
  1000. Bradshaw CS, Morton AN, Garland SM, Horvath LB, Kuzevska I, Fairley CK. Evaluation of a point-of-care test, BVBlue, and clinical and laboratory criteria for diagnosis of bacterial vaginosis. J Clin Microbiol. 2005;43(3):1304–8.
  1001. West B, Morison L, Schim van der Loeff M, et al. Evaluation of a new rapid diagnostic kit (FemExam) for bacterial vaginosis in patients with vaginal discharge syndrome in The Gambia. Sex Transm Dis. 2003;30(6):483–9.
  1002. Fredricks DN, Fiedler TL, Thomas KK, Oakley BB, Marrazzo JM. Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. J Clin Microbiol. 2007;45:3270–6.
  1003. Gaydos CA, Beqaj S, Schwebke JR, et al. Clinical validation of a test for the diagnosis of vaginitis. Obstet Gynecol. 2017;130(1):181–9.
  1004. Cartwright CP, Lembke BD, Ramachandran K, et al. Development and validation of a semiquantitative, multitarget PCR assay for diagnosis of bacterial vaginosis. J Clin Microbiol. 2012;50(7):2321–9.
  1005. Hilbert DW, Smith WL, Chadwick SG, et al. Development and validation of a highly accurate quantitative real-time PCR assay for diagnosis of bacterial vaginosis. J Clin Microbiol. 2016;54(4):1017–24.
  1006. Schwebke JR, Desmond R. A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am J Obstet Gynecol. 2007;196:517.e1–6.
  1007. Fjeld H, Raknes G. [Is combining metronidazole and alcohol really hazardous?]. Tidsskr Nor Laegeforen. 2014;134(17):1661–3. Norwegian.
  1008. Hillier SL, Nyirjesy P, Waldbaum AS, et al. secnidazole treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol. 2017;130(2):379–86.
  1009. Schwebke JR, Morgan FG Jr, Koltun W, Nyirjesy P. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol. 2017;217(6):678.e1–9.
  1010. Chavoustie SE, Gersten JK, Samuel MJ, Schwebke JR. A phase 3, multicenter, prospective, open-label study to evaluate the safety of a single dose of secnidazole 2 g for the treatment of women and postmenarchal adolescent girls with bacterial vaginosis. J Womens Health (Larchmt). 2018;27(4):492–7.
  1011. Livengood CH 3rd, Ferris DG, Wiesenfeld HC, et al. Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol. 2007;110(2 Pt 1):302–9.
  1012. Sobel JD, Nyirjesy P, Brown W. Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. Clin Infect Dis. 2001;33(8):1341–6.
  1013. Chavoustie SE, Jacobs M, Reisman HA, et al. Metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis: a dose-ranging study. J Low Genit Tract Dis. 2015;19(2):129–34.
  1014. Schwebke JR, Marrazzo J, Beelen AP, Sobel JD. A phase 3, multicenter, randomized, double-blind, vehicle-controlled study evaluating the safety and efficacy of metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis. Sex Transm Dis. 2015;42(7):376–81.
  1015. Faro S, Skokos CK; Clindesse Investigators Group. The efficacy and safety of a single dose of Clindesse vaginal cream versus a seven-dose regimen of Cleocin vaginal cream in patients with bacterial vaginosis. Infect Dis Obstet Gynecol. 2005;13(3):155–60.
  1016. Marrazzo JM, Dombrowski JC, Wierzbicki MR, et al. Safety and efficacy of a novel vaginal anti-infective, TOL-463, in the treatment of bacterial vaginosis and vulvovaginal candidiasis: a randomized, single-blind, phase 2, controlled trial. Clin Infect Dis. 2019;68(5):803–9.
  1017. Antonio MA, Meyn LA, Murray PJ, Busse B, Hillier SL. Vaginal colonization by probiotic Lactobacillus crispatus CTV-05 is decreased by sexual activity and endogenous Lactobacilli. J Infect Dis. 2009;199:1506–13.
  1018. Senok AC, Verstraelen H, Temmerman M, Botta GA. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst Rev. 2009;(4):CD006289.
  1019. Abad CL, Safdar N. The role of Lactobacillus probiotics in the treatment or prevention of urogenital infections–a systematic review. J Chemother. 2009;21:243–52.
  1020. Mastromarino P, Macchia S, Meggiorini L, et al. Effectiveness of Lactobacillus-containing vaginal tablets in the treatment of symptomatic bacterial vaginosis. Clin Microbiol Infect. 2009;15:67–74.
  1021. Hemmerling A, Harrison W, Schroeder A, et al. Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sex Transm Dis. 2010;37:745–50.
  1022. Bunge KE, Beigi RH, Meyn LA, Hillier SL. The efficacy of retreatment with the same medication for early treatment failure of bacterial vaginosis. Sex Transm Dis. 2009;36:711–3.
  1023. Aguin T, Akins RA, Sobel JD. High-dose vaginal maintenance metronidazole for recurrent bacterial vaginosis: a pilot study. Sex Transm Dis. 2014;41(5):290–1.
  1024. Sobel JD, Ferris D, Schwebke J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol. 2006;194:1283–9.
  1025. Reichman O, Akins R, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Transm Dis. 2009;36:732–4.
  1026. McClelland RS, Richardson BA, Hassan WM, et al. Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis. 2008;197:1361–8.
  1027. Schwebke J, Carter B, Waldbaum A, et al. Results of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of astodrimer gel for prevention of recurrent bacterial vaginosis. Am J Obstet Gynecol, 2019;221(6):672–3.
  1028. Cohen CR, Wierzbicki MR, French AL, et al. Randomized trial of Lactin-V to prevent recurrence of bacterial vaginosis. N Engl J Med. 2020;382(20):1906–15.
  1029. Turner AN, Carr Reese P, Fields KS, et al. A blinded, randomized controlled trial of high-dose vitamin D supplementation to reduce recurrence of bacterial vaginosis. Am J Obstet Gynecol. 2014;211(5):479.e1–13.
  1030. Plummer EL, Vodstrcil LA, Danielewski JA, et al. Combined oral and topical antimicrobial therapy for male partners of women with bacterial vaginosis: acceptability, tolerability and impact on the genital microbiota of couples – a pilot study. PLoS One. 2018;13(1):e0190199.
  1031. Koumans EH, Kendrick JS; CDC Bacterial Vaginosis Working Group. Preventing adverse sequelae of bacterial vaginosis: a public health program and research agenda. Sex Transm Dis. 2001;28(5):292–7.
  1032. Hauth JC, Goldenberg RL, Andrews WW, DuBard MB, Copper RL. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med. 1995;333:1732–6.
  1033. Morales WJ, Schorr S, Albritton J. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. Am J Obstet Gynecol. 1994;171:345–9.
  1034. Yudin MH, Landers DV, Meyn L, Hillier SL. Clinical and cervical cytokine response to treatment with oral or vaginal metronidazole for bacterial vaginosis during pregnancy: a randomized trial. Obstet Gynecol. 2003;102:527–34.
  1035. Ugwumadu A, Reid F, Hay P, Manyonda I. Natural history of bacterial vaginosis and intermediate flora in pregnancy and effect of oral clindamycin. Obstet Gynecol. 2004;104:114–9.
  1036. Burtin P, Taddio A, Ariburnu O, Einarson TR, Koren G. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol. 1995;172(2 Pt 1):525–9.
  1037. Piper JM, Mitchel EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol. 1993;82:348–52.
  1038. Sheehy O, Santos F, Ferreira E, Berard A. The use of metronidazole during pregnancy: a review of evidence. Curr Drug Saf. 2015;10(2):170–9.
  1039. Lamont RF, Nhan-Chang CL, Sobel JD, Workowski K, Conde-Agudelo A, Romero R. Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis. Am J Obstet Gynecol. 2011;205:177–90.
  1040. Odendaal HJ, Popov I, Schoeman J, Smith M, Grové D. Preterm labour–is bacterial vaginosis involved? S Afr Med J. 2002;92:231–4.
  1041. Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 2000;342:534–40.
  1042. Vermeulen GM, Bruinse HW. Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo-controlled double-blind trial. Br J Obstet Gynaecol. 1999;106:652–7.
  1043. McDonald HM, O’Loughlin JA, Vigneswaran R, et al. Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised, placebo controlled trial. Br J Obstet Gynaecol. 1997;104:1391–7.
  1044. Ugwumadu A, Manyonda I, Reid F, Hay P. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet. 2003;361:983–8.
  1045. Subtil D, Brabant G, Tilloy E, et al. Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial. Lancet. 2018;392(10160):2171–9.
  1046. Erickson SH, Oppenheim GL, Smith GH. Metronidazole in breast milk. Obstet Gynecol. 1981;57:48–50.
  1047. Passmore CM, McElnay JC, Rainey EA, D’Arcy PF. Metronidazole excretion in human milk and its effect on the suckling neonate. Br J Clin Pharmacol. 1988;26:45–51.
  1048. Golightly P, Kearney L. Metronidazole – is it safe to use with breastfeeding? [Internet]. United Kingdom National Health Service, UKMI; Mar 2012 [cited 2020]; 6 p. Available from: https://studylib.net/doc/7341270/metronidazole-in-breastfeeding-mothers
  1049. Jamieson DJ, Duerr A, Klein RS, et al. Longitudinal analysis of bacterial vaginosis: findings from the HIV epidemiology research study. Obstet Gynecol. 2001;98:656–63.
  1050. Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40(3):187–93.
  1051. Rowley J, Vander Hoorn S, Korenromp E, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019;97(8):548–62P.
  1052. Hoots BE, Peterman TA, Torrone EA, Weinstock H, Meites E, Bolan GA. A Trich-y question: should Trichomonas vaginalis infection be reportable? Sex Transm Dis. 2013;40:113–6.
  1053. Flagg EW, Meites E, Phillips C, Papp J, Torrone EA. Prevalence of Trichomonas vaginalis among males and females aged 14-59 years: United States, 2013-2016. Sex Transm Dis. 2019;46(10):e93–6.
  1054. Daugherty M, Glynn K, Byler T. Prevalence of Trichomonas vaginalis infection among US males, 2013–2016. Clin Infect Dis. 2019;68(3):460–5.
  1055. Alcaide, M.L., et al., The incidence of Trichomonas vaginalis infection in women attending nine sexually transmitted diseases clinics in the USA. Sex Transm Infect, 2016. 92(1): p. 58–62.
  1056. Muzny CA, Blackburn RJ, Sinsky RJ, Austin EL, Schwebke JR. Added benefit of nucleic acid amplification testing for the diagnosis of Trichomonas vaginalis among men and women attending a sexually transmitted diseases clinic. Clin Infect Dis. 2014;59(6):834–41.
  1057. Meites E, Llata E, Braxton J, et al. Trichomonas vaginalis in selected US sexually transmitted disease clinics: testing, screening, and prevalence. Sex Transm Dis. 2013;40(11):865–9.
  1058. Ginocchio CC, Chapin K, Smith JS, et al. Prevalence of Trichomonas vaginalis and coinfection with Chlamydia trachomatis and Neisseria gonorrhoeae in the United States as determined by the Aptima Trichomonas vaginalis nucleic acid amplification assay. J Clin Microbiol. 2012;50:2601–8.
  1059. Shuter J, Bell D, Graham D, Holbrook KA, Bellin EY. Rates of and risk factors for trichomoniasis among pregnant inmates in New York City. Sex Transm Dis. 1998;25:303–7.
  1060. Sosman JM, MacGowan RJ, Margolis AD, et al. Screening for sexually transmitted diseases and hepatitis in 18-29-year-old men recently released from prison: feasibility and acceptability. Int J STD AIDS. 2005;16:117–22.
  1061. Rogers SM, Turner CF, Hobbs M, et al. Epidemiology of undiagnosed trichomoniasis in a probability sample of urban young adults. PloS One. 2014;9(3):e90548.
  1062. Mayer KH, Bush T, Henry K, et al. Ongoing sexually transmitted disease acquisition and risk-taking behavior among US HIV-infected patients in primary care: implications for prevention interventions. Sex Transm Dis. 2012;39:1–7.
  1063. Seña AC, Miller WC, Hobbs MM, et al. Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis. 2007;44(1):13–22.
  1064. Kelley CF, Rosenberg ES, OʼHara BM, Sanchez T, del Rio C, Sullivan PS. Prevalence of urethral Trichomonas vaginalis in black and white men who have sex with men. Sex Transm Dis. 2012;39:739.
  1065. Sutton M, Sternberg M, Koumans EH, McQuillan G, Berman S, Markowitz L. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004. Clin Infect Dis. 2007;45(10):1319–26.
  1066. Peterman TA, Tian LH, Metcalf CA, et al. Persistent, undetected Trichomonas vaginalis infections? Clin Infect Dis. 2009;48:259–60.
  1067. Wølner-Hanssen P, Krieger JN, Stevens CE, et al. Clinical manifestations of vaginal trichomoniasis. JAMA. 1989;261(4):571–6.
  1068. Gray RH, Kigozi G, Serwadda D, et al. The effects of male circumcision on female partners’ genital tract symptoms and vaginal infections in a randomized trial in Rakai, Uganda. Am J Obstet Gynecol. 2009;200:e41–7.
  1069. Sobngwi-Tambekou J, Taljaard D, Nieuwoudt M, Lissouba P, Puren A, Auvert B. Male circumcision and Neisseria gonorrhoeae, Chlamydia trachomatis and Trichomonas vaginalis: observations after a randomised controlled trial for HIV prevention. Sex Transm Infect. 2009;85:116–20.
  1070. Tsai CS, Shepherd BE, Vermund SH. Does douching increase risk for sexually transmitted infections? A prospective study in high-risk adolescents. Am J Obstet Gynecol. 2009;200:e31–8.
  1071. Silver BJ, Guy RJ, Kaldor JM, Jamil MS, Rumbold AR. Trichomonas vaginalis as a cause of perinatal morbidity: a systematic review and meta-analysis. Sex Transm Dis. 2014;41(6):369–76.
  1072. Yang S, Zhao W, Wang H, Wang Y, Li J, Wu X. Trichomonas vaginalis infection-associated risk of cervical cancer: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2018;228:166–73.
  1073. Najafi A, Chaechi Nosrati MR, Ghasemi E, et al. Is there association between Trichomonas vaginalis infection and prostate cancer risk?: a systematic review and meta-analysis. Microb Pathog. 2019;137:103752.
  1074. Wang CC, McClelland RS, Reilly M, et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis. 2001;183(7):1017–22.
  1075. Kissinger P, Amedee A, Clark RA, et al. Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis. 2009;36:11–6.
  1076. Minkoff H, Grunebaum AN, Schwarz RH, et al. Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy. Am J Obstet Gynecol. 1984;150:965–72.
  1077. Cotch MF, Pastorek JG 2nd, Nugent RP, et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. Sex Transm Dis. 1997;24:353–60.
  1078. Moodley P, Wilkinson D, Connolly C, Moodley J, Sturm AW. Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis. 2002;34:519–22.
  1079. Francis SC, Kent CK, Klausner JD, et al. Prevalence of rectal Trichomonas vaginalis and Mycoplasma genitalium in male patients at the San Francisco STD clinic, 2005-2006. Sex Transm Dis. 2008;35:797–800.
  1080. Hollman D, Coupey SM, Fox AS, Herold BC. Screening for Trichomonas vaginalis in high-risk adolescent females with a new transcription-mediated nucleic acid amplification test (NAAT): associations with ethnicity, symptoms, and prior and current STIs. J Pediatr Adolesc Gynecol. 2010;23:312–6.
  1081. Roth AM, Williams JA, Ly R, et al. Changing sexually transmitted infection screening protocol will result in improved case finding for Trichomonas vaginalis among high-risk female populations. Sex Transm Dis. 2011;38:398–400.
  1082. Hobbs MM, Seña AC. Modern diagnosis of Trichomonas vaginalis infection. Sex Transm Infect. 2013;89(6):434–8.
  1083. Kingston MA, Bansal D, Carlin EM. ‘Shelf life’ of Trichomonas vaginalis. Int J STD AIDS. 2003;14:28–9.
  1084. Schwebke JR, Hobbs MM, Taylor SN, et al. Molecular testing for Trichomonas vaginalis in women: results from a prospective U.S. clinical trial. J Clin Microbiol. 2011;49(12):4106–11.
  1085. Huppert JS, Mortensen JE, Reed JL, et al. Rapid antigen testing compares favorably with transcription-mediated amplification assay for the detection of Trichomonas vaginalis in young women. Clin Infect Dis. 2007;45:194–8.
  1086. Van Der Pol B, Williams JA, Taylor SN, et al. Detection of Trichomonas vaginalis DNA by use of self-obtained vaginal swabs with the BD ProbeTec Qx assay on the BD Viper system. J Clin Microbiol. 2014;52(3):885–9.
  1087. Van Der Pol B, Williams JA, Fuller D, Taylor SN, Hook EW 3rd. Combined testing for chlamydia, gonorrhea, and trichomonas by use of the BD Max CT/GC/TV assay with genitourinary specimen types. J Clin Microbiol. 2017;55(1):155–64.
  1088. Schwebke JR, Gaydos CA, Davis T, et al. Clinical evaluation of the Cepheid Xpert TV Assay for detection of Trichomonas vaginalis with prospectively collected specimens from men and women. J Clin Microbiol. 2018;56(2): e01091-17.
  1089. Campbell L, Woods V, Lloyd T, Elsayed S, Church DL. Evaluation of the OSOM Trichomonas rapid test versus wet preparation examination for detection of Trichomonas vaginalis vaginitis in specimens from women with a low prevalence of infection. J Clin Microbiol. 2008;46:3467–9.
  1090. Huppert JS, Hesse E, Kim G, et al. Adolescent women can perform a point-of-care test for trichomoniasis as accurately as clinicians. Sex Transm Infect. 2010;86:514–9.
  1091. Sheele JM, Crandall CJ, Arko BL, et al. The OSOM® Trichomonas Test is unable to accurately diagnose Trichomonas vaginalis from urine in men. Am J Emerg Med. 2019;37(5):1002–3
  1092. Gaydos CA, Schwebke J, Dombrowski J, et al. Clinical performance of the Solana® Point-of-Care Trichomonas Assay from clinician-collected vaginal swabs and urine specimens from symptomatic and asymptomatic women. Expert Rev Mol Diagn. 2017;17(3):303–6.
  1093. Gaydos CA, Hobbs M, Marrazzo J, et al. Rapid diagnosis of Trichomonas vaginalis by testing vaginal swabs in an isothermal helicase-dependent AmpliVue Assay. Sex Transm Dis. 2016;43(6):369–73.
  1094. Patil MJ, Nagamoti JM, Metgud SC. Diagnosis of Trichomonas vaginalis from vaginal specimens by wet mount microscopy, In Pouch TV culture system, and PCR. J Glob Infect Dis. 2012;4(1):22–5.
  1095. Lawing LF, Hedges SR, Schwebke JR. Detection of trichomonosis in vaginal and urine specimens from women by culture and PCR. J Clin Microbiol. 2000;38(10):3585–3588.
  1096. Mohamed OA, Cohen CR, Kungu D, et al. Urine proves a poor specimen for culture of Trichomonas vaginalis in women. Sex Transm Infect. 2001;77:78–9.
  1097. Rivers CA, Muzny CA, Schwebke JR. Diagnostic rates differ on the basis of the number of read days with the use of the InPouch culture system for Trichomonas vaginalis screening. J Clin Microbiol. 2013;51(11):3875–6.
  1098. Audisio T, Pigini T, de Riutort SV, et al. Validity of the Papanicolaou smear in the diagnosis of Candida spp., Trichomonas vaginalis, and bacterial vaginosis. J Low Genit Tract Dis. 2001;5(4):223–5.
  1099. Loo SK, Tang WY, Lo KK. Clinical significance of Trichomonas vaginalis detected in Papanicolaou smear: a survey in female Social Hygiene Clinic. Hong Kong Med J. 2009;15(2):90–3.
  1100. Howe K, Kissinger PJ. Single-dose compared with multidose metronidazole for the treatment of trichomoniasis in women: a meta-analysis. Sex Transm Dis. 2017;44(1):29–34.
  1101. Kissinger P, Mena L, Levison J, et al. A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. J Acquir Immune Defic Syndr. 2010;55:565–71.
  1102. Wood BA, Monro AM. Pharmacokinetics of tinidazole and metronidazole in women after single large oral doses. Br J Vener Dis. 1975;51:51–53.
  1103. Viitanen J, Haataja H, Männistö PT. Concentrations of metronidazole and tinidazole in male genital tissues. Antimicrob Agents Chemother. 1985;28:812–4.
  1104. Gabriel G, Robertson E, Thin RN. Single dose treatment of trichomoniasis. J Int Med Res. 1982;10:129–30.
  1105. Mati JK, Wallace RJ. The treatment of trichomonal vaginitis using a single dose of tinidazole by mouth. East Afr Med J. 1974;51:883–8.
  1106. Anjaeyulu R, Gupte SA, Desai DB. Single-dose treatment of trichomonal vaginitis: a comparison of tinidazole and metronidazole. J Int Med Res. 1977;5:438–41.
  1107. Apte VV, Packard RS. Tinidazole in the treatment of trichomoniasis, giardiasis and amoebiasis; report of a multicentre study. Drugs. 1978;15 Suppl 1:43–8.
  1108. O-Prasertsawat P, Jetsawangsri T. Split-dose metronidazole or single-dose tinidazole for the treatment of vaginal trichomoniasis. Sex Transm Dis. 1992;19:295–7.
  1109. Kawamura N. Metronidazole and tinidazole in a single large dose for treating urogenital infections with Trichomonas vaginalis in men. Br J Vener Dis. 1978;54(2):81–3.
  1110. Forna F, Gülmezoglu AM. Interventions for treating trichomoniasis in women. Cochrane Database Syst Rev. 2003;2:CD000218.
  1111. Cu-Uvin S, Ko H, Jamieson DJ, et al. Prevalence, incidence, and persistence or recurrence of trichomoniasis among human immunodeficiency virus (HIV)-positive women and among HIV-negative women at high risk for HIV infection. Clin Infect Dis. 2002;34:1406–11.
  1112. Schwebke JR, Barrientes FJ. Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole. Antimicrob Agents Chemother. 2006;50(12):4209–10.
  1113. Van Der Pol B, Williams JA, Orr DP, Batteiger BE, Fortenberry JD. Prevalence, incidence, natural history, and response to treatment of Trichomonas vaginalis infection among adolescent women. J Infect Dis. 2005;192:2039–44.
  1114. Kirkcaldy RD, Augostini P, Asbel LE, et al. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009-2010. Emerg Infect Dis. 2012;18(6):939–43.
  1115. Crowell AL, Sanders-Lewis KA, Secor WE. In vitro metronidazole and tinidazole activities against metronidazole-resistant strains of Trichomonas vaginalis. Antimicrob Agents Chemother. 2003;47:1407–9.
  1116. Muzny CA, Mena L, Lillis RA, et al. A comparison of 2 g single-dose versus 7-day 500 mg twice daily metronidazole for the treatment trichomoniasis in women by selected clinical factors. Am J Obstet Gynecol. 2019;221(6):669.
  1117. Sobel JD, Nyirjesy P, Brown W. Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. Clin Infect Dis. 2001;33(8):1341–6.
  1118. Nyirjesy P, Gilbert J, Mulcahy LJ. Resistant trichomoniasis: successful treatment with combination therapy. Sex Transm Dis. 2011;38:962–3.
  1119. Muzny C, Barnes A, Mena L. Symptomatic Trichomonas vaginalis infection in the setting of severe nitroimidazole allergy: successful treatment with boric acid. Sex Health. 2012;9:389–91.
  1120. Aggarwal A, Shier RM. Recalcitrant Trichomonas vaginalis infections successfully treated with vaginal acidification. J Obstet Gynaecol Can. 2008;30:55–8.
  1121. Dan M, Sobel JD. Failure of nitazoxanide to cure trichomoniasis in three women. Sex Transm Dis. 2007;34:813–4.
  1122. Seña AC, Bachmann LH, Hobbs MM. Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations. Expert Rev Anti Infect Ther. 2014;12:673–85.
  1123. Helms DJ, Mosure DJ, Secor WE, Workowski KA. Management of Trichomonas vaginalis in women with suspected metronidazole hypersensitivity. Am J Obstet Gynecol. 2008;198:370.e1–7.
  1124. Gendelman SR, Pien LC, Gutta RC, Abouhassan SR. Modified oral metronidazole desensitization protocol. Allergy Rhinol (Providence). 2014;5(2):66–9.
  1125. Nyirjesy P, Sobel JD, Weitz MV, Leaman DJ, Gelone SP. Difficult-to-treat trichomoniasis: results with paromomycin cream. Clin Infect Dis. 1998;26(4):986–8.
  1126. Klebanoff MA, Carey JC, Hauth JC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med. 2001;345(7):487–93.
  1127. Stringer E, Read JS, Hoffman I, Valentine M, Aboud S, Goldenberg RL. Treatment of trichomoniasis in pregnancy in sub-Saharan Africa does not appear to be associated with low birth weight or preterm birth. S Afr Med J. 2010;100:58–64.
  1128. Caro-Patón T, Carvajal A, Martin de Diego I, Martin-Arias LH, Alvarez Requejo A, Rodríguez Pinilla E. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol. 1997;44(2):179–82.
  1129. Gülmezoglu AM. Interventions for trichomoniasis in pregnancy. Cochrane Database Syst Rev. 2002;(3):CD000220.
  1130. Goldenberg RL, Mwatha A, Read JS, et al. The HPTN 024 Study: the efficacy of antibiotics to prevent chorioamnionitis and preterm birth. Am J Obstet Gynecol. 2006;194:650–61.
  1131. Mann JR, McDermott S, Zhou L, Barnes TL, Hardin J. Treatment of trichomoniasis in pregnancy and preterm birth: an observational study. J Womens Health (Larchmt). 2009;18:493–7.
  1132. Carter JE, Whithaus KC. Neonatal respiratory tract involvement by Trichomonas vaginalis: a case report and review of the literature. Am J Trop Med Hyg. 2008;78:17–9.
  1133. Trintis J, Epie N, Boss R, Riedel S. Neonatal Trichomonas vaginalis infection: a case report and review of literature. Int J STD AIDS. 2010;21:606–7.
  1134. Miller M, Liao Y, Wagner M, Korves C. HIV, the clustering of sexually transmitted infections, and sex risk among African American women who use drugs. Sex Transm Dis. 2008;35:696–702.
  1135. Anderson BL, Firnhaber C, Liu T, et al. Effect of trichomoniasis therapy on genital HIV viral burden among African women. Sex Transm Dis. 2012;39:638–42.
  1136. Masese LN, Graham SM, Gitau R, et al. A prospective study of vaginal trichomoniasis and HIV-1 shedding in women on antiretroviral therapy. BMC Infect Dis. 2011;11:307.
  1137. Balkus JE, Richardson BA, Mochache V, et al. A prospective cohort study comparing the effect of single-dose 2 g metronidazole on Trichomonas vaginalis infection in HIV-seropositive versus HIV-seronegative women. Sex Transm Dis. 2013;40:499–505.
  1138. Gumbo FZ, Duri K, Kandawasvika GQ, et al. Risk factors of HIV vertical transmission in a cohort of women under a PMTCT program at three peri-urban clinics in a resource-poor setting. J Perinatol. 2010;30:717–23.
  1139. Brüggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48:1441–58.
  1140. Shahid Z, Sobel JD. Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy. Diagn Microbiol Infect Dis. 2009;64:354–6.
  1141. Marchaim D, Lemanek L, Bheemreddy S, Kaye KS, Sobel JD. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol. 2012;120:1407–14.
  1142. Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018;18(11):e339–47.
  1143. Crouss T, Sobel JD, Smith K, Nyirjesy P. Long-term outcomes of women with recurrent vulvovaginal candidiasis after a course of maintenance antifungal therapy. J Low Genit Tract Dis. 2018;22(4):382–6.
  1144. Kennedy MA, Sobel JD. Vulvovaginal candidiasis caused by non-albicans Candida species: new insights. Curr Infect Dis Rep. 2010;12:465–70.
  1145. Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol. 2003;189:1297–1300.
  1146. Mølgaard-Nielsen D, Svanström H, Melbye M, Hviid A, Pasternak B. Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth. JAMA. 2016;315(1):58–67.
  1147. Bérard A, Sheehy O, Zhao JP, et al. Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies. CMAJ. 2019;191(7):E179–87.
  1148. Ohmit SE, Sobel JD, Schuman P, et al. Longitudinal study of mucosal Candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis. 2003;188(1):118–27.
  1149. Duerr A, Heilig CM, Meikle SF, et al. Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women: risk factors and severity. Obstet Gynecol. 2003;101(3):548–56.
  1150. Vazquez JA, Peng G, Sobel JD, et al. Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis. Clin Infect Dis. 2001;33:1069–75.
  1151. Darville T; Pelvic Inflammatory Disease Workshop Proceedings Committee. Pelvic inflammatory disease: identifying research gaps–proceedings of a workshop sponsored by Department of Health and Human Services/National Institutes of Health/National Institute of Allergy and Infectious Diseases, November 3-4, 2011. Sex Transm Dis. 2013;40(10):761–7.
  1152. Wiesenfeld HC, Sweet RL, Ness RB, Krohn MA, Amortegui AJ, Hillier SL. Comparison of acute and subclinical pelvic inflammatory disease. Sex Transm Dis. 2005;32:400–5.
  1153. Wiesenfeld HC, Hillier SL, Meyn LA, Amortegui AJ, Sweet RL. Subclinical pelvic inflammatory disease and infertility. Obstet Gynecol. 2012;120:37–43.
  1154. Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) randomized trial. Am J Obstet Gynecol. 2002;186:929–37.
  1155. Burnett AM, Anderson CP, Zwank MD. Laboratory-confirmed gonorrhea and/or chlamydia rates in clinically diagnosed pelvic inflammatory disease and cervicitis. Am J Emerg Med. 2012;30:1114–7.
  1156. Wiesenfeld HC, Meyn LA, Darville T, Macio IS, Hillier SL. A randomized controlled trial of ceftriaxone and doxycycline, with or without metronidazole, for the treatment of acute pelvic inflammatory disease. Clin Infect Dis. 2020 Feb 13:ciaa101.
  1157. Ness RB, Kip KE, Hillier SL, et al. A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol. 2005;162:585–90.
  1158. Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med. 1996;334:1362–6.
  1159. Oakeshott P, Kerry S, Aghaizu A, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. BMJ. 2010;340:c1642.
  1160. Peipert JF, Ness RB, Blume J, et al. Clinical predictors of endometritis in women with symptoms and signs of pelvic inflammatory disease. Am J Obstet Gynecol. 2001;184:856–64.
  1161. Gaitán H, Angel E, Diaz R, Parada A, Sanchez L, Vargas C. Accuracy of five different diagnostic techniques in mild-to-moderate pelvic inflammatory disease. Infect Dis Obstet Gynecol. 2002;10:171–80.
  1162. Vicetti Miguel RD, Chivukula M, Krishnamurti U, et al. Limitations of the criteria used to diagnose histologic endometritis in epidemiologic pelvic inflammatory disease research. Pathol Res Pract. 2011;207(11):680–5.
  1163. Jacobson L, Weström L. Objectivized diagnosis of acute pelvic inflammatory disease; diagnostic and prognostic value of routine laparoscopy. Am J Obstet Gynecol. 1969;105:1088–98.
  1164. Sellors J, Mahony J, Goldsmith C, et al. The accuracy of clinical findings and laparoscopy in pelvic inflammatory disease. Am J Obstet Gynecol. 1991;164(1 Pt 1):113–20.
  1165. Bevan CD, Johal BJ, Mumtaz G, Ridgway GL, Siddle NC. Clinical, laparoscopic and microbiological findings in acute salpingitis: report on a United Kingdom cohort. Br J Obstet Gynaecol. 1995;102:407–14.
  1166. Jaiyeoba O, Soper DE. A practical approach to the diagnosis of pelvic inflammatory disease. Infect Dis Obstet Gynecol. 2011;2011:753037.
  1167. Sweet RL. Treatment of acute pelvic inflammatory disease. Infect Dis Obstet Gynecol. 2011;2011:561909.
  1168. Smith KJ, Ness RB, Wiesenfeld HC, Roberts MS. Cost-effectiveness of alternative outpatient pelvic inflammatory disease treatment strategies. Sex Transm Dis. 2007;34:960–6.
  1169. Petrina MAB, Cosentino LA, Wiesenfeld HC, Darville T, Hillier SL. Susceptibility of endometrial isolates recovered from women with clinical pelvic inflammatory disease or histological endometritis to antimicrobial agents. Anaerobe. 2019;56:61–5.
  1170. Haggerty CL, Ness RB, Amortegui A, et al. Endometritis does not predict reproductive morbidity after pelvic inflammatory disease. Am J Obstet Gynecol. 2003;188:141–8.
  1171. Haggerty CL, Totten PA, Tang G, et al. Identification of novel microbes associated with pelvic inflammatory disease and infertility. Sex Transm Infect. 2016;92(6):441–6.
  1172. Ness, RB, Randall H, Richter HE, et al. Condom use and the risk of recurrent pelvic inflammatory disease, chronic pelvic pain, or infertility following an episode of pelvic inflammatory disease. Am J Public Health. 2004;94:1327–9.
  1173. McGregor JA, Crombleholme WR, Newton E, Sweet RL, Tuomala R, Gibbs RS. Randomized comparison of ampicillin-sulbactam to cefoxitin and doxycycline or clindamycin and gentamicin in the treatment of pelvic inflammatory disease or endometritis. Obstet Gynecol. 1994;83:998–1004.
  1174. Bevan CD, Ridgway GL, Rothermel CD. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J Int Med Res. 2003;31:45–54.
  1175. Heystek M, Ross JD; PID Study Group. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Int J STD AIDS. 2009;20:690–5.
  1176. Boothby M, Page J, Pryor R, Ross JD. A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease. Int J STD AIDS. 2010;21:195–7.
  1177. Judlin P, Liao Q, Liu Z, Reimnitz P, Hampel B, Arvis P. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG. 2010;117:1475–84.
  1178. Korn AP. Pelvic inflammatory disease in women infected with HIV. AIDS Patient Care STDS. 1998;12(6):431–4.
  1179. Irwin KL, Moorman AC, O’Sullivan MJ, et al. Influence of human immunodeficiency virus infection on pelvic inflammatory disease. Obstet Gynecol. 2000;95:525–34.
  1180. Bukusi EA, Cohen CR, Stevens CE, et al. Effects of human immunodeficiency virus 1 infection on microbial origins of pelvic inflammatory disease and on efficacy of ambulatory oral therapy. Am J Obstet Gynecol. 1999;181:1374–81.
  1181. Mugo NR, Kiehlbauch JA, Nguti R, et al. Effect of human immunodeficiency virus-1 infection on treatment outcome of acute salpingitis. Obstet Gynecol. 2006;107:807–12.
  1182. Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet. 2000;356:1013–9.
  1183. Viberga I, Odlind V, Lazdane G, Kroica J, Berglund L, Olofsson S. Microbiology profile in women with pelvic inflammatory disease in relation to IUD use. Infect Dis Obstet Gynecol. 2005;13:183–90.
  1184. Jatlaoui TC, Riley, Curtis KM. The safety of intrauterine devices among young women: a systematic review. Contraception. 2017;95(1):17–39.
  1185. Chen MJ, Kim CR, Whitehouse KC, Berry-Bibee E, Gaffield ME. Development, updates, and future directions of the World Health Organization Selected Practice Recommendations for Contraceptive Use. Int J Gynaecol Obstet. 2017;136(2):113–9.
  1186. Tepper NK, Steenland MW, Gaffield ME, Marchbanks PA, Curtis KM. Retention of intrauterine devices in women who acquire pelvic inflammatory disease: a systematic review. Contraception. 2013;87:655–60.
  1187. Louette A, Krahn J, Caine V, Ha S, Lau TTY, Singh AE. Treatment of acute epididymitis: a systematic review and discussion of the implications for treatment based on etiology. Sex Transm Dis. 2018;45(12):e104–8.
  1188. Pilatz A, Hossain H, Kaiser R, et al. Acute epididymitis revisited: impact of molecular diagnostics on etiology and contemporary guideline recommendations. Eur Urol. 2015;68(3):428–35.
  1189. Hongo H, Kikuchi E, Matsumoto K, et al. Novel algorithm for management of acute epididymitis. Int J Urol. 2017;24(1):82–7.
  1190. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004;324(1):17–27.
  1191. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000;151:1158–71.
  1192. Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11):660–4.
  1193. Cogliano V, Baan R, Straif K, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6:204.
  1194. Senkomago V, Henley SJ, Thomas CC, Mix JM, Markowitz LE, Saraiya M. Human papillomavirus-attributable cancers – United States, 2012-2016. MMWR Morb Mortal Wkly Rep. 2019;68(33):724–8.
  1195. Chesson HW, Ekwueme DU, Saraiya M, Watson M, Lowy DR, Markowitz LE. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine. 2012;30:6016–9.
  1196. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis. 2013;208:385–93.
  1197. Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination. Am J Public Health. 2013;103(8):1428–35.
  1198. McClung NM, Lewis RM, Gargano JW, Querec T, Unger ER, Markowitz LE. Declines in vaccine-type human papillomavirus prevalence in females across racial/ethnic groups: data from a national survey. J Adolesc Health. 2019;65(6):715–22.
  1199. Drolet M, Bénard É, Pérez N, Brisson M; HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497–509.
  1200. Mayhew A, Mullins TL, Ding L, et al. Risk perceptions and subsequent sexual behaviors after HPV vaccination in adolescents. Pediatrics. 2014;133:404–11.
  1201. Brouwer AF, Delinger RL, Eisenberg MC, et al. HPV vaccination has not increased sexual activity or accelerated sexual debut in a college-aged cohort of men and women. BMC Public Health. 2019;19(1):821.
  1202. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199:805–14.
  1203. Flagg EW, Torrone EA. Declines in anogenital warts among age groups most likely to be impacted by human papillomavirus vaccination, United States, 2006-2014. Am J Public Health. 2018;108(1):112–9.
  1204. Hariri S, Schuler MS, Naleway AL, et al. Human papillomavirus vaccine effectiveness against incident genital warts among female health-plan enrollees, United States. Am J Epidemiol. 2018;187(2):298–305.
  1205. Wangu Z, Hsu KK. Impact of HPV vaccination on anogenital warts and respiratory papillomatosis. Hum Vaccin Immunother. 2016;12(6):1357–62.
  1206. Swedish KA, Goldstone SE. Prevention of anal condyloma with quadrivalent human papillomavirus vaccination of older men who have sex with men. PLoS One. 2014;9(4):e93393.
  1207. Sandø N, Kofoed K, Zachariae C, Fouchard J. A reduced national incidence of anogenital warts in young Danish men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women–an ecological study. Acta Derm Venereol. 2014;94(3):288–92.
  1208. Herweijer E, Ploner A, Sparén P. Substantially reduced incidence of genital warts in women and men six years after HPV vaccine availability in Sweden. Vaccine. 2018;36(15):1917–20.
  1209. Harrison C, Britt H, Garland S, et al. Decreased management of genital warts in young women in Australian general practice post introduction of national HPV vaccination program: results from a nationally representative cross-sectional general practice study. PLoS One. 2014;9(9):e105967.
  1210. Canvin M, Sinka K, Hughes G, Mesher D. Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16/18) vaccination programme in England: an ecological analysis. Sex Transm Infect. 2017;93(2):125–8.
  1211. Chow EP, Read TR, Wigan R, et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2015;91(3):214–9.
  1212. Petrosky EY, Liu G, Hariri S, Markowitz LE. Human papillomavirus vaccination and age at first sexual activity, National Health and Nutrition Examination Survey. Clin Pediatr (Phila). 2017;56(4):363–70.
  1213. Gotovtseva EP, Kapadia AS, Smolensky MH, Lairson DR. Optimal frequency of imiquimod (aldara) 5% cream for the treatment of external genital warts in immunocompetent adults: a meta-analysis. Sex Transm Dis. 2008;35:346–51.
  1214. Baker DA, Ferris DG, Martens MG, et al. Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo-controlled studies. Infect Dis Obstet Gynecol. 2011;2011:806105.
  1215. Mashiah J, Brenner S. Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod. Clin Exp Dermatol. 2008;33:74–6.
  1216. Domingues E, Chaney KC, Scharf MJ, Wiss K. Imiquimod reactivation of lichen planus. Cutis. 2012;89:276–83.
  1217. Patel U, Mark NM, Machler BC, Levine VJ. Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and mechanism. Br J Dermatol. 2011;164:670–2.
  1218. Kumar B, Narang T. Local and systemic adverse effects to topical imiquimod due to systemic immune stimulation. Sex Transm Infect. 2011;87:432.
  1219. Stockfleth E, Beti H, Orasan R, et al. Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. Br J Dermatol. 2008;158:1329–38.
  1220. Gross G, Meyer KG, Pres H, Thielert C, Tawfik H, Mescheder A. A randomized, double-blind, four-arm parallel-group, placebo-controlled phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts. J Eur Acad Dermatol Venereol. 2007;21(10):1404–12.
  1221. Tatti S, Swinehart JM, Thielert C, Tawfik H, Mescheder A, Beutner KR. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol. 2008;111:1371–9.
  1222. National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention. Control of smoke from laser/electric surgical procedures. US Department of Health and Human Services, NIOSH; 1996 [cited 2020]. 2 p. Available from https://www.cdc.gov/niosh/docs/hazardcontrol/pdfs/hc11.pdf?id=10.26616/NIOSHPUB96128pdf icon
  1223. Filley CM, Graff-Richard NR, Lacy JR, Heitner MA, Earnest MP. Neurologic manifestations of podophyllin toxicity. Neurology. 1982;32:308–11.
  1224. Conard PF, Hanna N, Rosenblum M, Gross JB. Delayed recognition of podophyllum toxicity in a patient receiving epidural morphine. Anesth Analg. 1990;71:191–3.
  1225. Karol MD, Conner CS, Watanabe AS, Murphrey KJ. Podophyllum: suspected teratogenicity from topical application. Clin Toxicol. 1980;16:283–6.
  1226. Silverberg MJ, Thorsen P, Lindeberg H, Grant LA, Shah KV. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol. 2003;101:645–52.
  1227. Dolev JC, Maurer T, Springer G, et al. Incidence and risk factors for verrucae in women. AIDS. 2008;22:1213–9.
  1228. Silverberg MJ, Ahdieh L, Munoz A, et al. The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis. 2002;29:427–35.
  1229. De Panfilis G, Melzani G, Mori G, Ghidini A, Graifemberghi S. Relapses after treatment of external genital warts are more frequent in HIV-positive patients than in HIV-negative controls. Sex Transm Dis. 2002;29:121–5.
  1230. Conley LJ, Ellerbrock TV, Bush TJ, Chiasson MA, Sawo D, Wright TC. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet. 2002;359:108–13.
  1231. Schlecht HP, Fugelso DK, Murphy RK, et al. Frequency of occult high-grade squamous intraepithelial neoplasia and invasive cancer within anal condylomata in men who have sex with men. Clin Infect Dis. 2010;51:107–10.
  1232. Maniar KP, Ronnett BM, Vang R, Yemelyanova A. Coexisting high-grade vulvar intraepithelial neoplasia (VIN) and condyloma acuminatum: independent lesions due to different HPV types occurring in immunocompromised patients. Am J Surg Pathol. 2013;37:53–60.
  1233. Massad LS, Xie X, Darragh T, et al. Genital warts and vulvar intraepithelial neoplasia: natural history and effects of treatment and human immunodeficiency virus infection. Obstet Gynecol. 2011;118:831–9.
  1234. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12–23.
  1235. Darragh TM, Colgan TJ, Cox JT, et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. 2012;136:1266–97. Erratum in: Arch Pathol Lab Med. 2013 Jun;137(6):738.
  1236. Committee on Practice Bulletins—Gynecology. Practice Bulletin No. 168 Summary: Cervical Cancer Screening and Prevention. Obstet Gynecol. 2016;128(4):923–5.
  1237. Perkins RB, Guido RL, Saraiya M, et al. Summary of current guidelines for cervical cancer screening and management of abnormal test results: 2016-2020. J Womens Health (Larchmt). 2021;30(1):5–13.
  1238. Kim JJ, Burger EA, Regan C, Sy S. Screening for cervical cancer in primary care: a decision analysis for the US Preventive Services Task Force. JAMA. 2018;320(7):706–14.
  1239. Sawaya GF, Sanstead E, Alarid-Escudero F, et al. Estimated quality of life and economic outcomes associated with 12 cervical cancer screening strategies: a cost-effectiveness analysis. JAMA Intern Med. 2019;179(7):867–78.
  1240. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62:147–72.
  1241. Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 131: Screening for cervical cancer. Obstet Gynecol. 2012;120:1222–38.
  1242. Meyerson BE, Sayegh MA, Davis A, et al. Cervical cancer screening in a sexually transmitted disease clinic: screening adoption experiences from a midwestern clinic. Am J Public Health. 2015;105(Suppl 2):e8–14.
  1243. Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020;24(2):102–31.
  1244. Saraiya M, Lee NC, Blackman D, Smith MJ, Morrow B, McKenna MA. Self-reported Papanicolaou smears and hysterectomies among women in the United States. Obstet Gynecol. 2001;98:269–78.
  1245. Sirovich BE, Welch HG. Cervical cancer screening among women without a cervix. JAMA. 2004;291:2990–3.
  1246. Stokes-Lampard H, Wilson S, Waddell C, Ryan A, Holder R, Kehoe S. Vaginal vault smears after hysterectomy for reasons other than malignancy: a systematic review of the literature. BJOG. 2006;113:1354–65.
  1247. Arbyn M, Herbert A, Schenck U, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology. 2007;18(3):133–9.
  1248. Daley E, Perrin K, Vamos C, et al. Confusion about Pap smears: lack of knowledge among high-risk women. J Womens Health (Larchmt). 2013;22:67–74.
  1249. Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565–80.
  1250. Ogbechie OA, Hacker MR, Dodge LE, Patil MM, Ricciotti HA. Confusion regarding cervical cancer screening and chlamydia screening among sexually active young women. Sex Transm Infect. 2012;88:35–7.
  1251. Dunne EF, Friedman A, Datta SD, Markowitz LE, Workowski KA. Updates on human papillomavirus and genital warts and counseling messages from the 2010 Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis. 2011;53 Suppl 3:S143–52.
  1252. Fry AM, Ferries-Rowe EA, Learman LA, Haas DM. Pap smear versus speculum examination: can we teach providers to educate patients? J Womens Health (Larchmt). 2010;19:1715–9.
  1253. Adab P, Marshall T, Rouse A, Randhawa B, Sangha H, Bhangoo N. Randomised controlled trial of the effect of evidence based information on women’s willingness to participate in cervical cancer screening. J Epidemiol Community Health. 2003;57:589–93.
  1254. Drolet M, Brisson M, Maunsell E, et al. The psychosocial impact of an abnormal cervical smear result. Psychooncology. 2012;21(10):1071–81.
  1255. McCaffery KJ, Irwig L, Turner R, et al. Psychosocial outcomes of three triage methods for the management of borderline abnormal cervical smears: an open randomised trial. BMJ. 2010;340:4491.
  1256. Daley EM, Perrin KM, McDermott RJ, et al. The psychosocial burden of HPV: a mixed-method study of knowledge, attitudes and behaviors among HPV+ women. J Health Psychol. 2010;15:279–90.
  1257. Pirotta M, Ung L, Stein A, et al. The psychosocial burden of human papillomavirus related disease and screening interventions. Sex Transm Infect. 2009;85:508–13.
  1258. Lin L, Benard VB, Greek A, Roland KB, Hawkins NA, Saraiya M. Communication practices about HPV testing among providers in Federally Qualified Health Centers. Prev Med Rep. 2015;2:436–9.
  1259. Kapeu AS, Luostarinen T, Jellum E, et al., Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks. Am J Epidemiol. 2009;169(4):480–8.
  1260. Plummer M, Herrero R, Franceschi S, et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case–control study. Cancer Causes Control. 2003;14(9):805–14.
  1261. de Sanjosé S, Brotons M, Pavón MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2018;47:2–13.
  1262. Louie KS, Castellsague X, de Sanjose S, et al. Smoking and passive smoking in cervical cancer risk: pooled analysis of couples from the IARC multicentric case-control studies. Cancer Epidemiol Biomarkers Prev. 2011;20(7):1379–90.
  1263. Nelson HD, Cantor A, Wagner J, et al. Effectiveness of patient navigation to increase cancer screening in populations adversely affected by health disparities: a meta-analysis. J Gen Intern Med. 2020;35(10):3026–35.
  1264. Stillson T, Knight AL, Elswick RK Jr. The effectiveness and safety of two cervical cytologic techniques during pregnancy. J Fam Pract. 1997;45:159–63.
  1265. Foster JC, Smith HL. Use of the cytobrush for Papanicolaou smear screens in pregnant women. J Nurse Midwifery. 1996;41:211–7.
  1266. Paraiso MF, Brady K, Helmchen R, Roat TW. Evaluation of the endocervical cytobrush and cervex-brush in pregnant women. Obstet Gynecol. 1994;84:539–43.
  1267. Silverberg MJ, Leyden WA, Chi A, et al. Human immunodeficiency virus (HIV)- and non-HIV-associated immunosuppression and risk of cervical neoplasia. Obstet Gynecol. 2018;131(1):47–55.
  1268. Videla S, Tarrats A, Ornelas A, et al. Incidence of cervical high-grade squamous intraepithelial lesions in HIV-1-infected women with no history of cervical pathology: up to 17 years of follow-up. Int J STD AIDS. 2019;30(1):56–63.
  1269. Liu G, Sharma M, Tan N, Barnabas RV. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS. 2018;32(6):795–808.
  1270. Sawaya GF, Lamar R, Perkins RB. Managing minimally abnormal cervical cancer screening test results. 2020. doi: 10.1001/jama.2020.12488. Epub ahead of print.
  1271. Silverberg MJ, Lau B, Justice AC, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012;54(7):1026–34.
  1272. Tomassi MJ, Abbas MA, Klaristenfeld DD. Expectant management surveillance for patients at risk for invasive squamous cell carcinoma of the anus: a large US healthcare system experience. Int J Colorectal Dis. 2019;34(1):47–54.
  1273. Colón-López V, Shiels MS, Machin M, et al. Anal cancer risk among people with HIV infection in the United States. J Clin Oncol. 2018;36(1):68–75.
  1274. Machalek DA, Grulich AE, Jin F, Templeton DJ, Poynten IM. The epidemiology and natural history of anal human papillomavirus infection in men who have sex with men. Sex Health. 2012;9(6):527–37.
  1275. Deshmukh AA, Suk R, Shiels MS, et al. Recent trends in squamous cell carcinoma of the anus incidence and mortality in the United States, 2001-2015. J Natl Cancer Inst. 2020;112(8):829–38.
  1276. Edgren G, Sparén P. Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncol. 2007;8(4):311–6.
  1277. Chaturvedi AK, Engels EA, Gilbert ES, et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst. 2007;99(21):1634–43.
  1278. Suk R, Mahale P, Sonawane K, et al. Trends in risks for second primary cancers associated with index human papillomavirus-associated cancers. JAMA Netw Open. 2018;1(5):e181999.
  1279. Hillman RJ, Berry-Lawhorn JM, Ong JJ, et al. International Anal Neoplasia Society guidelines for the practice of digital anal rectal examination. J Low Genit Tract Dis. 2019;23(2):138–46.
  1280. Ong JJ, Grulich A, Walker S, et al. Baseline findings from the Anal Cancer Examination (ACE) study: screening using digital ano-rectal examination in HIV-positive men who have sex with men. J Med Screen. 2016;23(2):70–6.
  1281. Read TR, Vodstrcil L, Grulich AE, et al. Acceptability of digital anal cancer screening examinations in HIV-positive homosexual men. HIV Med. 2013;14(8):491–6.
  1282. Jin F, Grulich AE, Poynten IM, et al. The performance of anal cytology as a screening test for anal HSILs in homosexual men. Cancer Cytopathol. 2016;124(6):415–24.
  1283. Silva M, Peixoto A, Sarmento JA, Coelho R, Macedo G. Anal cytology, histopathology and anoscopy in an anal dysplasia screening program: is anal cytology enough? Rev Esp Enferm Dig. 2018;110(2):109–14.
  1284. Iribarren Díaz M, Ocampo Hermida A, González-Carreró Fojón J, et al. Preliminary results of a screening program for anal cancer and its precursors for HIV-infected men who have sex with men in Vigo-Spain. Rev Esp Enferm Dig. 2017;109(4):242–9.
  1285. Burgos J, Hernández-Losa J, Landolfi S, et al. The role of oncogenic human papillomavirus determination for diagnosis of high-grade anal intraepithelial neoplasia in HIV-infected MSM. AIDS. 2017;31(16):2227–33.
  1286. Cheng SH, Wang CC, Chang SL, Chu FY, Hsueh YM. Oncogenic human papillomavirus is not helpful for cytology screening of the precursor lesions of anal cancers in Taiwanese men who are infected with human immunodeficiency virus. Int J Clin Oncol. 2015;20(5):943–51.
  1287. Hidalgo-Tenorio C, Rivero-Rodriguez M, Gil-Anguita C, et al. The role of polymerase chain reaction of high-risk human papilloma virus in the screening of high-grade squamous intraepithelial lesions in the anal mucosa of human immunodeficiency virus-positive males having sex with males. PLoS One. 2015;10(4):e0123590.
  1288. Richel O, de Vries HJ, van Noesel CJ, Dijkgraaf MG, Prins JM. Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. Lancet Oncol. 2013;14(4):346–53.
  1289. Goldstone SE, Johnstone AA, Moshier EL. Long-term outcome of ablation of anal high-grade squamous intraepithelial lesions: recurrence and incidence of cancer. Dis Colon Rectum. 2014;57(3):316–23.
  1290. Tong WW, Shepherd K, Garland S, et al. Human papillomavirus 16-specific T-cell responses and spontaneous regression of anal high-grade squamous intraepithelial lesions. J Infect Dis. 2015;211(3):405–15.
  1291. Tong WW, Jin F, McHugh LC, et al. Progression to and spontaneous regression of high-grade anal squamous intraepithelial lesions in HIV-infected and uninfected men. AIDS. 2013;27(14):2233–43.
  1292. Shin EC, Jeong SH. Natural history, clinical manifestations, and pathogenesis of hepatitis A. Cold Spring Harb Perspect Med. 2018;8(9):a031708.
  1293. Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of hepatitis A virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep. 2020;69(5):1–38.
  1294. Foster MA, Hofmeister MG, Kupronis BA, et al. Increase in hepatitis A virus infections – United States, 2013-2018. MMWR Morb Mortal Wkly Rep. 2019;68(18):413–15.
  1295. Bower WA, Nainan OV, Han X, Margolis HS. Duration of viremia in hepatitis A virus infection. J Infect Dis. 2000;182:12–7.
  1296. Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, André FE. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis. 1995;171 Suppl 1:S44–9.
  1297. Sharapov UM, Bulkow LR, Negus SE, et al. Persistence of hepatitis A vaccine induced seropositivity in infants and young children by maternal antibody status: 10-year follow-up. 2012;56:516–22.
  1298. Mosites E, Gounder P, Snowball M, et al. Hepatitis A vaccine immune response 22 years after vaccination. J Med Virol. 2018;90(8):1418–22.
  1299. Theeten H, Van Herck K, Van Der Meeren O, Crasta P, Van Damme P, Hens N. Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions. Vaccine. 2015;33(42):5723–7.
  1300. Hens N, Habteab Ghebretinsae A, Hardt K, Van Damme P, Van Herck K. Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults. Vaccine. 2014;32(13):1507–13.
  1301. Mosites E, Seeman S, Negus S, et al. Immunogenicity of the hepatitis A vaccine 20 years after infant immunization. 2020;38(32):4940–3.
  1302. Yin S, Barker L, Ly KN, et al. Susceptibility to hepatitis A virus infection in the United States, 2007-2016. Clin Infect Dis. 2020;ciaa298. doi: 10.1093/cid/ciaa298. Epub ahead of print.
  1303. Moro PL, Arana J, Marquez PL, et al. Is there any harm in administering extra-doses of vaccine to a person? Excess doses of vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2007-2017. 2019;37(28):3730–4.
  1304. Winokur PL, Stapleton JT. Immunoglobulin prophylaxis for hepatitis A. Clin Infect Dis. 1992;14(2):580–6.
  1305. Alter HJ, Purcell RH, Gerin JL, et al. Transmission of hepatitis B to chimpanzees by hepatitis B surface antigen-positive saliva and semen. Infect Immun. 1977;16:928–33.
  1306. Villarejos VM, Visoná KA, Gutiérrez A, Rodríguez A. Role of saliva, urine and feces in the transmission of type B hepatitis. N Engl J Med. 1974;291:1375–8.
  1307. Busch K, Thimme R. Natural history of chronic hepatitis B virus infection. Med Microbiol Immunol. 2015;204(1):5–10.
  1308. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis. 1995;20:992–1000.
  1309. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005;34:1329–39.
  1310. Thompson ND, Perz JF, Moorman AC, Holmberg SD. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008. Ann Intern Med. 2009;150:33–9.
  1311. Davis LG, Weber DJ, Lemon SM. Horizontal transmission of hepatitis B virus. Lancet. 1989;1:889–93.
  1312. Martinson FE, Weigle KA, Royce RA, Weber DJ, Suchindran CM, Lemon SM. Risk factors for horizontal transmission of hepatitis B virus in a rural district in Ghana. Am J Epidemiol. 1998;147:478–87.
  1313. Centers for Disease Control and Prevention. Healthcare-associated hepatitis B and C outbreaks (≥ 2 cases) reported to the CDC 2008-2019 [Internet]. US Department of Health and Human Services, CDC; 2019 [cited 2020]; 29 p. Available from: https://www.cdc.gov/hepatitis/outbreaks/pdfs/HealthcareInvestigationTable.pdf
  1314. Schillie S, Harris A, Link-Gelles R, Romero J, Ward J, Nelson N. Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant. MMWR Morb Mortal Wkly Rep. 2018;67(15):455–8.
  1315. Lu PJ, Byrd KK, Murphy TV, Weinbaum C. Hepatitis B vaccination coverage among high-risk adults 18-49 years, U.S., 2009. Vaccine. 2011;29:7049–57.
  1316. Williams WW, Lu PJ, O’Halloran A, et al. Surveillance of vaccination coverage among adult populations – United States, 2015. MMWR Surveill Summ. 2017;66(11):1–28.
  1317. Centers for Disease Control and Prevention. Hepatitis B vaccination coverage among adults–United States, 2004. MMWR Morb Mortal Wkly Rep. 2006;55(18):509–11.
  1318. MacKellar DA, Valleroy LA, Secura GM, et al. Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men. Am J Public Health. 2001;91:965–71.
  1319. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99.
  1320. Ezeanolue E, Harriman K, Hunter P, Kroger A, Pellegrini C. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP) [Internet]. [place unknown]: Advisory Committee on Immunization Practices; [cited 2019]. 196 p. Available from: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdfpdf icon
  1321. Bruce MG, Bruden D, Hurlburt D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose. J Infect Dis. 2016;214(1):16–22.
  1322. McMahon BJ, Bulkow LR, Singleton RJ, et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology. 2011;54(3):801–7.
  1323. Simons BC, Spradling PR, Bruden DJ, et al. A longitudinal hepatitis B vaccine cohort demonstrates long-lasting hepatitis B virus (HBV) cellular immunity despite loss of antibody against HBV surface antigen. J Infect Dis. 2016;214(2):273–80.
  1324. Bohlke K, Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003;112(4):815–20.
  1325. André FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med. 1989;87(3a):14S–20S.
  1326. Abara WE, Qaseem A, Schillie S, McMahon BJ, Harris AM; High Value Care Task Force of the American College of Physicians and the Centers for Disease Control and Prevention. Hepatitis B vaccination, screening, and linkage to care: best practice advice from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2017;167(11):794–804.
  1327. Minuk GY, Bohme CE, Bowen TJ, et al. Efficacy of commercial condoms in the prevention of hepatitis B virus infection. Gastroenterology. 1987;93:710–4.
  1328. Hofmeister MG, Rosenthal EM, Barker LK, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016. Hepatology. 2019;69(3):1020–31.
  1329. Lockart I, Matthews GV, Danta M. Sexually transmitted hepatitis C infection: the evolving epidemic in HIV-positive and HIV-negative MSM. Curr Opin Infect Dis. 2019;32(1):31–7.
  1330. Terrault NA, Dodge JL, Murphy EL, et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology. 2013;57:881–9.
  1331. Price JC, McKinney JE, Crouch PC, et al. Sexually acquired hepatitis C infection in HIV-uninfected men who have sex with men using preexposure prophylaxis against HIV. J Infect Dis. 2019;219(9):1373–6.
  1332. Tohme RA, Holmberg SD. Transmission of hepatitis C virus infection through tattooing and piercing: a critical review. Clin Infect Dis. 2012;54:1167–78.
  1333. Brettler DB, Mannucci PM, Gringeri A, et al. The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophilic males: an international, multicenter study. Blood. 1992;80:540–3.
  1334. Kao JH, Hwang YT, Chen PJ, et al. Transmission of hepatitis C virus between spouses: the important role of exposure duration. Am J Gastroenterol. 1996;91:2087–90.
  1335. Fierer DS, Mullen MP, Dieterich DT, Isabel Fiel M, Branch AD. Early-onset liver fibrosis due to primary hepatitis C virus infection is higher over time in HIV-infected men. Clin Infect Dis. 2012;55:887–9.
  1336. van de Laar TJ, van der Bij AK, Prins M, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis. 2007;196:230–8.
  1337. Nijmeijer BM, Koopsen J, Schinkel J, Prins M, Geijtenbeek TB. Sexually transmitted hepatitis C virus infections: current trends, and recent advances in understanding the spread in men who have sex with men. J Int AIDS Soc. 2019;22 Suppl 6:e25348.
  1338. Todesco E, Day N, Amiel C, et al. High clustering of acute HCV infections and high rate of associated STIs among Parisian HIV-positive male patients. Int J Antimicrob Agents. 2019;53(5):678–81.
  1339. Jin F, Matthews GV, Grulich AE. Sexual transmission of hepatitis C virus among gay and bisexual men: a systematic review. Sex Health. 2017;14(1):28–41.
  1340. Hegazi A, Lee MJ, Whittaker W, et al. Chemsex and the city: sexualised substance use in gay bisexual and other men who have sex with men attending sexual health clinics. Int J STD AIDS. 2017;28(4):362–6.
  1341. Page EE, Nelson M. Hepatitis C and sex. Clin Med (Lond). 2016;16(2):189–92.
  1342. Apers L, Vanden Berghe W, De Wit S, et al. Risk factors for HCV acquisition among HIV-positive MSM in Belgium. J Acquir Immune Defic Syndr. 2015;68(5):585–93.
  1343. Daskalopoulou M, Rodger AJ, Phillips AN, et al. Condomless sex in HIV-diagnosed men who have sex with men in the UK: prevalence, correlates, and implications for HIV transmission. Sex Transm Infect. 2017;93(8):590–8.
  1344. Vanhommerig JW, Lambers FA, Schinkel J, et al. Risk factors for sexual transmission of hepatitis C virus among human immunodeficiency virus-infected men who have sex with men: a case-control study. Open Forum Infect Dis. 2015;2(3):ofv115.
  1345. Turner SS, Gianella S, Yip MJ, et al. Shedding of hepatitis C virus in semen of human immunodeficiency virus-infected men. Open Forum Infect Dis. 2016;3(2):ofw057.
  1346. Foster AL, Gaisa MM, Hijdra RM, et al. Shedding of hepatitis C virus into the rectum of HIV-infected men who have sex with men. Clin Infect Dis. 2017;64(3):284–8.
  1347. Hammer GP, Kellogg TA, McFarland WC, et al. Low incidence and prevalence of hepatitis C virus infection among sexually active non-intravenous drug-using adults, San Francisco, 1997-2000. Sex Transm Dis. 2003;30:919–24.
  1348. Roy KM, Goldberg DJ, Hutchinson S, Cameron SO, Wilson K, MacDonald L. Hepatitis C virus among self declared non-injecting sexual partners of injecting drug users. J Med Virol. 2004;74:62–6.
  1349. Mele A, Stroffolini T, Tosti ME, et al. Heterosexual transmission of hepatitis C in Italy. J Med Virol. 1999;57:111–3.
  1350. Rauch A, Rickenbach M, Weber R, et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis. 2005;41(3):395–402.
  1351. Browne R, Asboe D, Gilleece Y, et al. Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase? Sex Transm Infect. 2004;80:326–7.
  1352. Danta M, Brown D, Bhagani S, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS. 2007;21:983–91.
  1353. Ghosn J, Pierre-François S, Thibault V, et al. Acute hepatitis C in HIV-infected men who have sex with men. HIV Med. 2004;5:303–6.
  1354. van de Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology. 2009;136:1609–17.
  1355. Hoornenborg E, Achterbergh RCA, Schim van der Loeff MF, et al. MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection. AIDS. 2017;31(11):1603–10.
  1356. Gras J, Mahjoub N, Charreau I, et al. Early diagnosis and risk factors of acute hepatitis C in high-risk MSM on preexposure prophylaxis. AIDS. 2020;34(1):47–52.
  1357. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology. 1997;26(3 Suppl 1):15S–20S.
  1358. Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology. 2001;33(2):321–327.
  1359. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med. 1992;327:1899–905.
  1360. Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med. 1991;325(2):98–104.
  1361. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000;132(4):296–305.
  1362. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis. 2005;9(3):383–98.
  1363. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58–68.
  1364. Zou S, Stramer SL, Dodd RY. Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations. Transfus Med Rev. 2012;26(2):119–28.
  1365. Bixler D, Annambholta P, Abara WE, et al. Hepatitis B and C virus infections transmitted through organ transplantation investigated by CDC, United States, 2014-2017. Am J Transplant. 2019;19(9):2570–82.
  1366. Centers for Disease Control and Prevention. Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep. 2013;62(18):362–5.
  1367. Marincovich B, Castilla J, del Romero J, et al. Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. Sex Transm Infect. 2003;79:160–2.
  1368. Tahan V, Karaca C, Yildirim B, et al. Sexual transmission of HCV between spouses. Am J Gastroenterol. 2005;100:821–4.
  1369. Vandelli C, Renzo F, Romanò L, et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gastroenterol. 2004;99:855–9.
  1370. Fierer DS, Uriel AJ, Carriero DC, et al. Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis. 2008;198:683–6.
  1371. Cottrell EB, Chou R, Wasson N, Rahman B, Guise JM. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;158:109–13.
  1372. Mast EE, Hwang LY, Seto DS, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005;192(11):1880–9.
  1373. Barbosa C, Fraser H, Hoerger TJ, et al. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs. Addiction. 2019;114(12):2267–78.
  1374. Lambers FA, Prins M, Thomas X, et al. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS. 2011;25(17):F21–7.
  1375. Martin TC, Singh GJ, McClure M, Nelson M. HCV reinfection among HIV-positive men who have sex with men: a pragmatic approach. Hepatology. 2015;61(4):1437.
  1376. Ingiliz P, Martin TC, Rodger A, et al. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. J Hepatol. 2017;66(2):282–7.
  1377. Briat A, Dulioust E, Galimand J, et al. Hepatitis C virus in the semen of men coinfected with HIV-1: prevalence and origin. AIDS. 2005;19:1827–35.
  1378. Bissessor M, Fairley CK, Read T, Denham I, Bradshaw C, Chen M. The etiology of infectious proctitis in men who have sex with men differs according to HIV status. Sex Transm Dis. 2013;40(10):768–70.
  1379. Gutierrez-Fernandez J, Medina V, Hidalgo-Tenorio C, Abad R. Two Cases of Neisseria meningitidis proctitis in HIV-positive men who have sex with men. Emerg Infect Dis. 2017;23(3):542–3.
  1380. Levy I, Gefen-Halevi S, Nissan I, et al. Delayed diagnosis of colorectal sexually transmitted diseases due to their resemblance to inflammatory bowel diseases. Int J Infect Dis. 2018;75:34–8.
  1381. Lebari D. Syphilis presenting as colorectal cancer. Sex Trans Dis. 2014;41(Suppl 1):S4.
  1382. Hines JZ, Pinsent T, Rees K, et al. Notes from the field: shigellosis outbreak among men who have sex with men and homeless persons – Oregon, 2015-2016. MMWR Morb Mortal Wkly Rep. 2016;65(31):812–3.
  1383. Marchand-Senécal X, Bekal S, Pilon PA, Sylvestre JL, Gaudreau C. Campylobacter fetus cluster among men who have sex with men, Montreal, Quebec, Canada, 2014-2016. Clin Infect Dis. 2017;65(10):1751–3.
  1384. Klausner JD, Kohn R, Kent C. Etiology of clinical proctitis among men who have sex with men. Clin Infect Dis. 2004;38:300–2.
  1385. Stoner BP, Cohen SE. Lymphogranuloma venereum 2015: clinical presentation, diagnosis, and treatment. Clin Infect Dis. 2015;61 Suppl 8:S865–73.
  1386. Mohrmann G, Noah C, Sabranski M, Sahly H, Stellbrink HJ. Ongoing epidemic of lymphogranuloma venereum in HIV-positive men who have sex with men: how symptoms should guide treatment. J Int AIDS Soc. 2014;17(4 Suppl 3):19657.
  1387. Hoffmann C, Sahly H, Jessen A, et al. High rates of quinolone-resistant strains of Shigella sonnei in HIV-infected MSM. Infection. 2013;41(5):999–1003.
  1388. Heiman KE, Karlsson M, Grass J, et al. Notes from the field: Shigella with decreased susceptibility to azithromycin among men who have sex with men – United States, 2002-2013. MMWR Morb Mortal Wkly Rep. 2014;63(6):132–3.
  1389. Galiczynski EM Jr, Elston DM. What’s eating you? pubic lice (Pthirus pubis). Cutis. 2008;81:109–14.
  1390. Meinking TL, Serrano L, Hard B, et al. Comparative in vitro pediculicidal efficacy of treatments in a resistant head lice population in the United States. Arch Dermatol. 2002;138:220–4.
  1391. Yoon KS, Gao JR, Lee SH, Clark JM, Brown L, Taplin D. Permethrin-resistant human head lice, Pediculus capitis, and their treatment. Arch Dermatol. 2003;139:994–1000.
  1392. Burkhart CG, Burkhart CN. Oral ivermectin for Phthirus pubis. J Am Acad Dermatol. 2004;51:1037–8.
  1393. Scott GR, Chosidow O; IUSTI/WHO. European guideline for the management of pediculosis pubis, 2010. Int J STD AIDS. 2011;22:304–5.
  1394. Goldust M, Rezaee E, Raghifar R, Hemayat S. Comparing the efficacy of oral ivermectin vs malathion 0.5% lotion for the treatment of scabies. Skinmed. 2014;12:284–7.
  1395. Veraldi S, Schianchi R, Ramoni S, Nazzaro G. Pubic hair removal and Phthirus pubis infestation. Int J STD AIDS. 2018;29(1):103–4.
  1396. Leung A, Lam J, Leong KF. Scabies: a neglected global disease. Curr Pediatr Rev. 2020;16:33–42.
  1397. Engelman D, Cantey PT, Marks M, et al. The public health control of scabies: priorities for research and action. Lancet. 2019;394(10192):81–92.
  1398. Shimose L, Munoz-Price LS. Diagnosis, prevention, and treatment of scabies. Curr Infect Dis Rep. 2013;15:426–31.
  1399. Walter B, Heukelbach J, Fengler G, Worth C, Hengge U, Feldmeier H. Comparison of dermoscopy, skin scraping, and the adhesive tape test for the diagnosis of scabies in a resource-poor setting. Arch Dermatol. 2011;147(4):468–73.
  1400. Micali G, Lacarrubba F, Verzì AE, Chosidow O, Schwartz RA. Scabies: advances in noninvasive diagnosis. PLoS Negl Trop Dis. 2016;10(6):e0004691.
  1401. Strong M, Johnstone P. Interventions for treating scabies. Cochrane Database Syst Rev. 2007(3):Cd000320.
  1402. Abdel-Raheem TA, Méabed EM, Nasef GA, Abdel Wahed WY, Rohaim RM. Efficacy, acceptability and cost effectiveness of four therapeutic agents for treatment of scabies. J Dermatolog Treat. 2016;27(5):473–9.
  1403. Alipour H, Goldust M. The efficacy of oral ivermectin vs. sulfur 10% ointment for the treatment of scabies. Ann Parasitol. 2015;61(2):79–84.
  1404. Al jaff D, Amin M. Comparison of the effectiveness of sulphur ointment, permethrin and oral ivermectin in treatment of scabies. Res J Pharm Biol Chem Sci. 2018;9(1):670–6.
  1405. Goldust M, Rezaee E, Raghifar R, Hemayat S. Treatment of scabies: the topical ivermectin vs. permethrin 2.5% cream. Ann Parasitol. 2013;59(2):79–84.
  1406. Ahmad HM, Abdel-Azim ES, Abdel-Aziz RT. Clinical efficacy and safety of topical versus oral ivermectin in treatment of uncomplicated scabies. Dermatol Ther. 2016;29(1):58–63.
  1407. Currie BJ, McCarthy JS. Permethrin and ivermectin for scabies. N Engl J Med. 2010;362:717–25.
  1408. Chiu S, Argaez C. Ivermectin for Parasitic Skin Infections of Scabies: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 May 16. Available from: https://www.ncbi.nlm.nih.gov/books/NBK545083/
  1409. Nolan K, Kamrath J, Levitt J. Lindane toxicity: a comprehensive review of the medical literature. Pediatr Dermatol. 2012;29:141–6.
  1410. Mounsey KE, Holt DC, McCarthy J, Currie BJ, Walton SF. Scabies: molecular perspectives and therapeutic implications in the face of emerging drug resistance. Future Microbiol. 2008;3:57–66.
  1411. Mounsey KE, Holt DC, McCarthy JS, Currie BJ, Walton SF. Longitudinal evidence of increasing in vitro tolerance of scabies mites to ivermectin in scabies-endemic communities. Arch Dermatol. 2009;145:840–1.
  1412. Mounsey KE, McCarthy JS, Walton SF. Scratching the itch: new tools to advance understanding of scabies. Trends Parasitol. 2013;29:35–42.
  1413. van der Linden N, van Gool K, Gardner K, et al. A systematic review of scabies transmission models and data to evaluate the cost-effectiveness of scabies interventions. PLoS Negl Trop Dis. 2019;13(3):e0007182.
  1414. Roberts LJ, Huffam SE, Walton SF, Currie BJ. Crusted scabies: clinical and immunological findings in seventy-eight patients and a review of the literature. J Infect. 2005;50:375–81.
  1415. Ortega-Loayza AG, McCall CO, Nunley JR. Crusted scabies and multiple dosages of ivermectin. J Drugs Dermatol. 2013;12:584–5.
  1416. Bouvresse S, Chosidow O. Scabies in healthcare settings. Curr Opin Infect Dis. 2010;23:111–8.
  1417. Marotta M, Toni F, Dallolio L, Toni G, Leoni E. Management of a family outbreak of scabies with high risk of spread to other community and hospital facilities. Am J Infect Control. 2018;46(7):808–13.
  1418. Romani L, Whitfeld MJ, Koroivueta J, et al. Mass drug administration for scabies control in a population with endemic disease. N Engl J Med. 2015;373(24):2305–13.
  1419. Ackerman DR, Sugar NF, Fine DN, Eckert LO. Sexual assault victims: factors associated with follow-up care. Am J Obstet Gynecol. 2006;194:1653–9.
  1420. Parekh V, Brown CB. Follow up of patients who have been recently sexually assaulted. Sex Transm Infect. 2003;79:349.
  1421. Vrees RA. Evaluation and management of female victims of sexual assault. Obstet Gynecol Surv. 2017;72(1):39–53.
  1422. Unger ER, Fajman NN, Maloney EM, et al. Anogenital human papillomavirus in sexually abused and nonabused children: a multicenter study. Pediatrics. 2011;128(3):e658–65.
  1423. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011;103:1444–51.
  1424. Claydon E, Murphy S, Osborne EM, Kitchen V, Smith JR, Harris JR. Rape and HIV. Int J STD AIDS. 1991;2:200–1.
  1425. Murphy S, Kitchen V, Harris JR, Forster SM. Rape and subsequent seroconversion to HIV. BMJ. 1989;299:718.
  1426. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med. 1997;337:1485–90.
  1427. Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013;34:875–92.
  1428. Du Mont J, Myhr TL, Husson H, Macdonald S, Rachlis A, Loutfy MR. HIV postexposure prophylaxis use among Ontario female adolescent sexual assault victims: a prospective analysis. Sex Transm Dis. 2008;35:973–8.
  1429. Neu N, Heffernan-Vacca S, Millery M, Stimell M, Brown J. Postexposure prophylaxis for HIV in children and adolescents after sexual assault: a prospective observational study in an urban medical center. Sex Transm Dis. 2007;34:65–8.
  1430. Loutfy MR, Macdonald S, Myhr T, et al. Prospective cohort study of HIV post-exposure prophylaxis for sexual assault survivors. Antiviral Therapy. 2008;13:87–95.
  1431. Inciarte A, Leal L, Masfarre L, et al. Post-exposure prophylaxis for HIV infection in sexual assault victims. HIV Med. 2020;21(1):43–52.
  1432. Announcement: Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV – United States, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(17):458.
  1433. Ford N, Venter F, Irvine C, Beanland RL, Shubber Z. Starter packs versus full prescription of antiretroviral drugs for postexposure prophylaxis: a systematic review. Clin Infect Dis. 2015;60 Suppl 3:S182–6.
  1434. Jenny C, Crawford-Jakubiak JE; Committee on Child Abuse and Neglect; American Academy of Pediatrics. The evaluation of children in the primary care setting when sexual abuse is suspected. Pediatrics. 2013;132:e558–67.
  1435. Girardet RG, Lahoti S, Howard LA, et al. Epidemiology of sexually transmitted infections in suspected child victims of sexual assault. Pediatrics. 2009;124:79–86.
  1436. Black CM, Driebe EM, Howard LA, et al. Multicenter study of nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in children being evaluated for sexual abuse. Pediatr Infect Dis J. 2009;28:608–13.
  1437. Trotman GE, Young-Anderson C, Deye KP. Acute sexual assault in the pediatric and adolescent population. J Pediatr Adolesc Gynecol. 2016;29(6):518–26.
  1438. Schwandt A, Williams C, Beigi RH. Perinatal transmission of Trichomonas vaginalis: a case report. J Reprod Med. 2008;53:59–61.
  1439. Bell TA, Stamm WE, Wang SP, Kuo CC, Holmes KK, Grayston JT. Chronic Chlamydia trachomatis infections in infants. JAMA. 1992;267:400–2.
  1440. Adachi K, Nielsen-Saines K, Klausner JD. Chlamydia trachomatis infection in pregnancy: the global challenge of preventing adverse pregnancy and infant outcomes in sub-Saharan Africa and Asia. Biomed Res Int. 2016;2016:9315757.
  1441. Schachter J, Grossman M, Sweet RL, Holt J, Jordan C, Bishop E. Prospective study of perinatal transmission of Chlamydia trachomatis. JAMA. 1986;255:3374–7.
  1442. Smith EM, Swarnavel S, Ritchie JM, Wang D, Haugen TH, Turek LP. Prevalence of human papillomavirus in the oral cavity/oropharynx in a large population of children and adolescents. Pediatr Infect Dis J. 2007;26(9):836–40.
  1443. Sabeena S, Bhat P, Kamath V, Arunkumar G. Possible non-sexual modes of transmission of human papilloma virus. J Obstet Gynaecol Res. 2017;43(3):429–35.
  1444. Adams JA, Farst KJ, Kellogg ND. Interpretation of medical findings in suspected child sexual abuse: an update for 2018. J Pediatr Adolesc Gynecol. 2018;31(3):225–31.
  1445. Kellogg ND, Melville JD, Lukefahr JL, Nienow SM, Russell EL. Genital and extragenital gonorrhea and chlamydia in children and adolescents evaluated for sexual abuse. Pediatr Emerg Care. 2018;34(11):761–6.
  1446. Gavril AR, Kellogg ND, Nair P. Value of follow-up examinations of children and adolescents evaluated for sexual abuse and assault. Pediatrics. 2012;129:282–9.
  1447. Bandea CI, Joseph K, Secor EW, et al. Development of PCR assays for detection of Trichomonas vaginalis in urine specimens. J Clin Microbiol. 2013;51:1298–300.
  1448. Gallion HR, Dupree LJ, Scott TA, Arnold DH. Diagnosis of Trichomonas vaginalis in female children and adolescents evaluated for possible sexual abuse: a comparison of the InPouch TV culture method and wet mount microscopy. J Pediatr Adolesc Gynecol. 2009;22:300–5.
  1449. Lalor K, McElvaney R. Child sexual abuse, links to later sexual exploitation/high-risk sexual behavior, and prevention/treatment programs. Trauma Violence Abuse. 2010;11:159–77.
  1450. Girardet RG, Lemme S, Biason TA, Bolton K, Lahoti S. HIV post-exposure prophylaxis in children and adolescents presenting for reported sexual assault. Child Abuse Negl. 2009;33:173–8.
  1451. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection [Internet]. US Department of Health and Human Services, AIDSinfo [cited 2020]. 412 p. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdfpdf iconexternal icon
  1452. Rietmeijer CA, Mettenbrink CJ. The diagnosis of nongonococcal urethritis in men: can there be a universal standard? Sex Transm Dis. 2017;44(3):195–6.
  1453. Leipertz G, Chambers L, Lowens S, et al. P796 Reassessing the Gram stain smear (GSS) polymorphonuclear leukocyte (PMN) cutoff for diagnosing non-gonococcal urethritis (NGU). Sex Transm Infect. 2019;95(Suppl 1):A339.
  1454. Moi H, Hartgill U, Skullerud KH, Reponen EJ, Syvertsen L, Moghaddam A. Microscopy of stained urethral smear in male urethritis; which cutoff should be used? Sex Transm Dis. 2017;44(3):189–94.